Summary of notifiable noninfectious conditions and disease outbreaks -- United States by Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services.
Weekly/ Vol. 63 / No. 55 October 14, 2016 
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Morbidity and Mortality Weekly Report
Summary of Notifiable Noninfectious Conditions 
and Disease Outbreaks — United States
Morbidity and Mortality Weekly Report
The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), 
U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.
Suggested citation: Centers for Disease Control and Prevention. [Summary of Noninfectious Conditions and Disease Outbreaks]. Published October 14, 2016 for MMWR 
Morb Mortal Wkly Rep 2014;63(No. 55):[inclusive page numbers].
Centers for Disease Control and Prevention
Thomas R. Frieden, MD, MPH, Director
Harold W. Jaffe, MD, MA, Associate Director for Science
Joanne Cono, MD, ScM, Director, Office of Science Quality 
Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services
Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services 
MMWR Editorial and Production Staff (Serials)
Sonja A. Rasmussen, MD, MS, Editor-in-Chief
Charlotte K. Kent, PhD, MPH, Executive Editor 
Christine G. Casey, MD, Editor
Teresa F. Rutledge, Managing Editor
David C. Johnson, Lead Technical Writer-Editor
Jeffrey D. Sokolow, MA, Project Editor
Martha F. Boyd, Lead Visual Information Specialist
Maureen A. Leahy, Julia C. Martinroe, 
Stephen R. Spriggs, Moua Yang, Tong Yang,
Visual Information Specialists
Quang M. Doan, MBA, Phyllis H. King, Terraye M. Starr,
Information Technology Specialists
MMWR Editorial Board
Timothy F. Jones, MD, Chairman
Matthew L. Boulton, MD, MPH
Virginia A. Caine, MD 
Katherine Lyon Daniel, PhD
Jonathan E. Fielding, MD, MPH, MBA
David W. Fleming, MD 
William E. Halperin, MD, DrPH, MPH
King K. Holmes, MD, PhD 
Robin Ikeda, MD, MPH 
Rima F. Khabbaz, MD
Phyllis Meadows, PhD, MSN, RN
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH 
Patrick L. Remington, MD, MPH 
Carlos Roig, MS, MA
William L. Roper, MD, MPH 
William Schaffner, MD
CONTENTS
Introduction to the Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks — United States.............................1
Acute Nonoccupational Pesticide-Related Illness and Injury — 
United States, 2007–2011 ................................................................................5
Acute Occupational Pesticide-Related Illness and Injury — 
United States, 2007–2011 ............................................................................. 11
Surveillance for Cancer Incidence and Mortality — 
United States, 2012 ......................................................................................... 17
Elevated Blood Lead Levels Among Employed Adults —  
United States, 1994–2013 ............................................................................. 59
Blood Lead Levels in Children Aged <5 Years —  
United States, 2007–2013 ............................................................................. 66
Surveillance for Silicosis — Michigan and New Jersey,  
2003–2011 .......................................................................................................... 73
Foodborne (1973–2013) and Waterborne (1971–2013) 
Disease Outbreaks — United States ......................................................... 79
Morbidity and Mortality Weekly Report
MMWR / October 14, 2016 / Vol. 63 / No. 55 1US Department of Health and Human Services/Centers for Disease Control and Prevention
With this 2016 Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks — United States, CDC is 
publishing official statistics for the occurrence of nationally 
notifiable noninfectious conditions and disease outbreaks for 
the second time in the same volume of MMWR as the annual 
Summary of Notifiable Infectious Diseases and Conditions (1). As 
was the case for the 2015 Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks (2), this joint publication is 
the result of a request by the Council of State and Territorial 
Epidemiologists (CSTE) to provide readers with information 
on all nationally notifiable conditions and disease outbreaks 
in a single publication.
The 2016 Summary of Notifiable Noninfectious Conditions and 
Disease Outbreaks includes for the first time a chapter on acute 
pesticide-related illness and injury from nonoccupational pesticide 
exposure whereas the 2015 Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks included only acute pesticide-
related illness and injury from occupational exposure (2). This 
summary includes seven chapters addressing the following 
subjects: acute pesticide-related illness and injury arising from 
occupational exposure (3), acute nonoccupational pesticide-related 
illness and injury (4), cancer (5), elevated blood lead levels among 
children (6), elevated blood lead levels among adults (7), silicosis 
(8), and foodborne and waterborne disease outbreaks (9).
Information on elevated lead exposure is provided in 
two separate chapters (6,7) because the principal source of 
elevated blood lead levels in children (lead paint in homes) is 
different from the principal source in adults (lead exposure at 
work). Responsibilities for monitoring blood lead levels are 
assigned to different Centers at CDC. The National Center 
for Environmental Health (NCEH) has primary responsibility 
for preventing disease from environmental hazards (principally 
nonoccupational) and manages the Childhood Blood Lead 
Surveillance (CBLS) system (7). The National Institute for 
Occupational Safety and Health (NIOSH) is responsible for 
preventing disease from workplace hazards and manages the 
Adult Blood Lead Epidemiology and Surveillance (ABLES) 
system (6). Information on acute pesticide-related illness and 
injury also is provided in separate chapters for occupational 
and nonoccupational exposure (3,4). NIOSH led preparation 
of the chapter on acute occupational pesticide-related illness 
and injury (3), and NCEH led preparation of the chapter on 
acute nonoccupational pesticide-related illness and injury (4). 
NCEH obtained data on acute nonoccupational pesticide 
related illness from the NIOSH Sentinel Event Notification 
System for Occupational Risks (SENSOR)–Pesticides program, 
which collects data from some states on both occupational and 
nonoccupational cases.
Each of the seven chapters in this summary presents the 
most recent statistics available to the applicable CDC program. 
Local, state, and territorial health departments and other 
agencies in their jurisdictions (e.g., departments of labor, 
environmental protection agencies, cancer registries, and 
their agents) submit data to the National Center for Chronic 
Disease Prevention and Health Promotion (NCCDPHP), 
the National Center for Emerging and Zoonotic Infectious 
Diseases (NCEZID), NCEH, and NIOSH.
CDC’s Center for Surveillance, Epidemiology, and Laboratory 
Services (CSELS) coordinated the development and publication 
of this annual summary. Comments and suggestions from 
readers on this new combined publication are encouraged, 
including ones about whether the information presented could 
be made more useful. Comments should be sent to the following 
e-mail account: NNDSSweb@cdc.gov, and display the term 
“Noninfectious Disease MMWR Report” in the subject line.
Introduction to the Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks — United States
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Background
As with nationally notifiable infectious diseases, to prevent 
and control nationally notifiable noninfectious conditions and 
disease outbreaks, public health authorities require regular, 
frequent, and timely information. A brief history of the 
reporting of nationally notifiable conditions in the United 
States is available at http://wwwn.cdc.gov/nndss/history.
html. In 1961, responsibility for collecting data on nationally 
notifiable diseases and deaths in 122 U.S. cities was transferred 
from the National Office of Vital Statistics to CDC.
CDC’s collection of data on nationally notifiable 
noninfectious conditions and disease outbreaks is based 
primarily on surveillance conducted at the local, state, and 
territorial levels by health departments and other agencies 
on reportable conditions in each jurisdiction. Legislation, 
regulation, or other rules in those jurisdictions require health 
care providers, hospitals, laboratories, and others to provide 
information on reportable conditions to public health 
authorities or their agents. The list of reportable conditions in 
each jurisdiction varies over time and across jurisdictions. More 
information is available at http://www.cste.org/?SRCA. Public 
health surveillance of noninfectious conditions and disease 
outbreaks at the local, state, and territorial levels protects 
the public’s health by ensuring the proper identification of 
conditions and health hazards. Public health officials use 
these data to monitor trends in these conditions, identify 
populations or geographic areas at high risk, plan prevention 
and control policies and other interventions, allocate resources 
effectively, coordinate activities, and assess the effectiveness of 
their efforts. Local, state, and territorial health departments 
also use these data to assist the federal government in meeting 
requirements under the International Health Regulations to 
identify, respond to, and share information about adverse 
health events that might constitute a Public Health Emergency 
of International Concern (PHEIC) (http://www.cdc.gov/
globalhealth/ihr). Health departments have agreed to report 
information about a potential PHEIC to federal agencies 
(including CDC) that have primary responsibility at the 
national level for monitoring such events. After evaluating 
whether an event constitutes a potential PHEIC, CDC notifies 
the U.S. Department of Health and Human Services (HHS). 
HHS, after further evaluation, reports potential PHEICs to 
the World Health Organization (WHO), which might declare 
the event a PHEIC. More detailed information on this process 
is found in the Summary of Notifiable Infections Diseases and 
Conditions (1) and from WHO (http://apps.who.int/iris/
bitstream/10665/43883/1/9789241580410_eng.pdf ).
A selected set of reportable conditions is designated as 
nationally notifiable. For most of these conditions, notifications 
are submitted to CDC by state, local, and territorial health 
departments. Public health officials at state, local, and territorial 
health departments and CDC collaborate in identifying 
conditions to consider for national notification. CSTE, in 
consultation with CDC, recommends revisions to the list of 
nationally notifiable conditions. Conditions are added to the 
list as new pathogens, environmental hazards, or conditions 
emerge as public health concerns. Conditions are deleted when 
surveillance is not found to be useful. Current and historic lists 
of nationally notifiable conditions and definitions used for 
classifying and counting cases consistently at the national level 
across jurisdictions are available at http://wwwn.cdc.gov/nndss. 
CDC uses these data to monitor trends at the national level, 
develop and implement programs, allocate resources, and assess 
the effectiveness of national efforts at prevention and control.
Reporting of conditions at the local, state, and territorial 
levels is mandated by legislation or regulations at those levels, 
and submission of notifications to CDC is voluntary. Under-
reporting of noninfectious conditions and disease outbreaks to 
local and state health departments occurs, and completeness 
of reporting and therefore of notification to CDC varies by 
condition (3–15).
Although the sources of data for nationally notifiable 
infectious diseases and nationally notifiable noninfectious 
conditions and disease outbreaks are the same (i.e., local, state, 
and territorial jurisdictions’ data on reportable conditions) and 
the purpose is the same (i.e., monitoring and responding to the 
condition to improve population health), there are a number of 
variations and differences among the conditions in this annual 
summary (1,3–8) (https://wwwn.cdc.gov/nndss/conditions/). 
Case-based surveillance of such nationally notifiable conditions 
as acute pesticide-related illness or injury, silicosis, and cancer 
is focused on detecting persons who have a condition that 
meets the criteria specified in national disease-specific case 
definitions and on collecting information about those persons’ 
conditions. In contrast, surveillance of outbreaks of foodborne 
and waterborne illness seeks to identify clusters of sick persons 
with a common exposure (as opposed to persons with a specific 
disease). Foodborne disease outbreaks are defined as two or 
more cases of similar illness resulting from common ingestion 
of a food. Waterborne disease outbreaks are defined as two or 
more cases of a similar illness resulting from common exposure 
to water or water-associated chemicals. Information is collected 
about the characteristics of the disease outbreaks, including 
data from epidemiologic and environmental investigations. 
Even among conditions for which case-based surveillance 
methods are used, substantial variation exists regarding the 
meaning of a condition. For example, for a condition such as 
elevated blood lead levels, surveillance identifies persons who 
have been exposed to a hazard on the basis of a laboratory test. 
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In contrast, for many other conditions, a diagnosis based on 
clinical and/or pathological criteria is needed to meet the case 
definition for a notification to CDC. This variability makes 
it challenging for readers to compare statistics easily across 
conditions and geographic locations.
The meaning of the date of the occurrence of the condition 
varies among the conditions. For infectious diseases, the 
meaning of the date varies across jurisdictions as well as by 
condition and might be a date of symptom or disease onset, 
diagnosis, or laboratory result; date of death; date the case 
was reported to a jurisdiction or date the case notification was 
sent to CDC; or date the criteria in the national surveillance 
case definition were met (http://wwwn.cdc.gov/nndss/
document/MMWR_Week_overview.pdf ). For cancer, as for 
some infectious diseases (including the arboviral diseases, 
tuberculosis, and human immunodeficiency virus infection 
diagnosis), the date of occurrence is the date the condition was 
diagnosed. For silicosis, the date of occurrence is the date of 
the initial report (e.g., the date of a hospital discharge report, 
clinician report, or a workers’ compensation claim). For lead 
screening test results, the date of occurrence is the date of a 
test. For disease outbreaks, the date of occurrence is the date of 
the illness onset of the first person with a case in the outbreak.
The source and definitions of race and ethnicity also vary 
over time and among conditions. For example, information 
about race and ethnicity for lead exposure is based on self-
report, whereas for cancer incidence, such information is based 
on medical records, which might or might not be based on 
self-report, or comes from matching the names of persons with 
cancer with lists of surnames for different ethnic groups or with 
tribal registries. For silicosis, race and ethnicity are based on self-
report, report from next-of-kin, or information from medical 
records. Race- and ethnicity-specific information among the 
conditions also might vary depending on differences in the 
jurisdictions’ systems for submitting notifications to CDC and 
the need to protect confidentiality of private health information.
The chapters in this summary use U.S. Census Bureau data 
sets for the denominators in the rate estimates. However, there 
is variation across the chapters in which specific U.S. Census 
Bureau data sets are used.
There are additional notable differences among the chapters 
in this annual summary concerning the criteria used by CDC 
programs to determine which case notifications are summarized 
and published in MMWR (i.e., publication criteria). For data 
on both infectious and noninfectious conditions submitted to 
CDC from the jurisdictions, the condition or disease must have 
been designated as a reportable condition in that jurisdiction 
for the year of notification to CDC. However, CDC publishes 
information on foodborne and waterborne disease outbreaks 
in this annual summary even if the condition was not on the 
jurisdiction’s reportable conditions list. Additional criteria, 
based on characteristics that define the conditions and disease 
outbreaks (http://wwwn.cdc.gov/nndss/conditions), are used 
in making a final determination on publication in this annual 
summary (Box).
BOX. Criteria defining nationally notifiable conditions and disease outbreaks used to determine whether notifications to CDC are published 
in the annual Summary of Notifiable Noninfectious Conditions and Disease Outbreaks
Condition/Outbreak Classification
Acute nonoccupational pesticide-related illness Definite, probable, possible, and suspicious
Acute occupational pesticide-related illness Definite, probable, possible, and suspicious
Cancer Confirmed
Lead exposure test results in children Confirmed
Lead exposure test results in adults Confirmed
Silicosis Confirmed
Foodborne disease outbreak Two or more cases of a similar illness resulting from the 
ingestion of the same food
Waterborne disease outbreak Two or more cases of a similar illness linked epidemiologi-
cally by time and location to exposure to water or water-
associated chemicals volatized into the air
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Data Sources
Final data for nationally notifiable noninfectious conditions 
and disease outbreaks are derived from the surveillance 
systems of the CDC Centers listed below. Requests for further 
information regarding these data should be directed to the 
appropriate Division or program:
• National Center for Chronic Disease Prevention and 
Health Promotion
 – Division of Cancer Prevention and Control
 ˏ National Program of Cancer Registries (cancer)
• National Center for Emerging and Zoonotic Infectious 
Diseases
 – Division of Foodborne, Waterborne, and Environmental 
Diseases
 ˏ Foodborne Disease Outbreak Surveillance System 
(foodborne disease outbreaks)
 ˏ Waterborne Disease and Outbreak Surveillance 
System (waterborne disease outbreaks)
• National Center for Environmental Health
 – Division of Environmental Hazards and Health Effects
 ˏ Environmental Public Health Tracking Program 
(acute nonoccupational pesticide-related illness) 
(from NIOSH Sentinel Event Notification System 
for Occupational Risks (SENSOR)–Pesticides 
Program and California Department of Pesticide 
Regulation)
 – Division of Emergency and Environmental Health 
Services
 ˏ Childhood Blood Lead Surveillance (lead exposure 
test results in children)
• National Institute for Occupational Safety and Health
 – Division of Surveillance, Hazard Evaluations, and Field 
Studies
 ˏ SENSOR-Pesticides Program (acute occupational 
pesticide-related illness)
 ˏ Adult Blood Lead Epidemiology and Surveillance 
(ABLES) Program (lead exposure test results in 
adults)
 – Respiratory Health Division
 ˏ State-Based Silicosis Surveillance (silicosis)
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Preface
CDC’s National Institute for Occupational Safety and 
Health (NIOSH) collects data on acute pesticide-related illness 
and injury reported by 12 states (California, Florida, Iowa, 
Louisiana, Michigan, North Carolina, Nebraska, New Mexico, 
New York, Oregon, Texas, and Washington). This report 
summarizes the data on illnesses and injuries arising from 
nonoccupational exposure to conventional pesticides that were 
reported during 2007–2011. Conventional pesticides include 
insecticides, herbicides, fungicides, and fumigants. They 
exclude disinfectants (e.g., chlorine and hypochlorites) and 
biological pesticides (1). This report is a part of the Summary 
of Notifiable Noninfectious Conditions and Disease Outbreaks 
— United States, which encompasses various surveillance years 
but is being published in 2016 (2). The Summary of Notifiable 
Noninfectious Conditions and Disease Outbreaks appears in the 
same volume of MMWR as the annual Summary of Notifiable 
Infectious Diseases (3). In a separate report, data on illnesses and 
injuries from occupational exposure to conventional pesticides 
during 2007–2011 are summarized (4).
Background
A pesticide is any substance or mixture of substances intended 
for preventing, destroying, repelling, or mitigating pests such 
as insects, mice and small animals, weeds, and fungi (5). Types 
of pesticides include insecticides, herbicides, and fungicides 
(5). In the United States, plant or insect growth regulators, 
defoliants, and desiccants also are referred to as pesticides (5). 
In 2007, approximately 5.1 billion pounds of pesticides were 
used in the United States; 17% (857 million pounds) were 
conventional pesticides. Of the conventional pesticides used 
in the United States during 2007, approximately 61% were 
herbicides, 15% were fumigants, 11% were insecticides, 9% 
were fungicides, and 3% were other conventional pesticides (6). 
During 2007, approximately 80% of conventional pesticide 
use in the United States was for agricultural use; 12% was for 
nonagricultural industry, commercial, or government use; and 
8% was for home and garden use (6).
Pesticides are used in agricultural, residential, recreational, 
and other settings. Nonoccupational, unintentional exposure 
to pesticides can occur from any of those uses. Persons might 
be exposed to low levels of pesticides used commonly in a 
variety of settings including homes, schools, and hospitals. 
Exposure could occur from pesticide drift or overspray from 
an airplane, tractor, or home sprayer onto persons living or 
going to school near agricultural fields or other application 
sites. Exposure could occur from consumption of contaminated 
water or food. Exposure also could occur from improper use, 
storage, or application of household pesticides such as insect 
Corresponding author: Gonza Namulanda, Division of Environmental 
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Health, CDC. Telephone: 404-488-3831; E-mail: fos0@cdc.gov.
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repellents, foggers, rodent poisons, weed killers, and mosquito 
or flea and tick control products (7).
Pesticides are toxic substances, and exposure to them can 
cause acute or chronic adverse health effects. This report 
focuses on pesticide-related illnesses and injuries from acute 
exposure events (i.e., a single, repeated, or continuous exposure 
to one or more pesticides that generally occurs for ≤8 hours) 
(8,9). U.S. poison control centers collect data on pesticide-
related illnesses and injuries from exposure calls, and upload 
them to the National Poison Data System (8). In 2013, of the 
approximately 2 million exposures that were reported to U.S. 
poison control centers, approximately 3% were attributed to 
acute exposures to pesticides (8). Pesticides were the eighth most 
frequent category of substances in poison exposures (intentional 
and unintentional combined) among children aged ≤5 years 
and the seventh most frequent category of poison exposures 
in persons aged ≥20 years (8). During 2013, a total of 15,430 
pesticide-related illnesses or injuries were documented from 
79,405 single substance pesticide exposure calls. Those results 
consisted of 13,313 minor health outcomes, 2,095 major and 
moderate health outcomes, and 22 deaths (8). Although 94% 
of the single substance pesticide exposures reported by poison 
control centers in 2013 were unintentional, 16 of the 22 deaths 
from pesticides were found to be either intentional suicide or 
the result of intentional misuse or abuse (8).
Surveillance of pesticide-related illness and injury instances 
can be used to monitor disease trends, detect disease outbreaks, 
design interventions for disease control and prevention, 
evaluate the effects of interventions, identify new pesticide-
exposure problems, and identify research needs (9,10). Since 
1987, NIOSH has provided financial and technical support 
for state-based acute pesticide-related illness and injury 
surveillance programs (i.e., the Sentinel Event Notification 
System for Occupational Risk [SENSOR]–Pesticides program) 
(9). The Environmental Protection Agency (EPA) also provides 
funding to NIOSH and three states (Florida, Louisiana, and 
North Carolina) that participate in the SENSOR-Pesticides 
program (9). All SENSOR-Pesticides program states report 
cases of acute pesticide-related illnesses and injury to NIOSH. 
However, not all of the state SENSOR-Pesticides programs 
collect data on nonoccupational exposures.
Data Sources
Among the 12 states that participate in the SENSOR-
Pesticides program, seven states (Florida, Louisiana, Michigan, 
North Carolina, New York, Oregon, and Washington) routinely 
collect information on nonoccupational pesticide-related 
illness and injury. This report summarizes data from these seven 
SENSOR-Pesticides program states. More information on the 
SENSOR-Pesticides program is available at http://www.cdc.
gov/niosh/topics/pesticides/overview.html.
State-level pesticide-related illness and injury surveillance 
programs receive case reports about pesticide-related 
illness and injury from hospitals and health care facilities, 
laboratories, regional or state poison control centers, agriculture 
departments, and affected persons or family members 
(9,11,12). Case ascertainment sources and the agencies to 
which cases are reported vary by state (12).
In Florida, health care practitioners and laboratories are 
required to report new cases of pesticide-related illness and 
injury within 24 hours of discovery (13). The Florida program 
also accepts reports from exposed person(s), witnesses, legal 
services, farmworker advocacy groups, other state agencies, 
news media representatives, and others willing to report (14). 
In Michigan, health care facilities, health care professionals, 
and Michigan’s Poison Control Center are required to provide 
reports of chemical poisonings only by request, except in cases 
of intentional or medicinal poisonings (15). The Michigan 
Department of Health and Human Services (previously known 
as the Department of Community Health) makes routine and 
broad-based requests for all unintentional pesticide-related 
illness reports. Requested reports must be provided within 
10 days. Data requests from the state to hospitals are made 
quarterly. Washington requires that physicians and other health 
professionals report pesticide-related illness and injury cases 
to the state health department. Serious or fatal poisonings in 
Washington must be reported immediately; all others must be 
reported within 3 days (16). In Louisiana, health care providers 
and poison control centers must report pesticide-related illness 
to the Louisiana Department of Health and Hospitals (17). 
New York operates a pesticide poisoning registry; physicians 
and other health care professionals are required to report 
suspected or confirmed pesticide-related illness and injury 
cases within 48 hours (18). In addition, the program receives 
reports from the two state poison control centers and pesticide 
product registrants. In North Carolina, health care providers 
must report cases of acute pesticide-related illness and injury 
resulting in death immediately to the state health department 
or state poison control center; other confirmed or suspicious 
cases must be reported within 48 hours of diagnosis (19). In 
Oregon, health care providers must report pesticide-related 
illness and injury cases to their local health department within 
24 hours (20).
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Case Definition
The SENSOR-Pesticides program case definitions for acute 
pesticide-related illness and injury and reporting details are 
described in detail elsewhere (9). A case of acute pesticide-
related illness and injury is characterized by an acute onset 
of symptoms that are dependent on the formulation of the 
pesticide product and involve one or more of the following: 
1) systemic signs or symptoms (including respiratory, 
gastrointestinal, allergic, and neurologic), 2) dermatologic 
lesions, and 3) ocular lesions (9). An illness and injury case is 
considered nonoccupational if the pesticide exposure occurred 
at some place other than the patient’s place of work (9).
State SENSOR-Pesticides programs classify pesticide-
related illness and injury cases as definite, probable, possible, 
suspicious, unlikely, insufficient information, asymptomatic, or 
unrelated. Only definite, probable, possible, or suspicious cases 
are reportable to NIOSH (9). Cases are considered definite if 
objective evidence (e.g., laboratory, clinical, or environmental 
evidence) confirms the occurrence of both an exposure and 
adverse health effects (9). A case is considered probable if there 
is objective evidence of either exposure or adverse health effects. 
A case is possible if only subjective information (e.g., self-
reported information of exposure or adverse health effects) is 
available. With respect to identifying cases as definite, probable, 
and possible, the reported health effects must be consistent with 
the known toxicology of the pesticide to which the patient was 
exposed. A case is considered suspicious if available toxicologic 
information is not sufficient (e.g., the pesticide is relatively new 
and limited human toxicologic data are available) to confirm 
a causal relationship between the exposure and the adverse 
health effects (9).
The SENSOR-Pesticides program uses standardized criteria 
to categorize the severity of acute pesticide-related illnesses 
and injuries (21). The program has four categories of severity: 
death, high severity, moderate severity, and low severity. Death 
is reported if the outcome of a pesticide-related illness or injury 
is fatal (21). High-severity illness and injury means that the 
condition is life threatening and requires treatment, usually 
hospitalization, to prevent death (21). Under this category, 
time lost from work or leisure activity might exceed 5 days. 
Permanent or long-term disability might result from this level 
of exposure (21). Moderate severity means that the person has 
systemic signs or symptoms of pesticide-related illness and 
injury and might lose 3–5 days from work or leisure-time 
activity. Although adverse effects might be prolonged, no 
permanent disability or impairment results. In low-severity 
illnesses and injuries, the person might have signs and 
symptoms of exposure (e.g., skin, eye, or upper respiratory 
irritation; headache; fever; fatigue; or dizziness). However, these 
conditions might resolve without treatment, and <3 days are 
lost from work or other activities (21).
Data Processing and Analyses
During 2007–2011, a total of 5,795 reported cases met 
the criteria for inclusion in this report. Totals and incidence 
rates of acute nonoccupational pesticide-related illness and 
injury cases were calculated by state, sex, and year. U.S. 
Census Bureau population estimates were used to calculate 
the incidence rates of pesticide-related illnesses and injury 
per 100,000 population by state, gender, and year (22). Sums 
of acute nonoccupational pesticide-related illness and injury 
cases were calculated by pesticide functional classes (i.e., 
insecticides, herbicides, fungicides, fumigants, rodenticides, 
and repellents) for the total population. Data were stratified 
by three age groups: ≤5 years, 6 to <18 years, and ≥18 years. 
The analyses determined the pesticide categories most often 
implicated in acute nonoccupational pesticide-related illnesses 
and injuries for exposure to a single substance and exposure 
to multiple substances.
Interpreting Data
For several reasons, the data provided in this report (Table 1) 
(Table 2 ) are likely to be underestimates of the actual magnitude 
of acute nonoccupational pesticide-related illness and injury. 
First, nonoccupational exposure calls reported to poison 
control centers are self-reported. State surveillance systems 
rarely capture data on persons who neither call a poison control 
center nor seek medical care (8,23,24). In addition, an exposed 
person might not link symptoms to a pesticide exposure, and 
therefore might not report it (23). Second, pesticide-related 
illnesses and injuries can be difficult to diagnose. The signs 
and symptoms of pesticide-related illnesses and injuries are 
similar to other common illnesses (e.g., upper respiratory 
illness), and some physicians might not recognize and diagnose 
pesticide-related illnesses and injuries (23). Other challenges 
in diagnosing pesticide-related illnesses and injuries include 
lack of sufficient environmental data on the exposure and a 
general lack of clinical tools to diagnose pesticide exposures 
(23). Therefore, the counts and rates presented in this report 
likely underestimate the magnitude of acute nonoccupational 
pesticide-related illnesses and injuries.
The higher incident rates of acute nonoccupational pesticide-
related illness and injury observed in Louisiana and North 
Carolina might reflect better case identification and follow-up 
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rather than a greater prevalence of illness and injuries. In 
addition, some cases not related to work might have been 
missed because NIOSH advises states to give priority to work-
related cases when staffing limitations preclude follow-up of all 
cases. Furthermore, some persons might have been identified 
incorrectly as having acute, nonoccupational pesticide-related 
illness because the signs and symptoms of pesticide-related 
illnesses and injuries are similar to those of other causes. Some 
physicians might not be familiar with the effects of pesticide 
exposures and diagnostic tests might not be available or rarely 
performed (23).
The pesticides most often implicated in acute nonoccupational 
pesticide-related illness and injury are listed (Table 3). Data 
are stratified by whether the person was exposed to a single 
substance (i.e., the active ingredient). When a person is exposed 
to a single substance, that substance likely was responsible for 
illness or injury. This might not be so for persons exposed to 
multiple substances because any of the other substances in 
the mixture might have produced the illness or injury (25). 
Pesticide products also contain solvents and other nonactive 
ingredients, some of which can produce illness (25). Because 
inert ingredients in pesticide products are almost never 
identified, attribution of illness and injury to these ingredients 
is not possible (25). This report includes only illnesses and 
injuries caused by exposure to conventional pesticides. Illnesses 
and injuries caused by chlorine, hypochlorites, and other 
disinfectants were not included because not all states track 
such illnesses (often because of resource constraints in the state 
health department) and therefore including them would have 
made the rate estimates not comparable across the seven states.
Publication Criteria
This report is limited to cases of unintentional 
nonoccupational pesticide-related illness and injury, classified 
as definite, probable, possible, or suspicious. Disinfectant-
related cases were excluded because not all state SENSOR-
Pesticides programs report these cases.
Highlights
Among the 5,795 cases of acute nonoccupational pesticide-
related illness and injury that were reported, 3,108 occurred 
among females and 2,664 occurred among males (Table 1). 
Most of cases (73%) occurred among persons aged ≥18 years, 
and 12% occurred in children aged ≤5 years (Table 2).
Florida had the highest number of cases (1,759), followed by 
North Carolina (1,547), and Louisiana (741). North Carolina 
and Louisiana had the highest incidence of cases per 100,000 
population (3.29 and 3.30, respectively), followed by Oregon 
(1.99) (Table 1).
TABLE 1. Number and incidence per 100,000 population of acute 
nonoccupational pesticide-related illness and injury cases — 
Sentinel Event Notification System for Occupational Risk–Pesticides 
program, United States, 2007–2011
Characteristic No. Population* Incidence rate†
State
Florida 1,759 93,477,327 1.88
Louisiana 741 22,423,404 3.30
Michigan 594 49,600,502 1.20
North Carolina 1,547 47,087,962 3.29
New York 346 96,552,793 0.36
Oregon 379 19,004,910 1.99
Washington 429 33,254,981 1.29
Sex§
Male 2,664 176,658,988 1.51
Female 3,108 184,742,891 1.68
Year
2007 1,141 71,179,083 1.60
2008 1,220 71,762,644 1.70
2009 1,314 72,278,541 1.82
2010 1,083 72,804,820 1.49
2011 1,037 73,376,791 1.41
* U.S. Census population estimates, summed for the years 2007–2011.
† Per 100,000 population.
§ Information on sex was not available for 23 cases (0.4%) that were excluded 
from analyses.
TABLE 2. Number and percentage of acute nonoccupational 
pesticide-related illness and injury cases, by age group, pesticide 
functional class, and illness and injury severity — Sentinel Event 













Insecticides 366 (10.0) 383 (10.5) 2,765 (75.9) 3,645 (62.9)
Herbicides 36 (6.0) 58 (9.7) 457 (76.3) 599 (10.3)
Insect 
repellents
183 (37.3) 106 (21.6) 191 (39.0) 490 (8.5)
Fumigants 14 (13.9) 8 (7.9) 77 ((76.2) 101 (1.7)
Rodenticides 23 (39.0) 3 (5.1) 33 (55.9) 59 (1.0)
Fungicides 0 4 (8.2) 38 (77.6) 49 (0.8)
Other§ 47 (11.4) 46 (11.2) 301 (73.2) 411 (7.1)
Multiple 38 (8.6) 42 (9.5) 341 (77.3) 441 (7.6)
Total 707 (12.2) 650 (11.2) 4,203 (72.5) 5,795
Severity
Low 632 (12.2) 604 (11.7) 3,716 (71.8) 5,173 (89.3)
Moderate 61 (11.2) 44 (8.1) 428 (78.5) 545 (9.4)
High 14 (19.4) 1 (1.4) 55 (76.4) 72 (1.2)
Death 0 1 (20.0) 4 (80.0) 5 (0.1)
Total 707 (12.2) 650 (11.2) 4,203 (72.5) 5,795
* Florida, Louisiana, Michigan, North Carolina, New York, Oregon, and Washington.
† Percentages might not total 100% because information on age was lacking 
for 235 cases (4%) that were excluded from analyses.
§ Includes insect growth regulators, antifouling agents, and other pesticides 
not otherwise categorized.
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Insecticides were responsible for most of the cases (63%), 
followed by herbicides (10%), and insect repellents (9%) 
(Table 2). Children aged ≤5 years comprised 39% of all 
persons with rodenticide cases and 37% of all those with insect 
repellent cases. Pyrethroids, pyrethrins, and organophosphates 
were the pesticides most often implicated in single-substance 
or multiple-substance exposures (Table 3).
Approximately 1% of all cases were fatal or had a high 
severity of illness and injury. Among the high-severity illness 
and injury cases, 19% involved children aged ≤5 years, but no 
deaths were reported for that age group (Table 2).
Children aged ≤5 years accounted for 39% of all cases from 
exposure to rodenticides and 37% of all cases from exposure 
to insect repellents. Exposure to rodenticides might be more 
common in children because rodenticide baits, which are 
designed to be attractive to animals, might be attractive to 
children. Therefore, parents should exercise caution when 
using rodenticides (e.g., store them out of sight and use them 
out of the reach of children) (26). EPA recommends reading 
and following the usage recommendations on the product 
label of insect repellents (27). EPA also recommends that 
young children should not handle or spray insect repellents 
themselves. In addition, parents should not apply these 
products to children’s hands because children frequently put 
their hands near their eyes or in their mouths (27).
Insecticides were responsible for most of the cases across all 
age groups. EPA recommends the following for the safe use 
of all pesticides, including insecticides: 1) read and follow 
the instructions on the label of the pesticide product, 2) keep 
pesticides in their original containers (do not transfer them to 
containers that someone might drink from by mistake), 3) use 
pesticides indoors only when necessary and with adequate 
ventilation, and 4) store pesticides in a locked cabinet out of 
reach of children (28).
The pesticides most often implicated in acute, 
nonoccupational pesticide-related illness and injury were 
pyrethroids and pyrethrins. When used as intended at low 
levels, the toxicity of these pesticides to humans is low (29). 
However, they can cause harm when not used as recommended 
(e.g., in larger amounts). Instructions on the product labels 
should be followed when using these pesticides.
Surveillance of acute nonoccupational pesticide-related 
illness and injury provides some information on pesticide-
related mortality and morbidity incidence and on the pesticides 
primarily implicated in illness and injury. Obtaining a more 
in-depth occupational and environmental exposure history 
(e.g., occupation, name of pesticide product, intended use 
of pesticide, amount of pesticide exposed to, and route of 
exposure) in the several settings where these cases are identified 
could improve identification of pesticide-related illness and 
injury cases and the pesticide(s) implicated (23,30).
References
 1. Environmental Protection Agency. Conventional pesticide registration. 
Washington, DC: Environmental Protection Agency; 2015. https://www2.
epa.gov/pesticide-registration/conventional-pesticide-registration
 2. CDC. Summary of notifiable noninfectious conditions and disease 
outbreaks—United States. MMWR Morb Mortal Wkly Rep 2014;63(55).
 3. CDC. Summary of notifiable infectious diseases and conditions—United 
States, 2014. MMWR Morb Mortal Wkly Rep 2014;63(54).
 4. Calvert GM, Orielb M, Beckmanc J, et al. Acute occupational pesticide-
related illness and injury—United States, 2007–2011. In: CDC. 
Summary of notifiable noninfectious conditions and disease outbreaks— 
United States. MMWR Morb Mortal Wkly Rep 2014;63(55):11–6.
 5. Environmental Protection Agency. About pesticides. Washington, DC: 
Environmental Protection Agency; 2015. https://www2.epa.gov/pesticides
 6. Grube A, Donaldson D, Kiely T, Wu L. Pesticide industry sales and 
usage: 2006 and 2007 market estimates. Washington, DC: Environmental 
Protection Agency; 2011.
 7. National Pesticide Information Center. Pesticides and human health. 
Corvallis, OR: National Pesticide Information Center; 2014. http://
npic.orst.edu/health/humhealth.html
 8. Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 
annual report of the American Association of Poison Control Centers’ 
National Poison Data System (NPDS): 31st annual report. Clin Toxicol 
(Phila) 2014;52:1032–283. http://dx.doi.org/10.3109/15563650.201
4.987397
TABLE 3. Number of cases of acute nonoccupational pesticide-related 
illness and injury, by pesticides most often implicated —Sentinel 












Pyrethroids Insecticide 1,168 1,541 2,709
Pyrethrins Insecticide 322 600 922
Organophosphates Insecticide 282 280 562
Glyphosate Herbicide 171 128 299
Carbamates Insecticide 181 84 265
Naphthalene Insect repellent 135 27 162
Triazines Herbicides 37 18 55
Imidacloprid Insecticide 0 88 88
Fipronil Insecticide 16 95 111
Phosphorus Fumigant 8 0 8




Dipyridyls Herbicide 20 65 85
Pyraclostrtrobin Fungicide 1 5 6
Chloropicrin Fumigant 10 5 15
Organochlorines Insecticides 13 18 31
All other 829 661 1,490
Total 3,258 2,537 5,795
* Florida, Louisiana, Michigan, North Carolina, New York, Oregon, and Washington
† Pesticide active ingredient.
§ Pesticide categories are not mutually exclusive for multiple exposures. Case 
counts for persons exposed to multiple substances are included in the totals 
of more than one pesticide category. Therefore, the sum of all case counts 
(6,943) exceeds the total number of exposed persons (5,795).
Morbidity and Mortality Weekly Report
10 MMWR / October 14, 2016 / Vol. 63 / No. 55 US Department of Health and Human Services/Centers for Disease Control and Prevention
 9. CDC. Pesticide-related illness and injury surveillance: a how-to guide 
for state based programs. Cincinnati, OH: US Department of Health 
and Human Services, Public Health Service, CDC, National Institute 
for Occupational Safety and Health; 2005. http://www.cdc.gov/niosh/
docs/2006-102
 10. Osorio AM. Surveillance for pesticide-related disease. J Agromed 
2007;12:57–66. http://dx.doi.org/10.1300/J096v12n01_06.
 11. Council of States and Territorial Epidemiologists. State reportable 
conditions assessment: toxic effects of pesticides, by state. Atlanta, GA: 
Council of States and Territorial Epidemiologists; 2010. http://www.
cste2.org/izenda/ReportViewer.aspx?rn=Condition+All&p1value=201
0&p2value=Toxic%20effects%20of%20pesticides
 12. Migrant Clinicians Network. Pesticide reporting and workers 
compensation map. Austin, TX: Migrant Clinicians Network; 2014. 
www.migrantclinician.org/issues/occupational-health/pesticides/
reporting-illnesses.html
 13. Florida Department of State. Florida Administrative Code and Florida 
Administrative Register Rule 64D-3.029. Tallahassee, FL: Florida 
Department of State; 2010. https://www.flrules.org/gateway/ruleno.
asp?id=64D-3.029&Section=0
 14. Florida Department of Health. Pesticide poisoning. Tallahassee, FL: 
Florida Department of Health. http://www.floridahealth.gov/
environmental-health/pesticide-poisoning/index.html
 15. Michigan Department of Community Health. Reporting of non-suicidal, 
non-medicinal chemical poisonings (R 325.71–5). Lansing, MI: 
Michigan Department of Community Health, Bureau of Epidemiology, 
Division of Environmental Health; 2010. http://w3.lara.state.mi.us/orr/
files/admincode/324_10302_admincode.pdf
 16. Washington State Legislature. WAC 246-101-101: Notifiable conditions 
and the health care provider. http://app.leg.wa.gov/wac/default.
aspx?cite=246-101-101
 17. Louisiana Department of Health and Hospitals. Pesticide surveillance 
program. Baton Rouge, LA: Louisiana Department of Health and 
Hospitals; 2008. http://new.dhh.louisiana.gov/index.cfm/page/836
 18. New York State Department of Health. Pesticide Poisoning Registry: 
recognizing and reporting pesticide-related illnesses and injuries. Albany, 
NY: New York State Department of Health; 2014. http://www.health.
ny.gov/environmental/workplace/pesticide_poisoning_registry/
pesticide_poisoning_registry_presentation.htm
 19. North Carolina Department of Health and Human Services. Pesticides 
and health: reporting illnesses and injuries. Raleigh, NC: North Carolina 
Department of Health and Human Services; 2014. http://epi.
publichealth.nc.gov/oee/pest/reporting.html
 20. Oregon Health Authority. What to do if you are exposed to pesticides. 
Portland, OR: Oregon Health Authority, Public Health Division; 2014. 
h t tp : / /pub l i c .h e a l th .o regon .gov /hea l thyenv i ronment s /
healthyneighborhoods/pesticides/Pages/index.aspx
 21. CDC. Severity index for use in state-based surveillance of acute pesticide-
related illness and injury. Atlanta, GA: US Department of Health and 
Human Services, CDC; 2001. http://www.cdc.gov/niosh/topics/
pesticides/pdfs/pest-sevindexv6.pdf
 22. US Census Bureau. Population estimates. Washington, DC: US Census 
Bureau; 2015. http://www.census.gov/popest
 23. Environmental Protection Agency. Recognition and management of 
pesticide poisonings. 6th ed. Washington, DC: Environmental Protection 
Agency, Office of Pesticide Programs; 2013. https://www2.epa.gov/
pesticide-worker-safety/recognition-and-management-pesticide-poisonings
 24. Calvert GM, Mehler LN, Alsop J, De Vries AL, Besbelli N. Surveillance 
of pesticide-related illness and injury in humans. In: Krieger RI, ed. 
Hayes’ handbook of pesticide toxicology. 3rd ed. New York, NY: Elsevier; 
2010:1313–69.
 25. Calvert GM, Beckman J, Prado JM, et al. Acute occupational pesticide-
related illness and injury—United States, 2007–2010. In: CDC. 
Summary of notifiable noninfectious conditions and disease outbreaks—
United States. MMWR Morb Mortal Wkly Rep 2013;62(54):5–9.
 26. CDC. Pesticide exposures: rodenticides. Atlanta, GA: US Department 
of Health and Human Services, CDC; 2014. http://ephtracking.cdc.
gov/showpesticideRodenticides.action
 27. Environmental Protection Agency. Using insect repellents safely 
and effectively. Washington, DC: Environmental Protection 
Agency ;  2015.  ht tps : / /www2.epa .gov/ insec t - repe l l ent s /
using-insect-repellents-safely-and-effectively
 28. Environmental Protection Agency. Citizen’s guide to pest control and 
pesticide safety. Washington, DC: Environmental Protection Agency; 
2005. https://www2.epa.gov/sites/production/files/2014-04/documents/
citizens_guide_to_pest_control_and_pesticide_safety.pdf
 29. Agency for Toxic Substances and Disease Registry. Toxicological profile 
for pyrethrins and pyrethroids. Atlanta, GA: US Department of Health 
and Human Services, Agency for Toxic Substances and Disease Registry, 
CDC; 2003.
 30. A National Environmental Education and Training Foundation. National 
pesticide practice skills guidelines for medical and nursing practice. 
Washington, DC: National Environmental Education and Training 
Foundation; 2003.
Morbidity and Mortality Weekly Report
MMWR / October 14, 2016 / Vol. 63 / No. 55 11US Department of Health and Human Services/Centers for Disease Control and Prevention
Preface
CDC’s National Institute for Occupational Safety and 
Health (NIOSH) collects data on acute pesticide-related 
illness and injury reported by 12 states (California, Florida, 
Iowa, Louisiana, Michigan, Nebraska, North Carolina, New 
Mexico, New York, Oregon, Texas, and Washington). This 
report summarizes the data on illnesses and injuries arising 
from occupational exposure to conventional pesticides from 
2007 through 2011. This report is a part of the Summary of 
Notifiable Noninfectious Conditions and Disease Outbreaks — 
United States, which encompasses various surveillance years 
but is being published in 2016 (1). The Summary of Notifiable 
Noninfectious Conditions and Disease Outbreaks appears in the 
same volume of MMWR as the annual Summary of Notifiable 
Infectious Diseases (2). In a separate report, data on illnesses and 
injuries from nonoccupational exposure to pesticides during 
2007–2011 are summarized (3).
Background
Pesticides are substances or mixtures of substances intended to 
prevent, destroy, repel, or mitigate pests (pests include insects, 
rodents, fungi, and weeds). In 2007, the year with the most 
currently available data, an estimated 2.1 billion pounds of 
conventional pesticides were used in the United States (4), which 
represents approximately 22% of the entire worldwide use of 
these pesticides. Conventional pesticides include insecticides, 
insect repellents, herbicides, fungicides, and fumigants and 
exclude chlorine, hypochlorites, and other biocides.
The benefits of pesticides are well recognized and primarily 
include their role in protecting the food supply and in 
controlling disease vectors (5). However, no form of pest 
control using pesticides is perfectly safe. Tracking the associated 
health effects of pesticides can help ensure that no pesticides 
pose an unreasonable burden (6). For this reason, public health 
surveillance of acute pesticide-related illness and injury serves a 
vital societal role by assessing the magnitude and characteristics 
of such illness and injury. Surveillance of acute pesticide-related 
illness and injury has been endorsed by several professional 
organizations and federal agencies including the American 
Medical Association (7), the Council of State and Territorial 
Epidemiologists (8), NIOSH (9) and the U.S. Government 
Accountability Office (10).
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Pesticide products must pass an extensive battery of testing 
prior to being registered by the Environmental Protection 
Agency (EPA). This testing forms the basis for the human 
health and environmental risk assessments conducted by 
EPA that guide identification of the conditions under which 
a pesticide can be used. These conditions of use are reflected 
in pesticide product labeling. Compliance with these use 
conditions is expected to prevent unreasonable adverse effects 
to human health and the environment. To verify the real-
world effectiveness of pesticide product labeling in preventing 
adverse human health effects, EPA reviews findings from acute 
pesticide-related illness and injury surveillance systems. These 
surveillance data assist EPA in determining whether labeling is 
effective or if labeling improvements are needed. When health 
effects occur despite adherence to label instructions, and EPA 
determines the magnitude to be unreasonable, EPA requires 
that interventions be instituted that involve changing pesticide 
use conditions and/or modifying regulatory measures (11). 
Acute pesticide-related illness and injury also can occur because 
of lack of compliance with existing pesticide regulations. The 
appropriate interventions for these cases include enhanced 
training and enforcement.
Data Sources
Acute occupational pesticide-related illness and injury is 
one of several conditions under surveillance by NIOSH. In 
1987, NIOSH established the Sentinel Event Notification 
System for Occupational Risks (SENSOR)–Pesticides program 
to track pesticide-related illness and injury in the United 
States. Detailed information on this program is available at 
http://www.cdc.gov/niosh/topics/pesticides/overview.html. 
During 2007–2011, a total of 12 states (California, Florida, 
Iowa, Louisiana, Michigan, Nebraska [2011 only], North 
Carolina, New Mexico [2007–2008 only], New York, Oregon, 
Texas, and Washington) participated in the SENSOR-
Pesticides program. All 12 states that participate in the 
SENSOR-Pesticides program require physicians to report 
confirmed and suspected cases of pesticide-related illness 
and injury to state health authorities. Besides identifying, 
classifying, and tabulating pesticide poisoning cases, states 
periodically perform in-depth investigations of pesticide-
related events, and develop interventions aimed at particular 
industries or pesticide hazards.
Case ascertainment sources used by the state programs include 
poison control centers, specific government agencies (e.g., a 
state’s Department of Agriculture), workers’ compensation 
documents, and physician reports. In some states, there are 
other sources that infrequently identify cases (e.g., medical 
record reviews, news reports, and reports from worker 
representatives) (12). Staff from some state surveillance 
programs attempt to interview persons to obtain more details 
about the event. All states use standardized variables to code 
available information about a case systematically (12).
Persons are considered to have an occupational pesticide-
related illness or injury if they became ill or injured soon 
(i.e., within seconds to hours) after exposure to one or more 
pesticides. An illness and injury is considered occupational if 
the pesticide exposure occurred at the person’s place of work. 
Agricultural cases are defined as cases among persons employed 
in an industry with one of the following codes: agricultural 
production, excluding livestock (1990 Census Industry Code 
[CIC]: 010; 2002 CIC: 0170); agricultural production, 
including livestock (1990 CIC: 011; 2002 CIC: 0180); and 
agricultural services (1990 CIC: 030; 2002 CIC: 0290). All 
other occupational cases with known industry are defined as 
“nonagricultural” cases.
The SENSOR-Pesticides case definition has been described 
in detail elsewhere (12). The definition requires information 
about pesticide exposure and health effects, which is compared 
with the known toxicology of the pesticide. Cases are 
categorized as definite, probable, possible, and suspicious on 
the basis of the level of detail known for each case. Cases are 
defined as definite exclusively on the basis of objective data 
about exposure and health effects (e.g., residues were measured 
to confirm exposure, and health effects were observed by the 
examining clinician). Cases are defined as probable on the basis 
of a mix of objective and self-reported data. Cases are defined as 
possible on the basis of self-reported exposure and health effects 
data. With respect to definite, probable, and possible cases, the 
reported health effects are consistent with the known toxicology 
of the pesticide that the case was exposed to. Suspicious cases 
arise when toxicologic information is insufficient to determine 
a causal relationship between pesticide exposure and illness, 
often because the given pesticide is relatively new and limited 
toxicologic data involving humans exist. Often reports of illness 
and injury cannot be categorized as definite, probable, possible, 
or suspicious because insufficient information is available 
about the circumstances of the exposure event or because 
available evidence suggests that the pesticide exposure either 
was unrelated to or was unlikely to have caused the observed 
health effects. Such exposures are not included in the analysis 
of confirmed illness and injury cases provided in this report.
Illness and injury severity was categorized into four groups 
using standardized criteria for state-based surveillance programs 
(12). In low-severity cases, the condition usually resolves 
without treatment and <3 days are lost from work. In moderate-
severity cases, the condition is not life threatening but requires 
medical treatment. No residual impairment is expected, and 
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time lost from work is ≤5 days. In high-severity cases, the 
condition is life threatening, requires hospitalization, often 
has >5 days lost from work, and might result in permanent 
impairment. Fatal cases of pesticide poisoning were placed in 
a separate category.
To calculate incidence rates (IRs) of acute occupational 
pesticide-related illness and injury, CDC obtained denominator 
data (i.e., hours worked) from the Current Population Survey 
(CPS) (13). The hours worked data were used to derive full 
time equivalent (FTE) estimates, with one FTE equal to 2,000 
hours worked. Denominator data correspond to the states and 
time periods of numerator availability.
This report includes only acute pesticide-related illness and 
injury arising from occupational exposures. Furthermore, 
12 occupational cases involving exposures with suicidal or 
homicidal intent were excluded. During 2007–2011, of the 
8,383 cases reported to SENSOR-Pesticides not involving 
suicidal or homicidal intent, 2,606 (31%) were from 
occupational exposures and are included in the analyses.
Interpreting Data
For multiple reasons, the data provided in this report 
(Table 1) (Table 2) are likely to be underestimates of the actual 
magnitude of acute occupational pesticide-related illness and 
injury (14). Many cases of pesticide-related illness or injury 
never are ascertained because affected persons neither seek 
medical care, nor call appropriate authorities. Furthermore, 
because the signs and symptoms of acute pesticide-related 
illnesses are not pathognomonic, and because most health 
care professionals are not acquainted with the recognition 
and management of these illnesses, many persons who seek 
medical care might not receive an accurate diagnosis (15). Even 
among those who do receive an accurate diagnosis, many cases 
are not reported to state surveillance systems, despite the fact 
that each of the participating states has mandatory reporting 
of occupational pesticide-related illness and injury (6). For 
these reasons, the reported counts and rates provided in this 
report must be considered minimum estimates. In contrast, 
some persons might have been categorized incorrectly as having 
TABLE 1. Distribution of cases of acute occupational pesticide-related illness and injury, FTE estimates, and incidence rates per 100,000 FTEs, 
by industrial sector, state, sex, and year of exposure — Sentinel Event Notification System for Occupational Risk–Pesticides program, United 
States, 2007–2011
Characteristic
Industrial Sector (CIC codes)
All Agricultural (010–030) Nonagricultural (all other codes)
No.* FTE estimates† Incidence rate§ No. FTE estimates† Incidence rate§ No. FTE estimates† Incidence rate§
State¶
California 858 77,468,156 1.1 306 1,529,999 20.0 483 75,938,157 0.6
Florida 171 40,035,419 0.4 13 222,155 5.9 87 39,823,264 0.2
Iowa 170 7,447,061 2.3 88 344,047 25.6 22 7,103,014 0.3
Louisiana 98 9,394,549 1.0 14 85,432 16.4 40 9,309,117 0.4
Michigan 190 20,083,617 0.9 23 287,402 8.0 153 19,796,215 0.8
Nebraska 22 920,350 2.4 6 61,932 9.7 1 858,418 0.1
New Mexico 9 1,767,303 0.5 0 47,773 0 4 1,719,530 0.2
New York 38 42,269,131 <0.1 5 219,275 2.3 20 42,049,856 <0.1
North Carolina 168 19,837,941 0.8 49 216,678 22.6 103 19,621,263 0.5
Oregon 55 8,253,984 0.7 8 281,245 2.8 28 7,972,739 0.4
Texas 363 54,490,716 0.7 25 882,039 2.8 276 53,608,677 0.5
Washington 464 14,786,285 3.1 296 308,556 95.9 160 14,477,729 1.1
Sex**
Male 1,734 169,412,691 1.0 631 3,550,759 17.8 823 165,861,932 0.5
Female 864 127,351,821 0.7 202 935,774 21.5 550 126,416,047 0.4
Year
2007 637 61,979,631 1.0 210 876,815 24.0 334 61,102,816 0.5
2008 555 61,751,566 0.9 202 909,306 22.2 288 60,842,260 0.5
2009 431 57,059,520 0.8 125 831,358 15.0 261 56,228,162 0.5
2010 462 57,295,585 0.8 139 883,451 15.7 249 56,412,134 0.4
2011 521 58,678,210 0.9 157 985,603 15.9 245 57,692,607 0.4
Total 2,606 296,764,512 0.9 833 4,486,533 18.6 1,377 292,277,979 0.5
Abbreviations: CIC codes = Bureau of the Census industry codes; FTE = full-time equivalent.
 * For 396 cases (15%), information on industry was missing.
 † The full-time equivalent (FTE) estimates were derived from the hours worked data obtained from the Current Population Survey (CPS) and summed for the years 
2007 through 2011 (9). One FTE equals 2,000 hours worked. Denominator data corresponds to the states and time periods of numerator availability.
 § Incidence rate per 100,000 FTEs.
 ¶ All states provided data for 2007–2011 except Nebraska (2011 only) and New Mexico (2007 and 2008 only). The summed FTE estimates include only the years for 
which there are case data.
 ** For eight cases, information about sex was missing.
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acute occupational pesticide-related illness because symptoms 
for acute illnesses associated with pesticides are nonspecific 
and not pathognomonic, and diagnostic tests are either not 
available or rarely performed. In addition, rates of pesticide 
illness and injury might have been affected by inaccurate 
estimates of the agricultural industry population. Many 
workers in this industry are difficult to count because of the 
transient employment of seasonal and migrant farmworkers 
and because workers with undocumented U.S. immigration 
status tend to avoid government contact (16). In addition, 
many agricultural workers have more than one job, and one 
of these other jobs not involving farming might be the one 
at which they work the greatest part of the day (17). Because 
CPS employment estimates include only the one job at 
which the worker worked the largest number of hours, some 
persons employed in agriculture might not be included in the 
agricultural employment estimates (18). Furthermore, the 
denominator inaccuracies might vary across states because 
some states might be more likely to have agricultural workers 
whose usual residence is elsewhere. Agricultural workers are 
not included in the CPS population estimates of those states 
in which they reside only temporarily (18).
Although the incidence rates for acute occupational 
pesticide-related illness and injury were highest in Washington, 
this finding might not necessarily mean that pesticide exposures 
are more hazardous or more prevalent in that state. Washington 
has stronger protections for agricultural workers and a larger 
and more robust pesticide illness and injury surveillance 
program when compared to other states, which likely accounts 
for some of the differences in incidence rates. As an example 
of stronger worker protections, Washington gives farmworkers 
the right to organize and bargain collectively, and requires 
cholinesterase monitoring for some pesticide handlers (6). 
These protections might make farmworkers in Washington less 
hesitant to seek medical care for pesticide illness and injury. 
In addition, Washington has a larger number of surveillance 
program staff (3.75 full-time equivalents [FTEs] versus an 
average of 1.3 FTEs in other states), and all but one are 
bilingual Spanish/English speakers. The odds of identifying 
agricultural worker cases might be improved when surveillance 
programs have a bilingual staff of ample size, as agricultural 
workers are often Spanish-speaking (19). Although workers’ 
compensation systems can be an important source of case 
reports, only two states (Washington and California) received 
reports from this source between 2007 and 2011. The workers’ 
compensation system can be an especially useful reporting 
source when it is organized as in Washington. For example, 
the Washington workers’ compensation system covers the 
first visit for any suspected work-related illness or injury, even 
if the illness or injury is determined not to be work-related. 
In so far as is known, this benefit does not exist in any other 
state. In addition, unless Washington employers are able to 
self-insure, workers’ compensation insurance is provided by 
an exclusive state-fund operated by the Washington State 
Department of Labor and Industries. No other private workers’ 
compensation insurers exist in the state. This avoids problems 
that can occur in other states when state authorities either do 
not receive or incorrectly process information from private 
workers’ compensation insurers. No other SENSOR-Pesticides 
state provides workers’ compensation insurance through an 
exclusive state-funded program. For all these reasons, case 
estimates might be more accurate for Washington than for 
other states, although even the Washington estimates likely 
underestimate the actual level of occupational pesticide-related 
illness and injury.
The pesticides most often implicated in acute occupational 
pesticide-related illness and injury are listed (Table 3). Data 
are stratified by whether the affected person was exposed to 
a single substance (i.e., a pesticidal active ingredient). When 
affected persons were exposed to a single substance, it is very 
likely that that substance was responsible for illness or injury. 
However, this might not be so for persons who were exposed 
to multiple substances because one of the other substances 
might have produced the illness or injury. Furthermore, 
pesticide products also contain solvents and other nonactive 
ingredients, some of which might produce illness. Because the 
TABLE 2. Distribution of cases of acute occupational pesticide-related 
illness and injury by industrial sector, pesticide functional class and 
illness and injury severity— Sentinel Event Notification System for 
Occupational Risk–Pesticides program, United States, 2007–2011
Characteristic






No. (%) No. (%) No. (%)
Pesticide functional class
Insecticides 912 (35) 207 (25) 526 (38)
Herbicides 464 (18) 146 (18) 246 (18)
Fungicides 129 (5) 82 (10) 36 (3)
Fumigants 229 (9) 73 (9) 135 (10)
Insecticides and 
fungicides
179 (7) 128 (15) 37 (3)
Other * 401 (15) 49 (6) 291 (21)
Multiple† 292 (11) 148 (18) 106 (8)
Severity category
Low 2,093 (80) 665 (80) 1,105 (80)
Moderate 479 (18) 153 (18) 257 (19)
High and death 34 (1) 15 (2) 15 (1)
Total 2,606 833 1,377
Abbreviation: CIC = Bureau of the Census industry codes.
* This category includes plant growth regulators, insect growth regulators, wood 
treatment products, preservatives and insect repellants.
† Exposed to pesticide products that were classified into more than one 
functional class, or to more than one pesticide product with each having a 
different functional class.
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identity of nonactive ingredients present in pesticide products 
is almost never available, attribution of illness and injury to 
these ingredients is rarely possible. In addition, only illnesses 
and injuries caused by exposure to conventional pesticides 
were included in this report. Illnesses and injuries caused 
by chlorine, hypochlorites, and other disinfectants are not 
included in this report because not all states capture such 
illnesses (often because of resource constraints in the state 
health department) and therefore including them would have 
made the rate estimates not comparable across the 12 states.
Publication Criteria
Cases met the print criteria if the affected person had 
confirmed acute occupational pesticide-related illness or injury, 
the person was exposed to conventional pesticides, the pesticide 
exposure occurred at the person’s place of work, no suicidal 
or homicidal intent was associated with the exposure, and the 
illness occurred during January 1, 2007–December 31, 2011.
Highlights
During 2007–2011, a total of 2,606 cases of acute 
occupational pesticide-related illness and injury were identified 
in 12 states (Table 1). Rates of illness and injury among 
agricultural industry workers (18.6/100,000) were 37 times 
greater than the rates for nonagricultural workers (0.5/100,000). 
Rates were found to be highest in Washington. Most affected 
persons were exposed to insecticides or herbicides (Table 2). 
Among persons exposed to insecticides, the chemical classes 
most often involved were pyrethroids, organophosphates, 
sulfur compounds, and pyrethrins (Table 3). Among persons 
exposed to herbicides, the specific herbicides most commonly 
involved were glyphosate and the dipyridyls (i.e., paraquat and 
diquat). A total of 80% of cases were classified as low severity, 
18% were moderate severity, and 1% were high severity. Two 
affected persons died.
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Preface
This report provides, in tabular and graphic form, official 
federal statistics on the occurrence of cancer for 2012 and 
trends for 1999–2012 as reported by CDC and the National 
Cancer Institute (NCI) (1). Cancer incidence data are from 
population-based cancer registries that participate in CDC’s 
National Program of Cancer Registries (NPCR) and NCI’s 
Surveillance, Epidemiology, and End Results (SEER) program 
reported as of November 2014. Cancer mortality data are from 
death certificate information reported to state vital statistics 
offices through 2012 and compiled into a national file for the 
entire United States by CDC’s National Center for Health 
Statistics’ (NCHS) National Vital Statistics System (NVSS). 
This report is a part of the Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks — United States, which 
encompasses various surveillance years but is being published in 
2016 (2). The Summary of Notifiable Noninfectious Conditions 
and Disease Outbreaks appears in the same volume of MMWR 
as the annual Summary of Notifiable Infectious Diseases (3).
This report presents information on new cancer cases and 
deaths for 2012. The number and rate of cancer cases and 
deaths are stratified by the primary cancer sites as reported for 
2012; information is provided by demographic characteristic 
(e.g., sex, age, race, and ethnicity) and primary cancer site 
(68 selected sites among men and 72 selected sites among 
women). Age-adjusted cancer incidence and death rates are 
shown by primary site and year for the period 1999–2012. Age-
adjusted cancer incidence and death rates for the most common 
sites are shown by race, sex, and ethnicity for 2012, the most 
recent year for which incidence data are available. Maps of the 
United States display age-adjusted cancer incidence and death 
rates, presented by quartiles, for 2012. Time trends in age-
adjusted cancer incidence and death rates during 1999–2012 
are shown by race, sex, and ethnicity for all sites combined, 
colorectal, lung and bronchus, prostate, and female breast.
Background
Cancer comprises a diverse mix of diseases occurring in every 
part of the body and is a leading cause of death in the United 
States (4). More than half of cancer cases could be prevented 
(5). Surveillance of cancer incidence and mortality can help 
public health officials target areas for control efforts (6) and 
track progress toward meeting the national health objectives 
set forth in Healthy People 2020 (7). Cancer is a reportable 
disease in every state and thus all hospitals, physicians’ 
offices, pathology laboratories, and other medical facilities are 
required to submit data on all reportable cancer diagnoses to a 
central cancer registry at the state or territorial level. A cancer 
registry is a database that contains individual records of all 
reportable cancer cases in a defined population and includes 
patient demographics, tumor characteristics (e.g., cancer site 
and pathology), and information about the notifying health 
provider or facility. In 1992, Congress established NPCR by 
enacting the Cancer Registries Amendment Act (Public Law 
102-515) (8). Administered by CDC, NPCR collects data on 
the occurrence of cancer and the type, extent, and location of 
the cancer. Before NPCR was established, 10 states had no 
registry, and most states with registries lacked the resources and 
state legislation needed to gather complete data (9). Presently, 
NPCR supports central cancer registries in 45 states, the 
District of Columbia (DC), Puerto Rico, and the U.S. Pacific 
Island Jurisdictions. NPCR data represent 96% of the overall 
U.S. population. Together, NPCR and NCI’s SEER Program 
collect data for the entire U.S. population. Cancer control 
planners and others can identify variations in cancer rates by 
population subgroups and monitor trends over time to guide 
the planning and evaluation of cancer prevention and control 
programs and allocation of health resources.
Data Sources
Data about cancer incidence and mortality in the Summary of 
Notifiable Noninfectious Conditions and Disease Outbreaks come 
from the official federal statistics on cancer, the U.S. Cancer 
Statistics (USCS) dataset (1). The USCS dataset includes 
cancer incidence data from NPCR registries in 45 states and 
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DC (cancer incidence data from Puerto Rico and the U.S. 
Pacific Island Jurisdictions were not available for this analysis) 
and from SEER program registries in the remaining five states 
(Connecticut, Hawaii, Iowa, New Mexico, and Utah) and 
cancer mortality data from NVSS.
Incidence Data
The primary source of data on cancer incidence is medical 
records. Staff at health care facilities abstract data from 
patients’ medical records, enter it into the facility’s own cancer 
registry if it has one, and then send the data to the regional 
or state registry. Both NPCR and SEER registries collect data 
using uniform data items and codes as documented by the 
North American Association of Central Cancer Registries 
(NAACCR). This uniformity ensures that data items 
collected by the two federal programs are comparable (10,11). 
Information on primary site and histology is coded according 
to the International Classification of Diseases for Oncology, 
Third Edition (ICD-O-3) and categorized according to the 
revised SEER recodes dated January 27, 2003, which define 
standard groupings of primary cancer sites (http://seer.cancer.
gov/siterecode) (12). Beginning with 2010 diagnoses, cases 
were first classified by anatomic site using ICD-O-3; cases 
with hematopoetic histologies were further classified by using 
the 2008 WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues (13). Data from the NPCR registries 
provided in this report were reported to CDC as of November 
30, 2014. Data from SEER registries were reported to NCI as 
of November 1, 2014.
NPCR and SEER cancer registries consider as reportable all 
incident cases with a behavior code of 2 (in situ, noninvasive) 
or 3 (malignant, primary site only) in ICD-O-3. Exceptions 
include in situ cancer of the cervix and all basal and squamous 
cell carcinomas of the skin, except for those on the skin of the 
genital organs (12). Beginning with 2001 diagnoses, several 
cancers that are coded as malignant in ICD-O-3 were not 
coded as malignant in ICD-O-2 (10). Additional information 




Cancer mortality statistics are based on information from all 
death certificates filed in the 50 states and DC and processed 
by NVSS at NCHS (14). The cancer mortality data were 
compiled in accordance with World Health Organization 
regulations, which specify that member nations classify and 
code causes of death in accordance with the current revision 
of the International Classification of Diseases (ICD) (15). For 
consistency with the data on cancer incidence, the cancer sites 
in mortality data were grouped according to the revised SEER 
recodes dated January 27, 2003 (available at http://seer.cancer.
gov/codrecode). Data for a specific calendar year are based on 
records of deaths that occurred during that calendar year and 
received by a particular date; for example, mortality data for 
2012 are based on records of deaths that occurred during 2012 
and were received as of June 30, 2014. Additional information 




Population denominators are race-specific, ethnicity-specific, 
and sex-specific county population estimates from the U.S. 
Census, modified by SEER and aggregated to the state and 




Each year, state cancer registries submit cancer cases for a 
new diagnosis year and an updated version of the previous 
years’ cancer cases to CDC or NCI. Therefore, each year, when 
USCS data are published, updates to the previous year’s data 
are published, using the most recent data submission and the 
most recent population data. Users of cancer incidence data 
published by federal agencies should be mindful of the data 
submission dates for all data used in their analyses.
Mortality Data
Cancer mortality statistics in USCS are influenced by the 
accuracy of information on the death certificate. Unlike 
incidence data, mortality data for a calendar year are considered 
complete when submitted and so are not updated after the 
aggregate data file is released. Mortality data for the entire 
United States refer only to deaths that occurred within the 
United States; data for geographic areas are provided by the 
decedent’s place of residence.
Race and Ethnicity Data
For cancer incidence, race and ethnicity data are abstracted 
from medical records and grouped into categories (11). When 
cancer mortality is reported, race and ethnic origin are recorded 
separately on the death certificate by the funeral director as 
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provided by an informant or, in the absence of an informant, 
on the basis of observation (16).
Differences in rates among racial and ethnic populations 
should be interpreted with caution. A study using SEER 
incidence data suggests that the quality of data on race in 
cancer registries is considered excellent for whites, blacks, 
and Asians/Pacific Islanders, good for Hispanics, and poor 
for American Indians/Alaska Natives (17). Previous studies 
involving cancer mortality data demonstrate that death rates 
for whites and blacks generally are estimated accurately whereas 
death rates for Asians/Pacific Islanders, American Indians/
Alaska Natives, and Hispanics are underestimated (18). For 
this reason, incidence and mortality data provided in this report 
might be underestimated for these groups, possibly because of 
misclassification of race or Hispanic ethnicity.
Three NPCR registries (Delaware, Kentucky, and South 
Carolina) opted not to present state-specific Asian/Pacific 
Islander counts and rates. Five NPCR registries (Delaware, 
Kentucky, Massachusetts, Pennsylvania, and South Carolina) 
opted not to present state-specific Hispanic (classified by the 
NAACCR Hispanic Identification [NHIA] Algorithm) counts 
and rates (19). Cancer registries regularly link their database 
to the Indian Health Service patient registration dataset to 
reduce misclassification of race for American Indian/Alaska 
Native cases. Seven NPCR registries (Delaware, Illinois, 
Kansas, Kentucky, New Jersey, New York, and South Carolina) 
opted not to present state-specific American Indian/Alaska 
Native counts and rates. However, in each of these cases, the 
aggregate national rates presented in this report include data 
for these registries.
Methods for Identifying Cancer
Medical facilities such as hospitals, doctors’ offices, and 
pathology laboratories send information about cancer cases to 
their cancer registry. Most information comes from hospitals, 
where highly trained cancer registrars transfer the information 
from the patient’s medical record to the registry’s computer 
software using standardized codes. The data are then sent to the 
central cancer registry. Every year the central cancer registries 
electronically submit incidence, demographic, and clinical data 
to NPCR or SEER.
Population Coverage
The population coverage for incidence data varies by 
diagnosis year. Population coverage might be affected by the 
suppression of state incidence data, if a state did not meet the 
publication criteria or did not submit data. In addition, state 
incidence data might be suppressed if <16 cases were reported 
or if the state requested that the data be suppressed. Additional 
information is provided by the USCS technical notes (http://
www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.
pdf#nameddest=CensusRegionPubCriteria). Mortality data 
from malignant neoplasms (i.e., cancers) as recorded in the 
NVSS from the 50 states and DC are available in USCS, 
and thus 100% of the U.S. population is covered each year. 
However, state death data might be suppressed if <16 deaths 
were reported.
Suppression of Rates and Counts
When the numbers of cases or deaths used to compute rates 
are small, those rates tend to have poor reliability. Therefore, 
in an effort to discourage misinterpretation or use of rates or 
counts that are unstable because case or death counts are small, 
incidence and death rates and counts of <16 are not shown in 
tables and figures. The use of a threshold value for suppressing 
cells helps protect the confidentiality of patients by reducing or 
eliminating the risk for disclosure of their identity. Additional 




Cancer incidence data that appear in this report are derived 
from state cancer registries that have high-quality cancer 
incidence data for individual (e.g., 2012) and combined 
(e.g., 1999–2012) years as demonstrated by meeting all of the 
following criteria on data quality for all cancer sites combined:
• case ascertainment is ≥90% (margin of error +5%)
complete,
• ≤5% of cases are ascertained solely on the basis of a death
certificate,
• ≤3% of cases are missing information on sex,
• ≤3% of cases are missing information on age,
• ≤5% of cases are missing information on race, and
• ≥97% of the registry’s records passed a set of single-field
and inter-field computerized edits that test the validity
and logic of data components.
Additional information about USCS is available at 
http://www.cdc.gov/uscs/.  
Highlights
Incidence and Death Rates
In 2012, approximately 1.5 million invasive cancers were 
diagnosed in the United States, an annual incidence rate of 
440 cases per 100,000 persons (Table 1). In the same year, 
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approximately 582,600 persons died of cancer nationally, an 
annual death rate of 166 deaths per 100,000 persons (Table 2). 
By state, overall (all cancer sites combined) cancer incidence 
rates in 2012 ranged from 371 to 515 cases per 100,000 persons 
(Table 3), and overall cancer death rates ranged from 129 to 
201 deaths per 100,000 persons (Table 4).
Cancer incidence (Table 5) and death (Table 6) rates 
increase with age. In 2012, among persons in the youngest age 
group (<15 years), 9,967 new cancer cases (rate: 17 cases per 
100,000 persons) and 1,367 cancer deaths (rate: two deaths 
per 100,000 persons) were reported. Among persons aged ≥65 
years, 826,841 new cancer cases (rate: 1,933 cases per 100,000 
persons) and 403,497 cancer deaths (rate: 935 deaths per 
100,000 persons) were reported. Overall, 54% of cancer cases 
and 69% of cancer deaths in 2012 occurred among persons 
aged ≥65 years.
Overall and for many cancer sites, males had higher incidence 
(Table 7) and death rates (Table 8) than did females. In 2012, 
blacks had the highest cancer incidence (Table 9) and death 
(Table 10) rates in the United States, and American Indians/
Alaska Natives and Asians/Pacific Islanders had the lowest 
cancer incidence and death rates. Overall and for most cancer 
sites, Hispanics had lower cancer incidence (Table 11) and 
death rates (Table 12) than did non-Hispanics. Differences 
in cancer rates by race and ethnicity (Figure 1) might reflect 
differences in risk factors, screening, and treatment although 
rates among some populations might be underestimated 
because of problems ascertaining race or ethnicity.
By state and site, cancer incidence rates in 2012 ranged from 
70 to 157 per 100,000 males for prostate cancer, 107 to 141 
per 100,000 females for breast cancer, 4 to 10 per 100,000 
females for cervical cancer, 29 to 92 per 100,000 persons for 
lung cancer, and 30 to 49 per 100,000 persons for colorectal 
cancer (Figure 2). By state and site, cancer death rates in 2012 
ranged from 13 to 32 per 100,000 males for prostate cancer, 16 
to 31 per 100,000 females for breast cancer, 1 to 5 per 100,000 
females for cervical cancer, 20 to 69 per 100,000 persons for 
lung cancer, and 11 to 19 per 100,000 persons for colorectal 
cancer (Figure 3).
Differing rates of cancer by race, ethnicity, and state of 
residence indicate that for some populations, Healthy People 
2020 objectives have already been achieved, whereas objectives 
for other populations have not been met and these populations 
might benefit from targeted cancer prevention and control efforts.
Four cancer sites accounted for 49% of all cases diagnosed 
in 2012, including 224,147 female breast cancers, 210,828 
lung and bronchus cancers (111,395 among men and 99,433 
among women), 177,489 prostate cancers, and 134,784 colon 
and rectum cancers (70,204 among men and 64,580 among 
women) (Table 13). These four sites also accounted for 48% of 
cancer deaths in 2012, including 157,423 lung cancer deaths, 
51,516 colon and rectum cancer deaths, 41,150 female breast 
cancer deaths, and 27,244 prostate cancer deaths (Table 14).
Time Trends in Incidence and Death Rates
On the basis of data from registries meeting data quality 
criteria during 1999–2012, cancer incidence rates declined 
from 484 cancer cases per 100,000 population in 1999 to 
434 cases in 2012 (Table 15). Although lung cancer incidence 
declined steadily among men from 1999 to 2012, it increased 
among women from 1999 to 2005 and has since declined 
from 2005 to 2012. Prostate cancer incidence declined 
from 170 cases per 100,000 men in 1999 to 105 cases in 
2012. Colorectal cancer incidence declined from 56 cases 
per 100,000 persons in 1999 to 39 cases in 2012. Female 
breast cancer incidence declined from 135 cases per 100,000 
women in 1999 to 121 cases in 2005, increased to 125 cases 
in 2009, and declined again to 122 cases in 2012. Time 
trends in cancer incidence rates are presented by cancer site, 
sex, and race (Figure 4) and by cancer site, sex, and ethnicity 
(Figure 5). During 1999–2012, cancer death rates declined 
from 201 deaths per 100,000 persons in 1999 to 166 deaths 
in 2012; during the same period, death rates declined for each 
of the four most common cancers (Table 16). Time trends in 
cancer death rates are presented by cancer site, sex, and race 
(Figure 6) and by cancer site, sex, and ethnicity (Figure 7).
National cancer surveillance data help public health officials 
track progress toward achieving the national cancer objectives 
set forth in Healthy People 2020 (20). For the national cancer 
burden to be reduced and Healthy People 2020 targets to be 
met, behavioral and environmental factors that increase cancer 
risk must be reduced, and high-quality screening services, 
timely follow-up, and evidence-based treatments must be 
available and accessible to all persons. Several effective primary 
and secondary prevention measures, such as vaccination against 
infectious agents that cause cancer (i.e., hepatitis B virus and 
human papillomavirus), help with smoking cessation, and 
cancer screening, when effectively implemented and sustained, 
could reduce the number of new cancer cases and prevent many 
cancer-related deaths (21). Evidence-based interventions can be 
implemented at both the individual level and the population 
level to reduce cancer risk factors, promote healthy living, and 
encourage cancer screening (5).
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FIGURE 1. Age-adjusted rate* of invasive† cancer cases for most common sites, by sex and race/ethnicity§ — United States, 2012¶
0 50 100 150 200
  Prostate
  Lung and bronchus
  Colon and rectum
  Prostate
  Lung and bronchus
  Colon and rectum
  Prostate
  Lung and bronchus
  Colon and rectum
  Prostate
  Lung and bronchus
  Colon and rectum
  Prostate
  Lung and bronchus


















Age-adjusted rate per 100,000 men
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Age-adjusted rate per 100,000 women
Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander.
Sources: CDC’s National Program of Cancer Registries and National Cancer Institute’s Surveillance, Epidemiology, and End Results program.
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Race categories are not mutually exclusive from Hispanic origin. Rates are not presented for persons of unknown or other race. Data for specified racial or ethnic 
populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/
pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. 
Caution should be used when comparing incidence and death rates because of the difference in population coverage.
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* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). 
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. 
Caution should be used when comparing incidence and death rates because of potential differences in population coverage.
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FIGURE 2. Age-adjusted rate* of invasive† cancer cases, by primary cancer site and state — United States, 2012§
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FIGURE 3. Age-adjusted rate* of cancer deaths, by primary cancer site and state — United States, 2012†
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS Technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS). Data for death rates cover 100% of the U.S. population. Caution should be used when comparing incidence 
and death rates because of potential differences in population coverage.
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See figure footnotes on the next page.
FIGURE 4. Age-adjusted rate* of invasive† cancer cases, by primary cancer site, race,§ and sex — United States, 1999–2012¶
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 Incidence rates by race, lung and bronchus cancer, 

















 Incidence rates by race, lung and bronchus cancer, 

















 Incidence rates by race, lung and bronchus cancer, 













1999 2001 2003 2005 2007 2009 2011
Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander.
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Rates are not presented for persons of unknown or other race. Data for specified racial populations other than white and black should be interpreted with caution. 
For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999–2012 (covering approximately 92% of the 
U.S. population). See registry-specific data quality information for all years, 1999–2012 (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest
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FIGURE 5. (Continued) Age-adjusted rate* of invasive† cancer cases, by primary cancer site, ethnicity,§ and sex — United States, 1999–2012¶
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary 
bladder. Urinary bladder cancer includes invasive and in situ.
§ Data for specified ethnical populations should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/
pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999–2012 (covering approximately 92% of 
the U.S. population). See registry-specific data quality information for all years, 1999-2012 (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#na
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FIGURE 6. (Continued) Age-adjusted rate* of cancer deaths, by primary cancer site, race,† and sex — United States, 1999–2012§
Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Rates are not presented for persons of unknown or other race. Data for specified racial populations other than white and black should be interpreted with caution. 
For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
§ Data are from the National Vital Statistics System (NVSS). Data for death rates cover 100% of the U.S. population. Caution should be used when comparing incidence 
and death rates because of potential differences in population coverage. 
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* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data for specified ethnic populations should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/
pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
§ Data are from the National Vital Statistics System (NVSS). Data for death rates cover 100% of the U.S. population. Caution should be used when comparing incidence 
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TABLE 1. Reported number and age-adjusted rate* of invasive† 




All cancer sites combined 1,529,078 440.3
Oral cavity and pharynx 39,879 11.2
Lip 1,842 0.5
Tongue 12,374 3.4
Salivary gland 4,254 1.3
Floor of mouth 1,936 0.5





Other oral cavity and pharynx 1,040 0.3
Digestive system 273,535 78.3
Esophagus 15,993 4.5
Stomach 22,623 6.6
Small intestine 7,894 2.3
Colon and rectum 134,784 38.9
Colon excluding rectum 95,962 27.8
Rectum and rectosigmoid junction 38,822 11.1
Anus, anal canal, and anorectum 6,338 1.8
Liver and Intrahepatic bile duct 28,012 7.7
Gallbladder 3,835 1.1
Other biliary 5,963 1.7
Pancreas 43,213 12.3
Retroperitoneum 1,321 0.4
Peritoneum, omentum, and mesentery 1,924 0.5
Other digestive organs 1,635 0.5
Respiratory system 225,933 64.7
Nose, nasal cavity, and middle ear 2,274 0.7
Larynx 12,152 3.4
Lung and bronchus 210,828 60.4
Pleura 105 0
Trachea, mediastinum, and other 
respiratory organs
574 0.2
Bones and joints 2,951 0.9
Soft tissue including heart 10,728 3.2
Skin excluding basal and squamous 73,181 21.5
Melanoma of the skin 67,753 19.9
Other nonepithelial skin 5,428 1.6
Male and female breast 226,272 65.6
Female breast 224,147 122.2
Male breast 2,125 1.4
Female genital system 90,303 48.8
Cervix 12,042 7.4
Corpus and uterus, NOS 49,154 25.7
Corpus 47,570 24.9




Other female genital organs 2,175 1.2
TABLE 1. (Continued) Reported number and age-adjusted rate* of 








Other male genital organs 347 0.2
Urinary system 128,103 37.0
Urinary bladder 69,974 20.2
Kidney and renal pelvis 55,231 15.9
Ureter 1,918 0.6
Other urinary organs 980 0.3
Eye and orbit 2,733 0.8
Brain and other nervous system 21,490 6.5
Brain 20,151 6.0
Cranial nerves other nervous system 1,339 0.4
Endocrine system 48,594 15.0
Thyroid 46,279 14.3
Other endocrine including thymus 2,315 0.7
Lymphomas 71,692 21.1
Hodgkin lymphoma 8,273 2.6
Non-Hodgkin lymphoma 63,419 18.5
Myeloma 21,829 6.3
Leukemias 44,396 13.2
Acute lymphocytic leukemia 4,846 1.6
Chronic lymphocytic leukemia 14,821 4.2
Acute myeloid leukemia 13,820 4.1
Chronic myeloid leukemia 5,543 1.7
Other leukemias 5,366 1.6
Mesothelioma 3,199 0.9
Kaposi Sarcoma 1,076 0.3
Miscellaneous 55,876 16.3
Abbreviation: NOS = not otherwise specified.
* Rates are the number of cases per 100,000 persons and are age-adjusted to 
the 2000 U.S. standard population (19 age groups – Census P25–1130). For 
more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/
uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin 
except when these occur on the skin of the genital organs, and in situ cancers 
except urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria 
for all invasive cancer sites combined (covering approximately 99% of the U.S. 
population). Registry-specific data quality information is available at http://
www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf.
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TABLE 2. Reported number and age-adjusted rate* of cancer deaths, 




All cancer sites combined 582,607 166.4
Oral cavity and pharynx 8,924 2.5
Lip 71 0
Tongue 2,224 0.6
Salivary gland 869 0.2
Floor of mouth 75 0





Other oral cavity and pharynx 1,618 0.4
Digestive system 147,024 41.6
Esophagus 14,649 4.1
Stomach 11,191 3.2
Small intestine 1,293 0.4
Colon and rectum 51,516 14.7
Colon excluding rectum 41,867 12.0
Rectum and rectosigmoid junction 9,649 2.7
Anus, anal canal, and anorectum 889 0.3
Liver and intrahepatic bile duct 22,972 6.3
Gallbladder 2,102 0.6
Other biliary 1,519 0.4
Pancreas 38,797 11.0
Retroperitoneum 207 0.1
Peritoneum, omentum, and mesentery 750 0.2
Other digestive organs 1,139 0.3
Respiratory system 161,851 46.2
Nose, nasal cavity, and middle ear 458 0.1
Larynx 3,662 1.0
Lung and bronchus 157,423 45.0
Pleura 82 0
Trachea, mediastinum, and other 
respiratory organs
226 0.1
Bones and joints 1,399 0.4
Soft tissue including heart 4,559 1.3
Skin excluding basal and squamous 12,463 3.6
Melanoma of the skin 9,251 2.7
Other nonepithelial skin 3,212 0.9
Male and female breast 41,555 11.8
Female breast 41,150 21.3
Male breast 405 0.3
TABLE 2. (Continued) Reported number and age-adjusted rate* of 




Female genital system 29,405 15.2
Cervix 4,074 2.3
Corpus and uterus, NOS 8,911 4.5
Corpus 3,812 1.9




Other female genital organs 553 0.3




Other male genital organs 52 0
Urinary system 29,594 8.5
Urinary bladder 15,245 4.4
Kidney and renal pelvis 13,518 3.8
Ureter 378 0.1
Other urinary organs 453 0.1
Eye and orbit 279 0.1
Brain and other nervous system 15,276 4.4
Endocrine system 2,660 0.8
Thyroid 1,690 0.5
Other endocrine including thymus 970 0.3
Lymphomas 21,518 6.2
Hodgkin lymphoma 1,130 0.3
Non-Hodgkin lymphoma 20,388 5.9
Myeloma 11,821 3.4
Leukemias 23,309 6.8
Acute lymphocytic leukemia 1,408 0.4
Chronic lymphocytic leukemia 4,598 1.3
Acute myeloid leukemia 9,484 2.8
Chronic myeloid leukemia 1,017 0.3
Other leukemias 6,802 2.0
Mesothelioma 2,686 0.8
Miscellaneous 40,276 11.5
Abbreviation: NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to 
the 2000 U.S. standard population (19 age groups – Census P25–1130). For 
more information, see UCSC technical notes (http://www.cdc.gov/cancer/
npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS).
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TABLE 3. Reported number and age-adjusted rate* of invasive† 
cancer cases, all cancer sites combined, by geographic division and 









New Hampshire 7,576 473.5
Rhode Island 6,095 484.0
Vermont 3,545 449.0
Middle Atlantic 230,064 476.1
New Jersey 48,545 477.7
New York 105,941 475.8
Pennsylvania 75,578 476.1
Midwest 345,611 448.8












North Dakota 3,577 450.5
South Dakota 4,174 434.3
South 566,112 434.9
South Atlantic 307,360 430.4
Delaware 5,306 483.5




North Carolina 48,367 443.0
South Carolina 24,737 447.7
Virginia 35,743 403.1
West Virginia 11,109 461.3
TABLE 3. (Continued) Reported number and age-adjusted rate* of 
invasive† cancer cases, all cancer sites combined, by geographic 






























* Rates are the number of cases per 100,000 persons and are age-adjusted to 
the 2000 U.S. standard population (19 age groups – Census P25–1130). For 
more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/
uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except 
when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria 
for all invasive cancer sites combined (covering approximately 99% of the U.S. 
population). Registry-specific data quality information is available at http://
www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#namedd
est=RegistriesPubCriteria.
¶ Rates and counts are not presented for the West Census Region, the Mountain 
Census Division, or Nevada because data from Nevada are not included in 
this analysis.
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TABLE 4. Reported cancer deaths and age-adjusted death rates,* all 





United States 582,607 166.4
Northeast 110,175 164.1




New Hampshire 2,660 167.7
Rhode Island 2,148 163.6
Vermont 1,325 164.8
Middle Atlantic 81,271 164.7
New Jersey 16,483 160.3
New York 35,881 159.5
Pennsylvania 28,907 174.8
Midwest 135,511 174.1












North Dakota 1,253 150.7
South Dakota 1,630 162.0
South 221,435 171.4
South Atlantic 118,858 165.8
Delaware 1,935 176.1




North Carolina 18,405 170.5
South Carolina 9,728 179.0
Virginia 14,294 165.3
West Virginia 4,684 191.1
TABLE 4. (Continued) Reported cancer deaths and age-adjusted death 































* Rates are the number of deaths per 100,000 persons and are age-adjusted to 
the 2000 U.S. standard population (19 age groups – Census P25–1130). For 
more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/
uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS).
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TABLE 5. Reported number and rate* of invasive† cancer cases, by primary cancer site and age group — United States, 2012§
Cancer site
Age group (yrs)
Total<15 15–24 25–39 40–64 ≥65
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate (crude)
All cancer sites combined 9,967 16.5 12,634 29 58,709 95.9 620,927 603 826,841 1,932.60 1,529,078 491.5
Oral cavity and pharynx 84 0.1 259 0.6 1,152 1.9 21,140 20.5 17,244 40.3 39,879 12.8
Esophagus —¶ — — — 127 0.2 6,383 6.2 9,480 22.2 15,993 5.1
Stomach — — — — 649 1.1 8,153 7.9 13,764 32.2 22,623 7.3
Colon and rectum 34 0.1 340 0.8 3,526 5.8 51,746 50.2 79,138 185 134,784 43.3
Liver and intrahepatic bile duct 222 0.4 78 0.2 292 0.5 14,698 14.3 12,722 29.7 28,012 9.0
Pancreas — — — — 391 0.6 14,178 13.8 28,585 66.8 43,213 13.9
Larynx — — — — 107 0.2 5,966 5.8 6,068 14.2 12,152 3.9
Lung and bronchus 27 0 99 0.2 893 1.5 66,105 64.2 143,704 335.9 210,828 67.8
Melanomas of the skin 107 0.2 897 2.1 5,507 9.0 28,901 28.1 32,341 75.6 67,753 21.8
Female breast — — — — 9,605 31.5 114,962 218.7 99,396 411.9 224,147 141.8
Cervix — — — — 2,795 9.2 6,730 12.8 2,368 9.8 12,042 7.6
Corpus and uterus, NOS — — — — 1,616 5.3 26,341 50.1 21,129 87.6 49,154 31.1
Ovary 102 0.3 348 1.6 1,071 3.5 9,564 18.2 9,700 40.2 20,785 13.2
Prostate — — — — 77 0.3 77,236 153.2 100,156 536.9 177,489 115.9
Testis 54 0.2 1,425 6.4 4,073 13.2 2,440 4.8 197 1.1 8,189 5.3
Urinary bladder†† 20 0 65 0.1 548 0.9 18,019 17.5 51,322 120.0 69,974 22.5
Kidney and renal pelvis 527 0.9 180 0.4 1,986 3.2 25,557 24.8 26,981 63.1 55,231 17.8
Brain and nervous system 2,103 3.5 968 2.2 2,084 3.4 8,127 7.9 8,208 19.2 21,490 6.9
Thyroid 197 0.3 2,029 4.7 9,545 15.6 24,876 24.2 9,632 22.5 46,279 14.9
Hodgkin lymphoma 340 0.6 1,599 3.7 2,245 3.7 2,614 2.5 1,475 3.4 8,273 2.7
Non-Hodgkin lymphoma 595 1.0 933 2.1 2,899 4.7 23,101 22.4 35,891 83.9 63,419 20.4
Myeloma — — — — 266 0.4 7,887 7.7 13,663 31.9 21,829 7.0
Leukemias 2,948 4.9 1,163 2.7 2,243 3.7 13,517 13.1 24,525 57.3 44,396 14.3
Mesothelioma — — — — 36 0.1 666 0.6 2,486 5.8 3,199 1.0
Kaposi Sarcoma — — — — 321 0.5 448 0.4 269 0.6 1,076 0.3
Abbreviation: NOS = not otherwise specified.
* Rates are the number of cases per 100,000 persons. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-
notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). 
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria.
¶ Counts and rates are suppressed if <16 cases were reported in a specific category. Some counts and rates are suppressed as complementary cell suppression.
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TABLE 6. Reported number and rate* of cancer deaths, by primary cancer site and age group — United States, 2012†
Cancer site
Age group (yrs)
Total (all ages)<15 15–24 25–39 40–64 ≥65
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate (crude)
All cancer sites combined 1,367 2.2 1,574 3.6 7,391 12 168,778 162.5 403,497 935.2 582,607 185.6
Oral cavity and pharynx —§ — — — 128 0.2 3,677 3.5 5,100 11.8 8,924 2.8
Esophagus — — — — 74 0.1 5,358 5.2 9,213 21.4 14,649 4.7
Stomach — — — — 271 0.4 3,590 3.5 7,309 16.9 11,191 3.6
Colon and rectum — — — — 775 1.3 15,199 14.6 35,480 82.2 51,516 16.4
Liver and intrahepatic bile duct 32 0.1 34 0.1 186 0.3 9,837 9.5 12,883 29.9 22,927 7.3
Pancreas — — — — 151 0.2 10,962 10.6 27,676 64.1 38,797 12.4
Larynx — — — — 18 0 1,374 1.3 2,269 5.3 3,662 1.2
Lung and bronchus — — — — 430 0.7 43,463 41.8 113,499 263.1 157,423 50.2
Melanomas of the skin — — — — 300 0.5 3,179 3.1 5,746 13.3 9,251 2.9
Female breast — — — — 971 3.2 16,104 30.4 24,062 98.9 41,150 25.8
Cervix — — — — 437 1.4 2,259 4.3 1,369 5.6 4,074 2.6
Corpus and uterus, NOS — — — — 108 0.4 2,855 5.4 5,944 24.4 8,911 5.6
Ovary — — — — 176 0.6 4,822 9.1 9,378 38.6 14,404 9.0
Prostate — — — — — — 2,962 5.8 24,271 128.9 27,244 17.6
Testis — — — — 131 0.4 149 0.3 51 0.3 386 0.2
Urinary bladder — — — — 35 0.1 2,390 2.3 12,814 29.7 15,245 4.9
Kidney and renal pelvis 30 0 31 0.1 109 0.2 4,134 4.0 9,214 21.4 13,518 4.3
Brain and nervous system 458 0.7 252 0.6 744 1.2 6,177 5.9 7,645 17.7 15,276 4.9
Thyroid — — — — 23 0 450 0.4 1,212 2.8 1,690 0.5
Hodgkin lymphoma — — — — 134 0.2 353 0.3 604 1.4 1,130 0.4
Non-Hodgkin lymphoma 36 0.1 85 0.2 344 0.6 4,304 4.1 15,619 36.2 20,388 6.5
Myeloma — — — — 32 0.1 2,624 2.5 9,164 21.2 11,821 3.8
Leukemias 378 0.6 356 0.8 649 1.1 4,627 4.5 17,299 40.1 23,309 7.4
Mesothelioma — — — — 16 0 479 0.5 2,190 5.1 2,686 0.9
Abbreviation: NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-
notes.pdf ).
† Data are from the National Vital Statistics System (NVSS).
§ Counts and rates are suppressed if <16 deaths were reported in a specific category. Some counts and rates are suppressed as complementary cell suppression.
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See table footnotes on page 40.
TABLE 7. Reported number and age-adjusted rate* of invasive† cancer cases, by primary cancer site and sex — United States, 2012§
Cancer site
Male Female Total
No. Rate No. Rate No. Rate
All cancer sites combined 767,366 483.0 761,712 411.7 1,529,078 440.3
Oral cavity and pharynx 27,997 16.8 11,882 6.3 39,879 11.2
Lip 1,353 0.9 489 0.3 1,842 0.5
Tongue 8,777 5.2 3,597 1.9 12,374 3.4
Salivary gland 2,404 1.6 1,850 1.0 4,254 1.3
Floor of mouth 1,333 0.8 603 0.3 1,936 0.5
Gum and other mouth 2,915 1.8 2,416 1.3 5,331 1.5
Nasopharynx 1,263 0.8 495 0.3 1,758 0.5
Tonsil 5,977 3.4 1,353 0.7 7,330 2.0
Oropharynx 1,325 0.8 408 0.2 1,733 0.5
Hypopharynx 1,838 1.1 443 0.2 2,281 0.6
Other oral cavity and pharynx 812 0.5 228 0.1 1,040 0.3
Digestive system 151,713 95.6 121,822 63.9 273,535 78.3
Esophagus 12,628 7.8 3,365 1.7 15,993 4.5
Stomach 13,964 9.0 8,659 4.6 22,623 6.6
Small intestine 4,187 2.6 3,707 2.0 7,894 2.3
Colon and rectum 70,204 44.8 64,580 34.1 134,784 38.9
Colon excluding rectum 47,448 30.7 48,514 25.4 95,962 27.8
Rectum and rectosigmoid junction 22,756 14.1 16,066 8.6 38,822 11.1
Anus, anal canal, and anorectum 2,304 1.4 4,034 2.1 6,338 1.8
Liver and Intrahepatic bile duct 20,207 11.8 7,805 4.0 28,012 7.7
Gallbladder 1,221 0.8 2,614 1.4 3,835 1.1
Other biliary 3,246 2.1 2,717 1.4 5,963 1.7
Pancreas 22,101 14.1 21,112 10.9 43,213 12.3
Retroperitoneum 653 0.4 668 0.4 1,321 0.4
Peritoneum, omentum, and mesentery 157 0.1 1,767 0.9 1,924 0.5
Other digestive organs 841 0.5 794 0.4 1,635 0.5
Respiratory system 122,785 78.5 103,148 54.0 225,933 64.7
Nose, nasal cavity, and middle ear 1,376 0.9 898 0.5 2,274 0.7
Larynx 9,565 5.8 2,587 1.3 12,152 3.4
Lung and bronchus 111,395 71.6 99,433 52.1 210,828 60.4
Pleura 60 0 45 0 105 0
Trachea, mediastinum, and other respiratory organs 389 0.3 185 0.1 574 0.2
Bones and joints 1,674 1.1 1,277 0.8 2,951 0.9
Soft tissue including heart 5,881 3.8 4,847 2.8 10,728 3.2
Skin excluding basal and squamous 42,992 27.8 30,189 17.0 73,181 21.5
Melanoma of the skin 39,673 25.5 28,080 15.9 67,753 19.9
Other nonepithelial skin 3,319 2.3 2,109 1.1 5,428 1.6
Male and female breast NA NA NA NA 226,272 65.6
Female breast NA NA 224,147 122.2 NA NA
Male breast 2,125 1.4 NA NA NA NA
Female genital system NA NA 90,303 48.8 NA NA
Cervix NA NA 12,042 7.4 NA NA
Corpus and uterus, NOS NA NA 49,154 25.7 NA NA
Corpus NA NA 47,570 24.9 NA NA
Uterus, NOS NA NA 1,584 0.8 NA NA
Ovary NA NA 20,785 11.3 NA NA
Vagina NA NA 1,296 0.7 NA NA
Vulva NA NA 4,851 2.6 NA NA
Other female genital organs NA NA 2,175 1.2 NA NA
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TABLE 7. (Continued) Reported number and age-adjusted rate* of invasive† cancer cases, by primary cancer site and sex — United States, 2012§
Cancer site
Male Female Total
No. Rate No. Rate No. Rate
Male genital system 187,308 111.8 NA NA NA NA
Prostate 177,489 105.3 NA NA NA NA
Testis 8,189 5.5 NA NA NA NA
Penis 1,283 0.8 NA NA NA NA
Other male genital organs 347 0.2 NA NA NA NA
Urinary system 89,322 58.0 38,781 20.5 128,103 37.0
Urinary bladder 53,006 35.4 16,968 8.7 69,974 20.2
Kidney and renal pelvis 34,459 21.3 20,772 11.2 55,231 15.9
Ureter 1,195 0.8 723 0.4 1,918 0.6
Other urinary organs 662 0.5 318 0.2 980 0.3
Eye and orbit 1,494 1.0 1,239 0.7 2,733 0.8
Brain and other nervous system 11,951 7.6 9,539 5.5 21,490 6.5
Brain 11,263 7.2 8,888 5.1 20,151 6.0
Cranial nerves other nervous system 688 0.5 651 0.4 1,339 0.4
Endocrine system 12,497 7.9 36,097 21.9 48,594 15.0
Thyroid 11,313 7.1 34,966 21.3 46,279 14.3
Other endocrine including thymus 1,184 0.8 1,131 0.7 2,315 0.7
Lymphomas 39,074 25.3 32,618 17.8 71,692 21.1
Hodgkin lymphoma 4,569 3.0 3,704 2.3 8,273 2.6
Non-Hodgkin lymphoma 34,505 22.3 28,914 15.5 63,419 18.5
Myeloma 12,199 7.8 9,630 5.0 21,829 6.3
Leukemias 25,699 16.9 18,697 10.3 44,396 13.2
Acute lymphocytic leukemia 2,732 1.8 2,114 1.4 4,846 1.6
Chronic lymphocytic leukemia 9,004 5.8 5,817 3.0 14,821 4.2
Acute myeloid leukemia 7,646 5.1 6,174 3.4 13,820 4.1
Chronic myeloid leukemia 3,118 2.1 2,425 1.4 5,543 1.7
Other leukemias 3,199 2.1 2,167 1.2 5,366 1.6
Mesothelioma 2,407 1.7 792 0.4 3,199 0.9
Kaposi Sarcoma 951 0.6 125 0.1 1,076 0.3
Miscellaneous 29,297 19.6 26,579 13.7 55,876 16.3
Abbreviations: NA = not applicable; NOS = not otherwise specified.
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). 
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria.
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TABLE 8. Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and sex — United States, 2012†
Cancer site
Male Female Total
No. Rate No. Rate No. Rate
All cancer sites combined 305,661 200.6 276,946 141.9 582,607 166.4
Oral cavity and pharynx 6,263 3.9 2,661 1.3 8,924 2.5
Lip 44 0 27 0 71 0
Tongue 1,488 0.9 736 0.4 2,224 0.6
Salivary gland 581 0.4 288 0.1 869 0.2
Floor of mouth 54 0 21 0 75 0
Gum and other mouth 746 0.5 529 0.3 1,275 0.4
Nasopharynx 454 0.3 212 0.1 666 0.2
Tonsil 714 0.4 165 0.1 879 0.2
Oropharynx 653 0.4 238 0.1 891 0.2
Hypopharynx 268 0.2 88 0 356 0.1
Other oral cavity and pharynx 1,261 0.8 357 0.2 1,618 0.4
Digestive system 83,782 53.4 63,242 32.0 147,024 41.6
Esophagus 11,697 7.3 2,952 1.5 14,649 4.1
Stomach 6,611 4.3 4,580 2.4 11,191 3.2
Small intestine 689 0.5 604 0.3 1,293 0.4
Colon and rectum 26,866 17.6 24,650 12.4 51,516 14.7
Colon excluding rectum 21,383 14.1 20,484 10.3 41,867 12.0
Rectum and rectosigmoid junction 5,483 3.5 4,166 2.1 9,649 2.7
Anus, anal canal, and anorectum 368 0.2 521 0.3 889 0.3
Liver and intrahepatic bile duct 15,563 9.4 7,409 3.8 22,972 6.3
Gallbladder 687 0.5 1,415 0.7 2,102 0.6
Other biliary 739 0.5 780 0.4 1,519 0.4
Pancreas 19,718 12.7 19,079 9.6 38,797 11.0
Retroperitoneum 110 0.1 97 0.1 207 0.1
Peritoneum, omentum, and mesentery 78 0 672 0.3 750 0.2
Other digestive organs 656 0.4 483 0.2 1,139 0.3
Respiratory system 90,091 58.4 71,760 37.0 161,851 46.2
Nose, nasal cavity, and middle ear 285 0.2 173 0.1 458 0.1
Larynx 2,925 1.8 737 0.4 3,662 1.0
Lung and bronchus 86,689 56.2 70,734 36.4 157,423 45.0
Pleura 51 0 31 0 82 0
Trachea, mediastinum, and other respiratory organs 141 0.1 85 0 226 0.1
Bones and joints 818 0.5 581 0.3 1,399 0.4
Soft tissue including heart 2,394 1.6 2,165 1.2 4,559 1.3
Skin excluding basal and squamous 8,329 5.5 4,134 2.1 12,463 3.6
Melanoma of the skin 6,013 4.0 3,238 1.7 9,251 2.7
Other nonepithelial skin 2,316 1.6 896 0.4 3,212 0.9
Male and female breast NA NA NA NA 41,555 11.8
Female breast NA NA 41,150 21.3 NA NA
Male breast 405 0.3 NA NA NA NA
See table footnotes on page 42.
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TABLE 8. (Continued) Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and sex — United States, 2012†
Cancer site
Male Female Total
No. Rate No. Rate No. Rate
Female genital system NA NA 29,405 15.2 NA NA
Cervix NA NA 4,074 2.3 NA NA
Corpus and uterus, NOS NA NA 8,911 4.5 NA NA
Corpus NA NA 3,812 1.9 NA NA
Uterus, NOS NA NA 5,099 2.6 NA NA
Ovary NA NA 14,404 7.4 NA NA
Vagina NA NA 429 0.2 NA NA
Vulva NA NA 1,034 0.5 NA NA
Other female genital organs NA NA 553 0.3 NA NA
Male genital system 27,955 20.0 NA NA NA NA
Prostate 27,244 19.6 NA NA NA NA
Testis 386 0.3 NA NA NA NA
Penis 273 0.2 NA NA NA NA
Other male genital organs 52 0 NA NA NA NA
Urinary system 20,136 13.6 9,458 4.7 29,594 8.5
Urinary bladder 10,886 7.6 4,359 2.1 15,245 4.4
Kidney and renal pelvis 8,772 5.6 4,746 2.4 13,518 3.8
Ureter 212 0.1 166 0.1 378 0.1
Other urinary organs 266 0.2 187 0.1 453 0.1
Eye and orbit 164 0.1 115 0.1 279 0.1
Brain and other nervous system 8,666 5.4 6,610 3.5 15,276 4.4
Endocrine system 1,264 0.8 1,396 0.7 2,660 0.8
Thyroid 775 0.5 915 0.5 1,690 0.5
Other endocrine including thymus 489 0.3 481 0.3 970 0.3
Lymphomas 11,902 8.0 9,616 4.9 21,518 6.2
Hodgkin lymphoma 638 0.4 492 0.3 1,130 0.3
Non-Hodgkin lymphoma 11,264 7.6 9,124 4.6 20,388 5.9
Myeloma 6,338 4.2 5,483 2.8 11,821 3.4
Leukemias 13,466 9.2 9,843 5.1 23,309 6.8
Acute lymphocytic leukemia 810 0.5 598 0.3 1,408 0.4
Chronic lymphocytic leukemia 2,837 2.0 1,761 0.9 4,598 1.3
Acute myeloid leukemia 5,401 3.6 4,083 2.2 9,484 2.8
Chronic myeloid leukemia 546 0.4 471 0.2 1,017 0.3
Other leukemias 3,872 2.7 2,930 1.5 6,802 2.0
Mesothelioma 2,112 1.5 574 0.3 2,686 0.8
Miscellaneous 21,538 14.1 18,738 9.4 40,276 11.5
Abbreviations: NA = not applicable; NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS).
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TABLE 9. Reported number and age-adjusted rate* of invasive† cancer cases, by primary cancer site and race§ —United States, 2012¶
Cancer site
AI/AN§ API§ Black White Total
No. Rate No. Rate No. Rate No. Rate No. Rate
All cancer sites combined 8,139 269.0 45,364 285.7 165,559 446.1 1,282,703 440.4 1,529,078 440.3
Oral cavity and pharynx 227 6.8 1,267 7.7 3,574 9.1 34,263 11.5 39,879 11.2
Lip —** — — — 42 0.1 1,718 0.6 1,842 0.5
Tongue 51 1.5 288 1.8 786 2.0 11,082 3.7 12,374 3.4
Salivary gland 18 0.5 180 1.1 393 1.0 3,597 1.3 4,254 1.3
Floor of mouth — — 26 0.2 206 0.5 1,666 0.5 1,936 0.5
Gum and other mouth 24 0.8 207 1.3 511 1.4 4,500 1.5 5,331 1.5
Nasopharynx 21 0.6 384 2.2 263 0.7 1,064 0.4 1,758 0.5
Tonsil 45 1.2 81 0.5 625 1.5 6,512 2.2 7,330 2.0
Oropharynx — — 20 0.1 241 0.6 1,449 0.5 1,733 0.5
Hypopharynx 21 0.7 54 0.3 390 1.0 1,796 0.6 2,281 0.6
Other oral cavity and pharynx 16 0.5 — — 117 0.3 879 0.3 1,040 0.3
Digestive system 1,722 58.4 11,016 72.1 34,404 94.8 223,154 75.7 273,535 78.3
Esophagus 73 2.6 303 2.0 1,514 4.1 13,963 4.7 15,993 4.5
Stomach 167 6.1 1,571 10.5 3,532 10.2 17,056 5.8 22,623 6.6
Small intestine 25 0.8 181 1.1 1,301 3.5 6,300 2.2 7,894 2.3
Colon and rectum 835 28.5 4,772 30.8 16,402 45.5 111,041 38.0 134,784 38.9
Colon excluding rectum 547 19.7 3,073 20.3 12,256 34.6 79,012 27.1 95,962 27.8
Rectum and rectosigmoid junction 288 8.8 1,699 10.5 4,146 10.9 32,029 11.0 38,822 11.1
Anus, anal canal, and anorectum 33 0.9 81 0.5 703 1.8 5,450 1.8 6,338 1.8
Liver and Intrahepatic bile duct 280 8.5 2,008 12.7 4,097 10.0 21,223 7.0 28,012 7.7
Gallbladder 48 1.9 204 1.4 558 1.6 2,979 1.0 3,835 1.1
Other biliary 28 0.9 363 2.5 506 1.5 5,023 1.7 5,963 1.7
Pancreas 197 7.0 1,340 9.3 5,293 15.1 36,001 12.1 43,213 12.3
Retroperitoneum — — 43 0.3 164 0.4 1,088 0.4 1,321 0.4
Peritoneum, omentum, and 
mesentery
— — 70 0.4 135 0.4 1,698 0.6 1,924 0.5
Other digestive organs — — 80 0.5 199 0.6 1,332 0.5 1,635 0.5
Respiratory system 1,167 42.3 5,369 36.8 24,484 68.6 193,417 65.2 225,933 64.7
Nose, nasal cavity, and middle ear — — 94 0.6 232 0.6 1,908 0.7 2,274 0.7
Larynx 56 1.8 159 1.0 1,706 4.4 10,123 3.3 12,152 3.4
Lung and bronchus 1,096 40.1 5,088 35.0 22,475 63.3 180,823 61.0 210,828 60.4
Pleura — — — — — — 91 0 105 0
Trachea, mediastinum, and other 
respiratory organs
— — 26 0.2 61 0.2 472 0.2 574 0.2
Bones and joints 19 0.4 109 0.6 308 0.7 2,458 1.0 2,951 0.9
Soft tissue including heart 72 2.1 356 2.1 1,308 3.4 8,809 3.2 10,728 3.2
Skin excluding basal and squamous 167 5.6 315 2.0 664 1.8 68,552 24.2 73,181 21.5
Melanoma of the skin 141 4.7 197 1.2 332 0.9 63,875 22.6 67,753 19.9
Other nonepithelial skin 26 0.8 118 0.8 332 0.9 4,677 1.6 5,428 1.6
Male and female breast 1,145 36.1 8,416 49.3 25,927 68.5 188,474 65.5 226,272 65.6
Female breast 1,143 67.8 8,357 89.7 25,630 120.1 186,726 123.3 224,147 122.2
Male breast — — 59 0.8 297 2.0 1,748 1.3 2,125 1.4
Female genital system 598 33.9 3,279 34.9 10,015 46.9 75,241 49.4 90,303 48.8
Cervix 119 6.3 576 6.1 1,907 9.0 9,174 7.1 12,042 7.4
Corpus and uterus, NOS 290 15.9 1,704 17.9 5,334 24.7 41,235 26.1 49,154 25.7
Corpus 281 15.3 1,648 17.3 4,995 23.1 40,082 25.3 47,570 24.9
Uterus, NOS — — 56 0.6 339 1.6 1,153 0.7 1,584 0.8
Ovary 138 8.4 810 8.7 1,959 9.3 17,671 11.6 20,785 11.3
Vagina — — 37 0.4 199 1.0 1,031 0.7 1,296 0.7
Vulva 24 1.5 66 0.8 413 2.0 4,285 2.7 4,851 2.6
Other female genital organs 16 1.0 86 1.0 203 1.0 1,845 1.2 2,175 1.2
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TABLE 9. (Continued) Reported number and age-adjusted rate* of invasive† cancer cases, by primary cancer site and race§ —United States, 2012¶
Cancer site
AI/AN§ API§ Black White Total
No. Rate No. Rate No. Rate No. Rate No. Rate
Male genital system 832 60.1 3,975 57.1 28,484 172.2 146,244 103.0 187,308 111.8
Prostate 750 56.4 3,755 54.5 28,003 169.4 137,488 95.6 177,489 105.3
Testis 76 3.2 164 1.8 305 1.5 7,410 6.3 8,189 5.5
Penis — — 37 0.6 142 1.0 1,070 0.8 1,283 0.8
Other male genital organs — — 19 0.3 34 0.2 276 0.2 347 0.2
Urinary system 710 23.9 2,443 16.4 10,399 28.8 112,781 38.4 128,103 37.0
Urinary bladder 222 8.6 1,208 8.6 3,778 11.3 63,564 21.5 69,974 20.2
Kidney and renal pelvis 480 15.0 1,165 7.3 6,420 16.9 46,625 16.0 55,231 15.9
Ureter — — 53 0.4 80 0.2 1,769 0.6 1,918 0.6
Other urinary organs — — 17 0.1 121 0.3 823 0.3 980 0.3
Eye and orbit — — 36 0.2 93 0.2 2,513 0.9 2,733 0.8
Brain and other nervous system 114 3.2 622 3.6 1,615 4.1 18,858 6.9 21,490 6.5
Brain 107 3.1 576 3.4 1,465 3.7 17,765 6.5 20,151 6.0
Cranial nerves other nervous system — — 46 0.3 150 0.4 1,093 0.4 1,339 0.4
Endocrine system 285 7.4 2,822 15.6 3,893 9.9 40,662 15.6 48,594 15.0
Thyroid 275 7.2 2,677 14.8 3,529 8.9 38,888 14.9 46,279 14.3
Other endocrine including thymus — — 145 0.8 364 0.9 1,774 0.7 2,315 0.7
Lymphomas 340 11.6 2,154 13.7 6,185 16.1 61,671 21.7 71,692 21.1
Hodgkin lymphoma 32 0.9 212 1.1 1,096 2.6 6,787 2.7 8,273 2.6
Non-Hodgkin lymphoma 308 10.8 1,942 12.5 5,089 13.5 54,884 19.0 63,419 18.5
Myeloma 116 4.1 491 3.2 4,392 12.4 16,480 5.6 21,829 6.3
Leukemias 252 7.9 1,200 7.5 3,838 10.5 37,968 13.5 44,396 13.2
Acute lymphocytic leukemia 51 1.2 242 1.4 440 1.0 4,011 1.7 4,846 1.6
Chronic lymphocytic leukemia 51 1.9 172 1.1 1,066 3.1 12,921 4.3 14,821 4.2
Acute myeloid leukemia 86 2.8 495 3.2 1,294 3.6 11,808 4.2 13,820 4.1
Chronic myeloid leukemia 36 1.2 177 1.1 564 1.5 4,631 1.7 5,543 1.7
Other leukemias 28 0.8 114 0.7 474 1.3 4,597 1.6 5,366 1.6
Mesothelioma — — 35 0.3 162 0.5 2,963 1.0 3,199 0.9
Kaposi Sarcoma — — 27 0.1 320 0.8 648 0.3 1,076 0.3
Miscellaneous 342 12.9 1,432 10.0 5,494 16.0 47,547 16.2 55,876 16.3
Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander; NOS = not otherwise specified.
 * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
 † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
 § Rates are not presented for persons of unknown or other race, therefore categories do not sum to total. Data for specified racial populations other than white and 
black should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.
pdf#nameddest=IntRaceEthnicityData).
 ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). 
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria.
 ** Counts and rates are suppressed if <16 cases were reported.
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TABLE 10. Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and race† — United States, 2012§
Cancer site
AI/AN† API† Black White Total
No. Rate No. Rate No. Rate No. Rate No. Rate
All cancer sites combined 3,018 112.5 15,339 104.2 67,374 194.4 496,876 166.4 582,607 166.4
Oral cavity and pharynx 48 1.6 320 2.0 1,074 2.9 7,482 2.5 8,924 2.5
Lip —¶ — — — — — 68 0 71 0
Tongue — — 58 0.4 200 0.5 1,956 0.6 2,224 0.6
Salivary gland — — 19 0.1 67 0.2 781 0.3 869 0.2
Floor of mouth — — — — — — 71 0 75 0
Gum and other mouth — — 41 0.3 118 0.3 1,108 0.4 1,275 0.4
Nasopharynx — — 141 0.8 100 0.3 419 0.1 666 0.2
Tonsil — — — — 108 0.3 753 0.2 879 0.2
Oropharynx — — 17 0.1 146 0.4 723 0.2 891 0.2
Hypopharynx — — — — 50 0.1 297 0.1 356 0.1
Other oral cavity and pharynx — — 21 0.1 281 0.8 1,306 0.4 1,618 0.4
Digestive system 908 33.1 5,511 37.5 18,930 53.9 121,675 40.5 147,024 41.6
Esophagus 67 2.5 241 1.6 1,387 3.7 12,954 4.3 14,649 4.1
Stomach 100 3.9 832 5.7 2,001 5.9 8,258 2.8 11,191 3.2
Small intestine — — 32 0.2 199 0.5 1,060 0.4 1,293 0.4
Colon and rectum 301 11.2 1,578 10.8 6,861 19.9 42,776 14.3 51,516 14.7
Colon excluding rectum 246 9.2 1,270 8.8 5,727 16.8 34,624 11.6 41,867 12.0
Rectum and rectosigmoid junction 55 2.0 308 2.0 1,134 3.2 8,152 2.7 9,649 2.7
Anus, anal canal, and anorectum — — — — 99 0.3 778 0.3 889 0.3
Liver and intrahepatic bile duct 207 7.0 1,499 9.9 3,190 8.3 18,076 5.9 22,972 6.3
Gallbladder 24 1.1 86 0.6 285 0.8 1,707 0.6 2,102 0.6
Other biliary — — 61 0.4 121 0.4 1,327 0.4 1,519 0.4
Pancreas 180 6.5 1,113 7.9 4,595 13.4 32,909 10.9 38,797 11.0
Retroperitoneum — — — — 16 0 184 0.1 207 0.1
Peritoneum, omentum, and mesentery — — 18 0.1 50 0.1 679 0.2 750 0.2
Other digestive organs — — 37 0.3 126 0.4 967 0.3 1,139 0.3
Respiratory system 818 31.1 3,528 24.6 17,484 50.3 140,021 46.9 161,851 46.2
Nose, nasal cavity, and middle ear — — 19 0.1 40 0.1 397 0.1 458 0.1
Larynx 18 0.6 56 0.4 628 1.7 2,960 1.0 3,662 1.0
Lung and bronchus 796 30.4 3,441 24.0 16,780 48.4 136,406 45.7 157,423 45.0
Pleura — — — — — — 75 0 82 0
Trachea, mediastinum, and other 
respiratory organs
— — — — 31 0.1 183 0.1 226 0.1
Bones and joints — — 42 0.3 165 0.4 1,186 0.4 1,399 0.4
Soft tissue including heart 35 1.1 147 0.9 567 1.5 3,810 1.3 4,559 1.3
Skin excluding basal and squamous 32 1.3 90 0.6 273 0.8 12,068 4.1 12,463 3.6
Melanoma of the skin 19 0.8 58 0.4 138 0.4 9,036 3.1 9,251 2.7
Other nonepithelial skin — — 32 0.2 135 0.4 3,032 1.0 3,212 0.9
Male and female breast 173 5.9 1,036 6.3 6,246 17.2 34,100 11.4 41,555 11.8
Female breast 172 10.8 1,032 11.3 6,186 29.4 33,760 20.7 41,150 21.3
Male breast — — — — 60 0.4 340 0.3 405 0.3
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TABLE 10. (Continued) Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and race† — United States, 2012§
Cancer site
AI/AN† API† Black White Total
No. Rate No. Rate No. Rate No. Rate No. Rate
Female genital system 171 11.1 858 9.6 3,984 19.4 24,392 15.0 29,405 15.2
Cervix 41 2.3 154 1.7 780 3.7 3,099 2.1 4,074 2.3
Corpus and uterus, NOS 47 3.1 280 3.2 1,666 8.2 6,918 4.1 8,911 4.5
Corpus 21 1.2 131 1.5 646 3.2 3,014 1.8 3,812 1.9
Uterus, NOS 26 1.8 149 1.7 1,020 5.0 3,904 2.3 5,099 2.6
Ovary 74 5.0 385 4.3 1,359 6.6 12,586 7.7 14,404 7.4
Vagina — — — — 56 0.3 360 0.2 429 0.2
Vulva — — — — 64 0.3 952 0.6 1,034 0.5
Other female genital organs — — 16 0.2 59 0.3 477 0.3 553 0.3
Male genital system 134 14.4 441 8.6 4,655 42.1 22,725 18.6 27,955 20.0
Prostate 127 14.0 429 8.4 4,595 41.8 22,093 18.1 27,244 19.6
Testis — — — — 26 0.1 347 0.3 386 0.3
Penis — — — — 27 0.2 241 0.2 273 0.2
Other male genital organs — — — — — — 44 0 52 0
Urinary system 148 5.5 507 3.7 2,411 7.2 26,528 8.8 29,594 8.5
Urinary bladder 33 1.3 232 1.8 1,090 3.5 13,890 4.6 15,245 4.4
Kidney and renal pelvis 107 3.9 256 1.7 1,267 3.6 11,888 4.0 13,518 3.8
Ureter — — — — — — 351 0.1 378 0.1
Other urinary organs — — — — 41 0.1 399 0.1 453 0.1
Eye and orbit — — — — — — 260 0.1 279 0.1
Brain and other nervous system 63 2.0 336 2.1 1,009 2.7 13,868 4.8 15,276 4.4
Endocrine system — — 134 0.9 311 0.9 2,208 0.8 2,660 0.8
Thyroid — — 90 0.6 165 0.5 1,430 0.5 1,690 0.5
Other endocrine including thymus — — 44 0.3 146 0.4 778 0.3 970 0.3
Lymphomas 75 3.2 587 4.1 1,595 4.6 19,261 6.5 21,518 6.2
Hodgkin lymphoma — — 20 0.1 133 0.3 974 0.3 1,130 0.3
Non-Hodgkin lymphoma 72 3.2 567 4.0 1,462 4.3 18,287 6.2 20,388 5.9
Myeloma 48 2.0 241 1.7 2,085 6.3 9,447 3.2 11,821 3.4
Leukemias 96 3.4 599 4.1 1,965 5.8 20,649 7.1 23,309 6.8
Acute lymphocytic leukemia — — 53 0.3 121 0.3 1,222 0.5 1,408 0.4
Chronic lymphocytic leukemia — — 38 0.3 365 1.2 4,183 1.4 4,598 1.3
Acute myeloid leukemia 44 1.5 323 2.2 768 2.2 8,349 2.9 9,484 2.8
Chronic myeloid leukemia — — 21 0.1 108 0.3 885 0.3 1,017 0.3
Other leukemias 25 1.0 164 1.2 603 1.8 6,010 2.0 6,802 2.0
Mesothelioma — — 28 0.2 125 0.4 2,519 0.9 2,686 0.8
Miscellaneous 236 8.9 930 6.5 4,471 12.9 34,639 11.5 40,276 11.5
Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander; NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data for specified racial populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (http://www.
cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
§ Data are from the National Vital Statistics System (NVSS).
¶ Counts and rates are suppressed if <16 deaths were reported.
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TABLE 11. Reported number and age-adjusted rate* of invasive† cancer cases, by primary cancer site and ethnicity§ — United States, 2012¶
Cancer site
Hispanic Non-Hispanic Total
No. Rate No. Rate No. Rate
All cancer sites combined 111,815 340.5 1,417,061 451.4 1,529,078 440.3
Oral cavity and pharynx 2,318 6.9 37,561 11.7 39,879 11.2
Lip 87 0.3 1,755 0.6 1,842 0.5
Tongue 629 1.9 11,745 3.6 12,374 3.4
Salivary gland 324 0.9 3,930 1.3 4,254 1.3
Floor of mouth 90 0.3 1,846 0.6 1,936 0.5
Gum and other mouth 366 1.2 4,965 1.6 5,331 1.5
Nasopharynx 148 0.4 1,610 0.5 1,758 0.5
Tonsil 364 1.0 6,966 2.1 7,330 2.0
Oropharynx 97 0.3 1,636 0.5 1,733 0.5
Hypopharynx 139 0.4 2,142 0.6 2,281 0.6
Other oral cavity and pharynx 74 0.2 966 0.3 1,040 0.3
Digestive system 24,117 78.3 249,370 78.5 273,535 78.3
Esophagus 847 2.8 15,143 4.7 15,993 4.5
Stomach 2,926 9.5 19,694 6.2 22,623 6.6
Small intestine 561 1.7 7,333 2.3 7,894 2.3
Colon and rectum 10,585 34.0 124,186 39.5 134,784 38.9
Colon excluding rectum 7,158 23.8 88,791 28.3 95,962 27.8
Rectum and rectosigmoid junction 3,427 10.2 35,395 11.2 38,822 11.1
Anus, anal canal, and anorectum 449 1.4 5,888 1.9 6,338 1.8
Liver and Intrahepatic bile duct 4,066 12.7 23,937 7.2 28,012 7.7
Gallbladder 539 1.9 3,295 1.0 3,835 1.1
Other biliary 650 2.2 5,313 1.7 5,963 1.7
Pancreas 3,079 10.7 40,116 12.5 43,213 12.3
Retroperitoneum 128 0.3 1,193 0.4 1,321 0.4
Peritoneum, omentum, and mesentery 134 0.4 1,790 0.6 1,924 0.5
Other digestive organs 153 0.5 1,482 0.5 1,635 0.5
Respiratory system 9,655 34.4 216,231 67.5 225,933 64.7
Nose, nasal cavity, and middle ear 191 0.6 2,083 0.7 2,274 0.7
Larynx 736 2.4 11,413 3.5 12,152 3.4
Lung and bronchus 8,648 31.2 202,136 63.2 210,828 60.4
Pleura —** — 101 0 — 0
Trachea, mediastinum, and other respiratory organs 76 0.1 498 0.2 574 0.2
Bones and joints 415 0.9 2,536 0.9 2,951 0.9
Soft tissue including heart 1,092 2.8 9,636 3.3 10,728 3.2
Skin excluding basal and squamous 1,726 5.1 71,452 23.6 73,181 21.5
Melanoma of the skin 1,423 4.2 66,328 21.9 67,753 19.9
Other nonepithelial skin 303 0.9 5,124 1.7 5,428 1.6
Male and female breast 17,129 49.0 209,135 67.6 226,272 65.6
Female breast 17,014 91.3 207,125 125.9 224,147 122.2
Male breast 115 0.8 2,010 1.4 2,125 1.4
Female genital system 8,557 44.5 81,736 49.1 90,303 48.8
Cervix 1,998 9.5 10,044 7.1 12,042 7.4
Corpus and uterus, NOS 4,135 21.8 45,015 26.0 49,154 25.7
Corpus 3,976 20.9 43,593 25.2 47,570 24.9
Uterus, NOS 159 0.9 1,422 0.8 1,584 0.8
Ovary 1,885 10.0 18,894 11.4 20,785 11.3
Vagina 108 0.6 1,188 0.7 1,296 0.7
Vulva 268 1.7 4,583 2.7 4,851 2.6
Other female genital organs 163 0.9 2,012 1.2 2,175 1.2
See table footnotes on page 48.
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No. Rate No. Rate No. Rate
Male genital system 13,653 95.7 173,628 113.7 187,308 111.8
Prostate 12,121 89.8 165,342 107.0 177,489 105.3
Testis 1,311 4.4 6,877 5.7 8,189 5.5
Penis 204 1.4 1,079 0.8 1,283 0.8
Other male genital organs 17 0.1 330 0.2 347 0.2
Urinary system 8,518 27.4 119,571 37.9 128,103 37.0
Urinary bladder 3,041 11.1 66,925 21.1 69,974 20.2
Kidney and renal pelvis 5,350 15.9 49,875 15.9 55,231 15.9
Ureter 80 0.3 1,838 0.6 1,918 0.6
Other urinary organs 47 0.2 933 0.3 980 0.3
Eye and orbit 206 0.5 2,527 0.9 2,733 0.8
Brain and other nervous system 1,990 4.9 19,497 6.7 21,490 6.5
Brain 1,846 4.6 18,302 6.3 20,151 6.0
Cranial nerves other nervous system 144 0.3 1,195 0.5 1,339 0.4
Endocrine system 5,806 13.7 42,783 15.4 48,594 15.0
Thyroid 5,555 13.1 40,722 14.6 46,279 14.3
Other endocrine including thymus 251 0.6 2,061 0.7 2,315 0.7
Lymphomas 6,462 18.9 65,222 21.5 71,692 21.1
Hodgkin lymphoma 1,029 2.3 7,244 2.7 8,273 2.6
Non-Hodgkin lymphoma 5,433 16.6 57,978 18.7 63,419 18.5
Myeloma 1,869 6.2 19,955 6.3 21,829 6.3
Leukemias 3,988 10.3 40,403 13.4 44,396 13.2
Acute lymphocytic leukemia 1,264 2.2 3,582 1.5 4,846 1.6
Chronic lymphocytic leukemia 542 1.9 14,278 4.5 14,821 4.2
Acute myeloid leukemia 1,272 3.6 12,546 4.1 13,820 4.1
Chronic myeloid leukemia 490 1.4 5,051 1.7 5,543 1.7
Other leukemias 420 1.2 4,946 1.6 5,366 1.6
Mesothelioma 200 0.7 2,997 1.0 3,199 0.9
Kaposi Sarcoma 198 0.5 878 0.3 1,076 0.3
Miscellaneous 3,916 13.6 51,943 16.5 55,876 16.3
Abbreviation: NOS = not otherwise specified.
 * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
 † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except 
urinary bladder. Urinary bladder cancer includes invasive and in situ.
 § Rates and counts are not presented for persons of unknown ethnicity, therefore categories do not sum to total. Data for specified ethnic populations should be 
interpreted with caution. For more information, see USCS technical notes http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=
IntRaceEthnicityData).
 ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). 
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria.
 ** Counts and rates are suppressed if <16 cases were reported. Some counts and rates are suppressed as complementary cell suppression.
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TABLE 12. Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and ethnicity† — United States, 2012§
Cancer site
Hispanic§ Non-Hispanic Total
No. Rate No. Rate No. Rate
All cancer sites combined 34,146 117.8 547,027 170.4 582,607 166.4
Oral cavity and pharynx 476 1.6 8,421 2.6 8,924 2.5
Lip —¶ — 65 0 71 0
Tongue 118 0.4 2,099 0.6 2,224 0.6
Salivary gland 48 0.2 819 0.3 869 0.2
Floor of mouth — — 68 0 75 0
Gum and other mouth 66 0.2 1,206 0.4 1,275 0.4
Nasopharynx 37 0.1 627 0.2 666 0.2
Tonsil 39 0.1 835 0.3 879 0.2
Oropharynx 43 0.1 848 0.3 891 0.2
Hypopharynx 25 0.1 329 0.1 356 0.1
Other oral cavity and pharynx 87 0.3 1,525 0.5 1,618 0.4
Digestive system 11,382 39.3 135,287 41.8 147,024 41.6
Esophagus 621 2.1 13,995 4.3 14,649 4.1
Stomach 1,590 5.2 9,570 3.0 11,191 3.2
Small intestine 68 0.2 1,221 0.4 1,293 0.4
Colon and rectum 3,349 11.8 48,034 15.0 51,516 14.7
Colon excluding rectum 2,737 9.7 39,017 12.2 41,867 12.0
Rectum and rectosigmoid junction 612 2.0 9,017 2.8 9,649 2.7
Anus, anal canal, and anorectum 40 0.1 845 0.3 889 0.3
Liver and intrahepatic bile duct 2,780 9.3 20,135 6.1 22,972 6.3
Gallbladder 262 1.0 1,833 0.6 2,102 0.6
Other biliary 136 0.5 1,383 0.4 1,519 0.4
Pancreas 2,407 8.6 36,307 11.2 38,797 11.0
Retroperitoneum 16 0 190 0.1 207 0.1
Peritoneum, omentum, and mesentery 46 0.1 703 0.2 750 0.2
Other digestive organs 67 0.2 1,071 0.3 1,139 0.3
Respiratory system 5,503 20.4 155,925 48.4 161,851 46.2
Nose, nasal cavity, and middle ear 37 0.1 420 0.1 458 0.1
Larynx 214 0.8 3,433 1.0 3,662 1.0
Lung and bronchus 5,225 19.4 151,793 47.1 157,423 45.0
Pleura — — 77 0 82 0
Trachea, mediastinum, and other respiratory organs 22 0.1 202 0.1 226 0.1
Bones and joints 136 0.3 1,262 0.4 1,399 0.4
Soft tissue including heart 390 1.1 4,155 1.4 4,559 1.3
Skin excluding basal and squamous 350 1.2 12,085 3.8 12,463 3.6
Melanoma of the skin 224 0.7 9,010 2.9 9,251 2.7
Other nonepithelial skin 126 0.5 3,075 0.9 3,212 0.9
Male and female breast 2,627 8.1 38,826 12.1 41,555 11.8
Female breast 2,613 14.7 38,436 21.9 41,150 21.3
Male breast — — 390 0.3 405 0.3
See table footnotes on page 50.
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TABLE 12. (Continued) Reported number and age-adjusted rate* of cancer deaths, by primary cancer site and ethnicity† — United States, 2012§
Cancer site
Hispanic§ Non-Hispanic Total
No. Rate No. Rate No. Rate
Female genital system 2,212 12.8 27,113 15.4 29,405 15.2
Cervix 520 2.7 3,536 2.2 4,074 2.3
Corpus and uterus, NOS 619 3.7 8,269 4.6 8,911 4.5
Corpus 245 1.5 3,555 2.0 3,812 1.9
Uterus, NOS 374 2.2 4,714 2.6 5,099 2.6
Ovary 963 5.8 13,407 7.5 14,404 7.4
Vagina 32 0.2 396 0.2 429 0.2
Vulva 45 0.3 986 0.5 1,034 0.5
Other female genital organs 33 0.2 519 0.3 553 0.3
Male genital system 1,706 17.1 26,189 20.2 27,955 20.0
Prostate 1,592 16.5 25,595 19.8 27,244 19.6
Testis 75 0.2 309 0.2 386 0.3
Penis 36 0.3 237 0.2 273 0.2
Other male genital organs — — 48 0 52 0
Urinary system 1,660 6.0 27,875 8.6 29,594 8.5
Urinary bladder 584 2.3 14,630 4.5 15,245 4.4
Kidney and renal pelvis 1,042 3.6 12,451 3.8 13,518 3.8
Ureter — — 362 0.1 378 0.1
Other urinary organs 19 0.1 432 0.1 453 0.1
Eye and orbit 18 0.1 260 0.1 279 0.1
Brain and other nervous system 1,049 3.0 14,194 4.6 15,276 4.4
Endocrine system 248 0.8 2,409 0.8 2,660 0.8
Thyroid 168 0.6 1,521 0.5 1,690 0.5
Other endocrine including thymus 80 0.2 888 0.3 970 0.3
Lymphomas 1,551 5.4 19,914 6.3 21,518 6.2
Hodgkin lymphoma 123 0.4 1,005 0.3 1,130 0.3
Non-Hodgkin lymphoma 1,428 5.0 18,909 6.0 20,388 5.9
Myeloma 782 2.9 11,019 3.4 11,821 3.4
Leukemias 1,603 5.0 21,661 6.9 23,309 6.8
Acute lymphocytic leukemia 325 0.7 1,080 0.4 1,408 0.4
Chronic lymphocytic leukemia 125 0.5 4,463 1.4 4,598 1.3
Acute myeloid leukemia 582 1.9 8,885 2.9 9,484 2.8
Chronic myeloid leukemia 76 0.3 936 0.3 1,017 0.3
Other leukemias 495 1.7 6,297 2.0 6,802 2.0
Mesothelioma 132 0.5 2,545 0.8 2,686 0.8
Miscellaneous 2,313 8.2 37,842 11.7 40,276 11.5
Abbreviation: NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more 
information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS).
§ Data for specified ethnic populations should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/
pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData).
¶ Counts and rates are suppressed if <16 deaths were reported.
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TABLE 13. Reported number of invasive* cancer cases by primary cancer site and year — United States, 1999–2012†
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
All cancer sites combined 1,227,562 1,249,559 1,273,017 1,285,618 1,279,510 1,296,877 1,318,814 1,349,590 1,387,116 1,402,567 1,414,111 1,403,565 1,424,734 1,399,978
Oral cavity and pharynx 27,491 27,954 28,236 28,904 29,506 29,980 30,315 31,314 32,798 34,214 34,619 35,395 36,790 36,990
Lip 2,444 2,393 2,309 2,333 2,041 1,961 1,859 1,880 1,883 1,867 1,832 1,952 1,886 1,725
Tongue 6,640 6,859 7,017 7,478 7,737 8,091 8,298 8,725 9,399 10,100 10,224 10,282 11,118 11,476
Salivary gland 2,982 3,147 3,180 3,220 3,305 3,357 3,470 3,599 3,628 3,754 3,774 3,762 3,792 3,986
Floor of mouth 2,074 2,053 2,075 2,018 1,940 1,916 1,827 1,944 1,923 1,934 1,920 1,924 1,838 1,787
Gum and other mouth 4,357 4,197 4,312 4,236 4,387 4,348 4,338 4,372 4,564 4,759 4,663 4,846 4,927 4,915
Nasopharynx 1,471 1,527 1,416 1,535 1,622 1,559 1,618 1,565 1,722 1,713 1,601 1,660 1,635 1,640
Tonsil 3,409 3,584 3,780 4,032 4,316 4,570 4,756 5,068 5,307 5,730 6,263 6,348 6,754 6,786
Oropharynx 995 1,060 1,106 1,110 1,277 1,295 1,298 1,404 1,416 1,479 1,460 1,666 1,704 1,598
Hypopharynx 2,187 2,153 2,085 2,066 2,163 2,131 2,120 2,034 2,131 2,082 2,127 2,074 2,124 2,106
Other oral cavity and pharynx 932 981 956 876 718 752 731 723 825 796 755 881 1,012 971
Digestive system 232,437 235,790 238,113 239,050 242,294 243,671 244,545 246,111 249,358 252,542 252,284 250,837 254,183 254,508
Esophagus 12,691 12,886 13,082 13,105 13,606 14,152 14,058 14,522 14,535 15,092 15,220 14,598 14,998 14,884
Stomach 19,350 19,227 19,184 19,418 19,689 19,653 19,392 19,400 19,827 19,674 20,036 20,925 21,054 21,168
Small intestine 4,312 4,314 4,614 4,882 5,038 5,379 5,593 5,974 6,179 6,502 6,706 7,124 7,188 7,336
Colon and rectum 142,816 144,059 143,905 142,685 142,037 140,094 138,690 136,944 136,405 135,443 131,492 127,515 127,219 124,944
Colon excluding rectum 104,182 105,255 105,235 104,439 103,760 102,098 100,503 99,464 98,772 98,055 94,444 91,344 91,134 88,810
Rectum and rectosigmoid junction 38,634 38,804 38,670 38,246 38,277 37,996 38,187 37,480 37,633 37,388 37,048 36,171 36,085 36,134
Anus, anal canal, and anorectum 3,467 3,541 3,626 3,801 4,198 4,314 4,506 4,503 4,967 5,230 5,614 5,442 5,694 5,876
Liver and Intrahepatic bile duct 12,470 13,415 13,502 14,451 15,221 16,460 17,381 18,426 20,097 21,264 23,130 23,862 25,028 26,279
Gallbladder 3,102 2,992 3,149 2,980 3,122 3,140 3,231 3,279 3,314 3,330 3,550 3,538 3,607 3,614
Other biliary 3,356 3,544 4,221 4,401 4,565 4,624 4,677 4,862 4,874 5,141 5,349 5,437 5,635 5,603
Pancreas 28,024 28,801 29,421 29,804 31,085 31,922 32,985 34,137 34,961 36,519 36,950 38,112 39,242 40,229
Retroperitoneum 990 963 1,033 1,062 1,038 1,057 1,125 1,094 1,114 1,136 1,135 1,151 1,227 1,257
Peritoneum, omentum, and 
mesentery
1,101 1,188 1,391 1,472 1,646 1,818 1,813 1,751 1,895 1,981 1,838 1,808 1,835 1,791
Other digestive organs 758 860 985 989 1,049 1,058 1,094 1,219 1,190 1,230 1,264 1,325 1,456 1,527
Respiratory system 193,612 194,368 196,473 198,631 201,452 202,402 206,455 207,257 208,946 211,173 211,521 208,570 207,967 207,627
Nose, nasal cavity, and middle ear 1,805 1,799 1,765 1,870 1,815 1,928 1,966 1,953 2,116 2,080 2,104 2,005 2,045 2,126
Larynx 11,696 11,513 11,409 11,081 11,202 11,427 11,373 11,457 11,507 11,489 11,499 11,627 11,400 11,106
Lung and bronchus 179,444 180,405 182,729 185,079 187,813 188,372 192,465 193,219 194,673 196,903 197,245 194,261 193,906 193,768
Pleura 104 101 77 97 92 98 93 83 102 99 104 103 92 100
Trachea, mediastinum, and other 
respiratory organs
563 550 493 504 530 577 558 545 548 602 569 574 524 527
Bones and joints 2,472 2,462 2,627 2,645 2,577 2,640 2,752 2,692 2,755 2,687 2,808 2,708 2,766 2,769
Soft tissue including heart 7,333 7,687 7,846 8,035 8,383 8,792 9,025 8,897 9,449 9,589 9,707 9,978 9,810 10,000
Skin excluding basal and 
squamous
42,231 45,624 49,078 50,756 51,026 54,246 58,466 58,591 60,959 63,467 65,477 65,306 67,704 68,633
Melanoma of the skin 38,867 41,925 45,141 46,757 46,935 50,040 54,096 54,225 56,303 58,484 60,335 60,397 62,674 63,502
Other nonepithelial skin 3,364 3,699 3,937 3,999 4,091 4,206 4,370 4,366 4,656 4,983 5,142 4,909 5,030 5,131
Male and female breast 187,922 187,408 189,541 188,438 181,949 182,828 185,308 189,451 194,935 200,299 205,221 201,894 208,322 210,356
Female breast 186,459 185,946 188,139 186,934 180,386 181,216 183,738 187,819 193,211 198,411 203,405 199,991 206,446 208,404
Male breast 1,463 1,462 1,402 1,504 1,563 1,612 1,570 1,632 1,724 1,888 1,816 1,903 1,876 1,952
Female genital system 71,591 72,193 72,986 72,698 71,893 72,881 74,556 75,675 77,446 79,354 81,185 81,437 83,020 84,199
Cervix 12,991 12,984 12,399 12,079 11,726 11,491 11,719 11,653 11,705 11,623 11,807 11,395 11,339 11,145
Corpus and uterus, NOS 33,458 33,501 34,731 34,927 34,388 35,868 36,928 37,859 39,260 40,755 42,496 43,347 44,709 45,902
Corpus 32,350 32,366 33,573 33,763 33,224 34,727 35,751 36,721 38,124 39,440 41,081 41,970 43,247 44,449
Uterus, NOS 1,108 1,135 1,158 1,164 1,164 1,141 1,177 1,138 1,136 1,315 1,415 1,377 1,462 1,453
Ovary 19,875 20,339 20,361 20,075 20,187 19,805 20,113 20,175 20,131 20,409 20,000 19,569 19,524 19,382
Vagina 1,020 1,088 1,075 1,100 1,052 1,103 1,010 1,083 1,097 1,146 1,154 1,163 1,178 1,199
Vulva 3,401 3,348 3,494 3,515 3,551 3,579 3,700 3,788 3,986 4,017 4,201 4,223 4,355 4,502
Other female genital organs 846 933 926 1,002 989 1,035 1,086 1,117 1,267 1,404 1,527 1,740 1,915 2,069
See table footnotes on page 52.
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TABLE 13. Reported number of invasive* cancer cases by primary cancer site and year — United States, 1999–2012†
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Male genital system 194,920 200,489 206,681 208,978 196,114 195,842 196,522 214,202 226,520 215,968 211,749 203,731 207,234 173,864
Prostate 186,717 192,151 198,257 200,678 187,529 187,229 187,731 205,526 217,631 206,730 202,691 194,600 198,110 164,613
Testis 6,937 7,052 7,160 7,017 7,251 7,355 7,501 7,346 7,509 7,690 7,650 7,673 7,579 7,724
Penis 1,004 1,008 991 1,025 1,053 988 997 1,025 1,099 1,211 1,106 1,143 1,206 1,194
Other male genital organs 262 278 273 258 281 270 293 305 281 337 302 315 339 333
Urinary system 89,166 91,902 94,178 97,018 100,211 103,654 106,689 108,167 111,587 114,459 115,944 115,668 117,650 119,465
Urinary bladder 55,822 56,845 57,153 58,168 59,242 60,732 61,706 60,721 62,484 63,354 64,138 64,051 64,872 65,494
Kidney and renal pelvis 31,073 32,824 34,756 36,629 38,706 40,615 42,661 44,965 46,608 48,383 49,203 49,018 50,068 51,269
Ureter 1,553 1,536 1,560 1,565 1,573 1,608 1,600 1,721 1,668 1,701 1,723 1,720 1,764 1,783
Other urinary organs 718 697 709 656 690 699 722 760 827 1,021 880 879 946 919
Eye and orbit 2,185 2,266 2,283 2,258 2,441 2,459 2,440 2,484 2,538 2,514 2,537 2,438 2,474 2,589
Brain and other nervous system 17,611 17,830 17,766 18,267 18,353 18,879 18,993 19,201 19,512 19,858 20,019 19,809 19,893 19,929
Brain 16,446 16,581 16,541 17,069 17,000 17,542 17,661 17,975 18,204 18,543 18,709 18,587 18,703 18,727
Cranial nerves other nervous 
system
1,165 1,249 1,225 1,198 1,353 1,337 1,332 1,226 1,308 1,315 1,310 1,222 1,190 1,202
Endocrine system 19,093 21,074 22,594 24,401 25,856 28,353 31,030 33,174 36,000 39,386 41,693 42,584 43,924 45,696
Thyroid 17,385 19,322 20,731 22,557 23,905 26,263 28,946 31,071 33,816 37,089 39,506 40,322 41,814 43,523
Other endocrine including thymus 1,708 1,752 1,863 1,844 1,951 2,090 2,084 2,103 2,184 2,297 2,187 2,262 2,110 2,173
Lymphomas 56,381 57,054 58,147 59,578 60,948 62,813 63,613 63,762 65,116 66,350 67,262 67,800 67,173 67,005
Hodgkin lymphoma 7,272 7,461 7,346 7,678 7,617 7,726 7,981 7,905 7,972 8,273 8,012 8,069 7,884 7,704
Non-Hodgkin lymphoma 49,109 49,593 50,801 51,900 53,331 55,087 55,632 55,857 57,144 58,077 59,250 59,731 59,289 59,301
Myeloma 14,184 14,849 15,308 15,608 15,901 16,548 16,879 16,946 17,236 18,122 18,828 19,416 19,942 20,284
Leukemias 32,688 34,533 35,367 34,808 35,970 36,580 36,752 37,614 37,875 38,508 39,192 41,214 41,530 41,569
Acute lymphocytic leukemia 3,670 3,823 3,939 3,916 3,970 4,131 4,066 4,269 4,380 4,536 4,491 4,600 4,701 4,536
Chronic lymphocytic leukemia 10,499 11,455 12,049 12,149 12,669 13,133 13,511 13,683 13,352 13,548 13,605 13,759 13,897 13,938
Acute myeloid leukemia 9,535 10,089 10,192 9,895 10,143 10,132 10,015 10,292 10,407 10,824 10,938 12,208 12,448 12,883
Chronic myeloid leukemia 4,122 4,305 4,343 4,104 4,302 4,437 4,370 4,612 4,643 4,758 5,045 5,278 5,305 5,223
Other leukemias 4,862 4,861 4,844 4,744 4,886 4,747 4,790 4,758 5,093 4,842 5,113 5,369 5,179 4,989
Mesothelioma 2,825 2,889 2,891 2,935 2,925 2,964 3,074 2,978 2,974 3,012 3,048 3,070 3,079 3,002
Kaposi Sarcoma 1,406 1,399 1,391 1,306 1,349 1,315 1,355 1,226 1,263 1,191 1,172 1,112 1,113 1,036
Miscellaneous 32,014 31,788 31,511 31,304 30,362 30,030 30,045 29,848 29,849 29,874 29,845 30,598 30,160 30,457
Abbreviation: NOS = not otherwise specified.
* Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary 
bladder cancer includes invasive and in situ.
† Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999–2012 (covering approximately 92% of the U.S. population). 
See registry-specific data quality information for all years, 1999–2012 (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria). Caution 
should be used when comparing number of cases and deaths because of potential differences in population coverage.
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TABLE 14. Reported number of cancer deaths, by primary cancer site and year — United States, 1999–2012*
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
All cancer sites combined 549,829 553,080 553,760 557,264 556,890 553,880 559,303 559,880 562,867 565,460 567,614 574,738 576,685 582,607
Oral cavity and pharynx 7,486 7,492 7,701 7,737 7,777 7,826 7,773 7,720 8,067 8,019 7,922 8,474 8,657 8,924
Lip 52 67 77 74 72 74 60 51 66 68 57 69 83 71
Tongue 1,738 1,767 1,818 1,887 1,875 1,881 1,948 1,906 2,034 1,983 1,971 2,125 2,089 2,224
Salivary gland 656 663 685 722 696 697 701 699 742 718 795 827 820 869
Floor of mouth 180 153 135 149 147 122 135 114 102 99 109 93 84 75
Gum and other mouth 1,215 1,213 1,179 1,152 1,176 1,168 1,118 1,108 1,109 1,160 1,091 1,212 1,245 1,275
Nasopharynx 638 650 621 628 598 637 615 633 677 645 662 701 630 666
Tonsil 543 518 612 638 608 592 647 654 688 724 736 795 842 879
Oropharynx 600 547 592 606 626 658 655 650 721 734 720 806 861 891
Hypopharynx 385 359 348 323 318 368 281 301 324 294 279 324 322 356
Other oral cavity and pharynx 1,479 1,555 1,634 1,558 1,661 1,629 1,613 1,604 1,604 1,594 1,502 1,522 1,681 1,618
Digestive system 130,070 131,455 131,726 132,541 133,010 132,215 133,562 135,140 136,419 138,469 139,200 142,680 144,007 147,024
Esophagus 11,917 12,232 12,529 12,700 12,860 13,023 13,499 13,685 13,592 13,714 13,908 14,490 14,446 14,649
Stomach 12,711 12,645 12,319 12,198 12,110 11,859 11,514 11,345 11,388 11,352 11,184 11,390 11,035 11,191
Small intestine 1,036 1,057 1,082 1,017 1,070 1,115 1,117 1,091 1,083 1,192 1,195 1,218 1,256 1,293
Colon and rectum 57,222 57,434 56,808 56,603 55,783 53,580 53,005 53,196 53,219 52,857 51,848 52,045 51,783 51,516
Colon excluding rectum 48,962 49,019 48,292 47,987 47,248 44,988 44,325 44,331 44,247 43,650 42,471 42,245 42,181 41,867
Rectum and rectosigmoid junction 8,260 8,415 8,516 8,616 8,535 8,592 8,680 8,865 8,972 9,207 9,377 9,800 9,602 9,649
Anus, anal canal, and anorectum 462 492 511 539 555 589 583 623 644 718 818 813 863 889
Liver and intrahepatic bile duct 12,382 12,916 13,351 14,047 14,706 15,321 16,075 16,525 17,146 18,213 19,352 20,304 21,608 22,972
Gallbladder 2,059 1,949 1,971 1,907 1,915 1,936 1,989 2,000 1,914 1,971 2,048 2,105 2,101 2,102
Other biliary 1,531 1,717 1,630 1,501 1,491 1,461 1,464 1,427 1,436 1,377 1,384 1,519 1,510 1,519
Pancreas 29,081 29,331 29,802 30,263 30,777 31,771 32,759 33,454 34,117 35,234 35,628 36,888 37,344 38,797
Retroperitoneum 220 262 220 219 191 219 238 190 204 226 186 202 219 207
Peritoneum, omentum, and 
mesentery
429 503 543 616 602 686 648 698 721 695 703 702 807 750
Other digestive organs 1,020 917 960 931 950 655 671 906 955 920 946 1,004 1,035 1,139
Respiratory system 156,708 160,051 160,602 162,148 162,589 162,400 163,751 163,134 163,065 163,141 162,492 162,730 161,376 161,851
Nose, nasal cavity, and middle ear 456 419 485 444 457 458 484 426 475 516 530 495 416 458
Larynx 3,815 3,861 3,797 3,722 3,791 3,668 3,796 3,821 3,634 3,760 3,630 3,691 3,732 3,662
Lung and bronchus 152,061 155,426 155,969 157,630 157,990 158,006 159,217 158,599 158,683 158,592 158,081 158,248 156,953 157,423
Pleura 99 76 84 73 76 78 67 64 48 54 55 54 61 82
Trachea, mediastinum, and other 
respiratory organs
277 269 267 279 275 190 187 224 225 219 196 242 214 226
Bones and joints 1,224 1,212 1,298 1,194 1,262 1,301 1,391 1,340 1,362 1,357 1,384 1,378 1,423 1,399
Soft tissue including heart 3,679 3,693 3,646 3,554 3,651 3,722 3,849 3,960 4,023 4,093 4,229 4,376 4,408 4,559
Skin excluding basal and squamous 9,530 9,672 9,992 9,904 10,214 10,301 10,798 11,068 11,234 11,337 12,130 12,089 12,212 12,463
Melanoma of the skin 7,215 7,420 7,542 7,513 7,818 7,952 8,345 8,441 8,461 8,623 9,199 9,154 9,128 9,251
Other nonepithelial skin 2,315 2,252 2,450 2,391 2,396 2,349 2,453 2,627 2,773 2,714 2,931 2,935 3,084 3,212
Male and female breast 41,528 42,300 41,809 41,883 41,998 41,316 41,491 41,209 40,969 41,026 41,076 41,435 41,374 41,555
Female breast 41,144 41,872 41,394 41,514 41,619 40,954 41,116 40,820 40,598 40,589 40,676 40,996 40,931 41,150
Male breast 384 428 415 369 379 362 375 389 371 437 400 439 443 405
See table footnotes on page 54.
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TABLE 14. (Continued) Reported number of cancer deaths, by primary cancer site and year — United States, 1999–2012*
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Female genital system 25,881 26,411 26,838 27,091 27,011 27,049 27,259 27,848 27,739 27,813 27,817 28,770 29,027 29,405
Cervix 4,204 4,200 4,092 3,952 3,919 3,850 3,924 3,976 4,021 4,008 3,909 3,939 4,092 4,074
Corpus and uterus, NOS 6,468 6,585 6,783 6,853 6,899 6,990 7,096 7,384 7,456 7,675 7,713 8,402 8,641 8,911
Corpus 3,121 3,139 3,185 3,187 3,261 3,272 3,259 3,449 3,377 3,436 3,333 3,644 3,714 3,812
Uterus, NOS 3,347 3,446 3,598 3,666 3,638 3,718 3,837 3,935 4,079 4,239 4,380 4,758 4,927 5,099
Ovary 13,627 14,060 14,414 14,682 14,657 14,716 14,787 14,857 14,621 14,362 14,436 14,572 14,346 14,404
Vagina 403 405 382 378 391 416 382 396 376 417 398 423 428 429
Vulva 762 752 765 794 775 806 809 862 865 921 946 942 1,022 1,034
Other female genital organs 417 409 402 432 370 271 261 373 400 430 415 492 498 553
Male genital system 32,349 31,675 31,300 31,084 30,176 29,627 29,514 29,022 29,703 29,120 28,744 29,276 28,630 27,955
Prostate 31,728 31,078 30,719 30,446 29,554 29,002 28,905 28,372 29,093 28,471 28,088 28,560 27,970 27,244
Testis 378 338 335 393 344 357 359 358 326 358 376 399 380 386
Penis 202 217 205 209 250 231 217 245 246 246 234 258 239 273
Other male genital organs 41 42 41 36 28 37 33 47 38 45 46 59 41 52
Urinary system 23,666 24,344 24,910 25,443 25,422 25,928 26,404 26,649 27,319 27,682 27,941 28,726 29,317 29,594
Urinary bladder 11,910 12,002 12,225 12,627 12,483 13,030 13,253 13,474 13,843 14,036 14,201 14,730 15,014 15,245
Kidney and renal pelvis 11,116 11,736 12,078 12,165 12,286 12,313 12,517 12,379 12,703 12,895 12,995 13,219 13,559 13,518
Ureter 345 302 294 297 323 334 347 361 340 354 371 350 338 378
Other urinary organs 295 304 313 354 330 251 287 435 433 397 374 427 406 453
Eye and orbit 227 236 226 240 231 208 252 219 249 262 278 283 280 279
Brain and other nervous system 12,765 12,655 12,609 12,830 12,901 12,829 13,152 12,886 13,234 13,724 14,176 14,164 14,491 15,276
Endocrine system 2,146 2,210 2,299 2,231 2,155 2,272 2,354 2,404 2,488 2,555 2,634 2,641 2,689 2,660
Thyroid 1,241 1,328 1,354 1,367 1,312 1,409 1,462 1,518 1,562 1,649 1,707 1,686 1,747 1,690
Other endocrine including thymus 905 882 945 864 843 863 892 886 926 906 927 955 942 970
Lymphomas 24,205 24,016 23,628 23,262 22,822 22,214 22,145 21,920 21,799 21,539 21,639 21,525 21,485 21,518
Hodgkin lymphoma 1,403 1,287 1,323 1,352 1,347 1,276 1,272 1,327 1,271 1,171 1,250 1,231 1,168 1,130
Non-Hodgkin lymphoma 22,802 22,729 22,305 21,910 21,475 20,938 20,873 20,593 20,528 20,368 20,389 20,294 20,317 20,388
Myeloma 10,508 10,639 10,714 10,913 10,809 10,578 10,758 10,712 10,872 10,606 10,690 11,022 11,411 11,821
Leukemias 21,071 21,397 21,532 21,581 21,608 21,472 21,716 22,016 21,928 22,431 22,688 22,673 23,194 23,309
Acute lymphocytic leukemia 1,361 1,395 1,433 1,432 1,429 1,371 1,460 1,393 1,418 1,424 1,423 1,436 1,432 1,408
Chronic lymphocytic leukemia 4,476 4,323 4,386 4,443 4,476 4,342 4,391 4,498 4,471 4,395 4,557 4,486 4,608 4,598
Acute myeloid leukemia 6,932 7,413 7,749 7,914 8,126 8,214 8,267 8,539 8,568 8,962 9,223 9,150 9,491 9,484
Chronic myeloid leukemia 1,788 1,802 1,649 1,367 1,233 1,164 1,067 1,077 984 1,000 1,003 1,019 1,091 1,017
Other leukemias 6,514 6,464 6,315 6,425 6,344 6,381 6,531 6,509 6,487 6,650 6,482 6,582 6,572 6,802
Mesothelioma 2,343 2,384 2,371 2,430 2,476 2,504 2,553 2,452 2,432 2,538 2,606 2,574 2,651 2,686
Miscellaneous 44,401 41,176 40,519 41,144 40,723 40,070 40,534 40,140 39,920 39,700 39,926 39,886 40,002 40,276
Abbreviation: NOS = not otherwise specified.
* Data are from the National Vital Statistics System (NVSS). Data for deaths cover 100% of the U.S. population. Use caution when comparing numbers of cases and deaths because of potential 
differences in population coverage. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
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TABLE 15. Age-adjusted rate* of invasive† cancer cases, by primary cancer site and year — United States, 1999–2012§
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
All cancer sites combined 483.9 485.1 487.2 483.7 473.1 471.6 470.9 473.4 476.5 471.8 466.0 453.2 450.9 433.7
Oral cavity and pharynx 10.9 10.8 10.8 10.8 10.8 10.8 10.7 10.8 11.1 11.3 11.2 11.2 11.4 11.2
Lip 1.0 0.9 0.9 0.9 0.8 0.7 0.7 0.7 0.7 0.6 0.6 0.6 0.6 0.5
Tongue 2.6 2.7 2.7 2.8 2.8 2.9 2.9 3.0 3.1 3.3 3.3 3.2 3.4 3.4
Salivary gland 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.3 1.3 1.2 1.2 1.3
Floor of mouth 0.8 0.8 0.8 0.8 0.7 0.7 0.6 0.7 0.6 0.6 0.6 0.6 0.6 0.5
Gum and other mouth 1.7 1.6 1.6 1.6 1.6 1.6 1.5 1.5 1.6 1.6 1.5 1.6 1.6 1.5
Nasopharynx 0.6 0.6 0.5 0.6 0.6 0.6 0.6 0.5 0.6 0.6 0.5 0.5 0.5 0.5
Tonsil 1.4 1.4 1.4 1.5 1.6 1.6 1.6 1.7 1.7 1.8 2.0 1.9 2.0 2.0
Oropharynx 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Hypopharynx 0.9 0.8 0.8 0.8 0.8 0.8 0.7 0.7 0.7 0.7 0.7 0.6 0.6 0.6
Other oral cavity and pharynx 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.3
Digestive system 91.8 91.6 91.2 90.1 89.7 88.7 87.3 86.3 85.6 84.8 82.9 80.7 80.1 78.4
Esophagus 5.0 5.0 5.0 4.9 5.0 5.1 5.0 5.0 4.9 5.0 4.9 4.6 4.6 4.5
Stomach 7.6 7.5 7.4 7.3 7.3 7.2 7.0 6.8 6.8 6.7 6.6 6.8 6.7 6.6
Small intestine 1.7 1.7 1.8 1.8 1.9 2.0 2.0 2.1 2.1 2.2 2.2 2.3 2.3 2.3
Colon and rectum 56.4 56.0 55.1 53.8 52.6 51.0 49.6 48.1 46.9 45.7 43.4 41.3 40.4 38.8
Colon excluding rectum 41.1 40.9 40.4 39.4 38.5 37.3 36.0 35.0 34.1 33.2 31.3 29.7 29.0 27.7
Rectum and rectosigmoid junction 15.2 15.1 14.8 14.4 14.1 13.8 13.6 13.1 12.8 12.5 12.1 11.6 11.4 11.1
Anus, anal canal, and anorectum 1.4 1.4 1.4 1.4 1.5 1.6 1.6 1.6 1.7 1.7 1.8 1.7 1.8 1.8
Liver and Intrahepatic bile duct 4.9 5.2 5.2 5.4 5.6 5.9 6.1 6.3 6.8 7.0 7.4 7.4 7.6 7.8
Gallbladder 1.2 1.2 1.2 1.1 1.2 1.1 1.2 1.2 1.1 1.1 1.2 1.2 1.1 1.1
Other biliary 1.3 1.4 1.6 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.7
Pancreas 11.1 11.2 11.3 11.2 11.5 11.6 11.8 12.0 12.0 12.3 12.2 12.3 12.4 12.4
Retroperitoneum 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Peritoneum, omentum, and 
mesentery
0.4 0.5 0.5 0.6 0.6 0.7 0.6 0.6 0.7 0.7 0.6 0.6 0.6 0.6
Other digestive organs 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5
Respiratory system 76.3 75.6 75.4 74.9 74.7 73.9 74.0 73.1 72.1 71.3 69.9 67.5 65.8 64.0
Nose, nasal cavity, and middle ear 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Larynx 4.6 4.5 4.4 4.1 4.1 4.1 4.0 3.9 3.9 3.8 3.7 3.6 3.5 3.3
Lung and bronchus 70.7 70.1 70.1 69.9 69.7 68.8 69.1 68.2 67.3 66.6 65.3 62.9 61.5 59.8
Pleura 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Trachea, mediastinum, and other 
respiratory organs
0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Bones and joints 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 0.9 0.9 0.9
Soft tissue including heart 2.9 3.0 3.0 3.0 3.1 3.2 3.3 3.2 3.3 3.3 3.3 3.3 3.2 3.2
Skin excluding basal and squamous 16.6 17.7 18.7 19.1 18.9 19.8 21.0 20.7 21.1 21.6 21.9 21.5 21.9 21.7
Melanoma of the skin 15.3 16.2 17.2 17.6 17.4 18.2 19.4 19.1 19.5 19.9 20.2 19.8 20.2 20.1
Other nonepithelial skin 1.3 1.4 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.7 1.7 1.6 1.6 1.6
Male and female breast 74.3 72.7 72.3 70.6 66.9 66.1 65.7 66.0 66.7 67.2 67.6 65.3 66.3 65.7
Female breast 135.2 132.8 132.3 129.3 122.9 121.5 121.0 121.9 123.2 124.4 125.3 121.2 123.2 122.3
Male breast 1.4 1.3 1.2 1.3 1.3 1.3 1.3 1.3 1.3 1.4 1.3 1.4 1.3 1.3
See table footnotes on page 56.
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TABLE 15. (Continued) Age-adjusted rate* of invasive† cancer cases, by primary cancer site and year — United States, 1999–2012§
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Female genital system 51.9 51.6 51.4 50.4 49.0 48.9 49.1 49.1 49.3 49.6 49.9 49.0 49.1 48.9
Cervix 9.7 9.6 9.1 8.7 8.4 8.2 8.2 8.1 8.1 7.9 8.0 7.6 7.5 7.4
Corpus and uterus, NOS 24.2 23.8 24.3 24.0 23.2 23.8 24.0 24.2 24.5 24.9 25.4 25.4 25.7 25.8
Corpus 23.4 23.1 23.6 23.3 22.5 23.0 23.3 23.4 23.8 24.1 24.6 24.6 24.9 25.0
Uterus, NOS 0.8 0.8 0.8 0.8 0.8 0.7 0.7 0.7 0.7 0.8 0.8 0.8 0.8 0.8
Ovary 14.3 14.4 14.2 13.8 13.6 13.2 13.1 13.0 12.7 12.7 12.2 11.8 11.6 11.3
Vagina 0.7 0.8 0.7 0.7 0.7 0.7 0.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Vulva 2.4 2.3 2.4 2.4 2.4 2.3 2.4 2.4 2.5 2.5 2.5 2.5 2.5 2.6
Other female genital organs 0.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.9 0.9 1.0 1.1 1.2
Male genital system 176.5 178.4 180.6 178.4 163.7 159.7 156.4 166.0 170.1 157.0 148.7 139.2 137.5 111.7
Prostate 170.0 171.9 174.1 172.0 157.1 153.1 149.7 159.5 163.4 150.1 142.0 132.5 130.9 105.1
Testis 5.3 5.4 5.4 5.3 5.5 5.5 5.6 5.5 5.5 5.7 5.6 5.6 5.5 5.5
Penis 0.9 0.9 0.9 0.9 0.9 0.8 0.8 0.8 0.9 0.9 0.8 0.8 0.9 0.8
Other male genital organs 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2
Urinary system 35.2 35.7 36.1 36.6 37.1 37.8 38.2 38.1 38.5 38.7 38.4 37.5 37.4 37.1
Urinary bladder 22.0 22.1 21.9 22.0 22.0 22.2 22.2 21.5 21.7 21.5 21.3 20.9 20.7 20.4
Kidney and renal pelvis 12.3 12.7 13.3 13.7 14.3 14.7 15.2 15.7 16.0 16.2 16.2 15.8 15.8 15.9
Ureter 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Other urinary organs 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Eye and orbit 0.9 0.9 0.9 0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.8 0.8 0.8
Brain and other nervous system 6.9 6.9 6.8 6.9 6.8 6.9 6.9 6.8 6.8 6.8 6.8 6.6 6.5 6.4
Brain 6.4 6.4 6.3 6.4 6.3 6.4 6.4 6.4 6.4 6.4 6.3 6.2 6.1 6.0
Cranial nerves other nervous system 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.4 0.4 0.4
Endocrine system 7.5 8.1 8.6 9.2 9.6 10.4 11.2 11.8 12.7 13.7 14.3 14.5 14.7 15.2
Thyroid 6.8 7.4 7.9 8.5 8.9 9.6 10.5 11.1 11.9 12.9 13.6 13.7 14.0 14.5
Other endocrine including thymus 0.7 0.7 0.7 0.7 0.7 0.8 0.8 0.8 0.8 0.8 0.7 0.8 0.7 0.7
Lymphomas 22.2 22.1 22.2 22.4 22.6 22.9 22.9 22.6 22.6 22.7 22.6 22.4 21.8 21.3
Hodgkin lymphoma 2.8 2.9 2.8 2.9 2.8 2.9 2.9 2.9 2.9 2.9 2.8 2.8 2.7 2.6
Non-Hodgkin lymphoma 19.3 19.2 19.4 19.5 19.8 20.1 19.9 19.7 19.8 19.7 19.8 19.5 19.0 18.6
Myeloma 5.6 5.8 5.9 5.9 5.9 6.0 6.0 5.9 5.9 6.1 6.2 6.3 6.3 6.3
Leukemias 12.9 13.4 13.5 13.1 13.4 13.4 13.3 13.4 13.2 13.2 13.2 13.6 13.5 13.3
Acute lymphocytic leukemia 1.4 1.5 1.5 1.5 1.5 1.6 1.5 1.6 1.6 1.6 1.6 1.6 1.7 1.6
Chronic lymphocytic leukemia 4.1 4.5 4.6 4.6 4.7 4.8 4.8 4.8 4.6 4.6 4.5 4.4 4.4 4.3
Acute myeloid leukemia 3.7 3.9 3.9 3.7 3.8 3.7 3.6 3.7 3.6 3.7 3.7 4.1 4.1 4.1
Chronic myeloid leukemia 1.6 1.7 1.7 1.5 1.6 1.6 1.6 1.6 1.6 1.6 1.7 1.8 1.7 1.7
Other leukemias 1.9 1.9 1.9 1.8 1.8 1.7 1.7 1.7 1.8 1.7 1.7 1.8 1.7 1.6
Mesothelioma 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.0 1.0 1.0
Kaposi Sarcoma 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.4
Miscellaneous 12.6 12.4 12.1 11.8 11.2 10.9 10.7 10.5 10.3 10.1 9.8 9.9 9.6 9.4
Abbreviation: NOS = not otherwise specified.
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130). For more information, see USCS technical 
notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary 
bladder cancer includes invasive and in situ.
§ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999–2012 (covering approximately 92% of the U.S. population). 
See registry-specific data quality information for all years, 1999–2012 (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria). Caution 
should be used when comparing incidence and death rates because of potential differences in population coverage.
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TABLE 16. Age-adjusted rate* of cancer deaths, by primary cancer site and year — United States, 1999–2012†
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
All cancer sites combined 200.7 198.8 196.3 194.4 190.9 186.8 185.2 182.0 179.3 176.3 173.4 171.8 168.7 166.4
Oral cavity and pharynx 2.7 2.7 2.7 2.7 2.6 2.6 2.5 2.5 2.5 2.5 2.4 2.5 2.5 2.5
Lip 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tongue 0.6 0.6 0.6 0.7 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Salivary gland 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Floor of mouth 0.1 0.1 0 0.1 0 0 0 0 0 0 0 0 0 0
Gum and other mouth 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.4
Nasopharynx 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Tonsil 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Oropharynx 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Hypopharynx 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Other oral cavity and pharynx 0.5 0.6 0.6 0.5 0.6 0.5 0.5 0.5 0.5 0.5 0.4 0.4 0.5 0.4
Digestive system 47.5 47.3 46.7 46.2 45.6 44.5 44.1 43.8 43.3 43.0 42.3 42.3 41.8 41.6
Esophagus 4.3 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.3 4.2 4.2 4.3 4.2 4.1
Stomach 4.6 4.5 4.4 4.3 4.2 4.0 3.8 3.7 3.6 3.5 3.4 3.4 3.3 3.2
Small intestine 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.4 0.4
Colon and rectum 20.9 20.7 20.2 19.8 19.1 18.1 17.6 17.3 16.9 16.5 15.8 15.5 15.1 14.7
Colon excluding rectum 17.9 17.6 17.1 16.8 16.2 15.2 14.7 14.4 14.1 13.6 13.0 12.6 12.3 12.0
Rectum and rectosigmoid junction 3.0 3.0 3.0 3.0 2.9 2.9 2.9 2.9 2.8 2.9 2.8 2.9 2.8 2.7
Anus, anal canal, and anorectum 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3
Liver and intrahepatic bile duct 4.5 4.6 4.7 4.9 5.0 5.1 5.3 5.3 5.4 5.6 5.8 5.9 6.1 6.3
Gallbladder 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.6 0.6 0.6 0.6 0.6 0.6
Other biliary 0.6 0.6 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.4 0.5 0.4 0.4
Pancreas 10.6 10.5 10.6 10.6 10.5 10.7 10.8 10.9 10.8 11.0 10.8 11.0 10.9 11.0
Retroperitoneum 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Peritoneum, omentum, and 
mesentery
0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Other digestive organs 0.4 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Respiratory system 57.1 57.5 57.0 56.6 55.8 54.8 54.3 53.2 52.1 51.0 49.7 48.7 47.3 46.2
Nose, nasal cavity, and middle ear 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1
Larynx 1.4 1.4 1.3 1.3 1.3 1.2 1.2 1.2 1.1 1.2 1.1 1.1 1.1 1.0
Lung and bronchus 55.4 55.8 55.3 55.0 54.2 53.4 52.9 51.7 50.7 49.6 48.4 47.4 46.0 45.0
Pleura 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Trachea, mediastinum, and other 
respiratory organs
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Bones and joints 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Soft tissue including heart 1.3 1.3 1.3 1.2 1.2 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3
Skin excluding basal and 
squamous
3.5 3.5 3.5 3.4 3.5 3.5 3.6 3.6 3.6 3.5 3.7 3.6 3.6 3.6
Melanoma of the skin 2.6 2.7 2.7 2.6 2.7 2.7 2.8 2.7 2.7 2.7 2.8 2.7 2.7 2.7
Other nonepithelial skin 0.8 0.8 0.9 0.8 0.8 0.8 0.8 0.8 0.9 0.8 0.9 0.9 0.9 0.9
Male and female breast 15.2 15.2 14.8 14.5 14.3 13.8 13.6 13.2 12.9 12.7 12.4 12.3 12.0 11.8
Female breast 26.6 26.6 26.0 25.6 25.3 24.5 24.1 23.6 23.0 22.6 22.2 21.9 21.5 21.3
Male breast 0.3 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
See table footnotes on page 58.
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TABLE 16. (Continued) Age-adjusted rate* of cancer deaths, by primary cancer site and year — United States, 1999–2012†
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Female genital system 16.7 16.7 16.8 16.7 16.4 16.2 16.0 16.1 15.8 15.5 15.2 15.5 15.3 15.2
Cervix 2.8 2.8 2.7 2.6 2.5 2.4 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3
Corpus and uterus, NOS 4.1 4.1 4.2 4.2 4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.5 4.5 4.5
Corpus 2.0 2.0 2.0 1.9 2.0 1.9 1.9 2.0 1.9 1.9 1.8 1.9 1.9 1.9
Uterus, NOS 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.4 2.5 2.6 2.6
Ovary 8.8 8.9 9.0 9.0 8.9 8.8 8.7 8.6 8.3 8.0 7.9 7.8 7.5 7.4
Vagina 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Vulva 0.5 0.4 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Other female genital organs 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3
Male genital system 32.1 30.9 30.0 29.2 27.7 26.7 25.8 24.7 24.7 23.5 22.6 22.3 21.2 20.0
Prostate 31.6 30.4 29.5 28.7 27.2 26.2 25.4 24.2 24.2 23.0 22.1 21.8 20.8 19.6
Testis 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3
Penis 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Other male genital organs 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Urinary system 8.7 8.8 8.8 8.9 8.7 8.8 8.8 8.7 8.7 8.6 8.5 8.6 8.6 8.5
Urinary bladder 4.4 4.3 4.3 4.4 4.3 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4
Kidney and renal pelvis 4.1 4.2 4.3 4.2 4.2 4.1 4.1 4.0 4.0 4.0 3.9 3.9 3.9 3.8
Ureter 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Other urinary organs 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Eye and orbit 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Brain and other nervous system 4.6 4.5 4.4 4.5 4.4 4.3 4.3 4.2 4.2 4.3 4.3 4.2 4.3 4.4
Endocrine system 0.8 0.8 0.8 0.8 0.7 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8
Thyroid 0.5 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Other endocrine including thymus 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Lymphomas 8.8 8.6 8.4 8.1 7.8 7.5 7.4 7.2 7.0 6.8 6.7 6.5 6.4 6.2
Hodgkin lymphoma 0.5 0.5 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.3
Non-Hodgkin lymphoma 8.3 8.2 7.9 7.7 7.4 7.1 6.9 6.7 6.6 6.4 6.3 6.1 6.0 5.9
Myeloma 3.8 3.8 3.8 3.8 3.7 3.6 3.6 3.5 3.5 3.3 3.3 3.3 3.4 3.4
Leukemias 7.7 7.7 7.6 7.5 7.4 7.3 7.3 7.2 7.1 7.1 7.1 6.9 6.9 6.8
Acute lymphocytic leukemia 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.4
Chronic lymphocytic leukemia 1.6 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4 1.3
Acute myeloid leukemia 2.5 2.7 2.7 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.9 2.8 2.8 2.8
Chronic myeloid leukemia 0.7 0.6 0.6 0.5 0.4 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3
Other leukemias 2.4 2.3 2.2 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.0 2.0 2.0 2.0
Mesothelioma 0.9 0.9 0.8 0.9 0.9 0.9 0.9 0.8 0.8 0.8 0.8 0.8 0.8 0.8
Miscellaneous 16.2 14.8 14.4 14.4 14.0 13.5 13.4 13.0 12.7 12.4 12.2 11.9 11.7 11.5
Abbreviation: NOS = not otherwise specified.
* Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25-1130). For more information, see USCS technical 
notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ).
† Data are from the National Vital Statistics System (NVSS). Data for deaths cover 100% of the U.S. population. Caution should be used when comparing incidence and death rates because 
of potential differences in population coverage.
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Preface
CDC’s National Institute for Occupational Safety and 
Health (NIOSH) and state health departments collect data 
on laboratory-reported adult blood lead levels (BLLs). This 
report presents data on elevated BLLs among employed adults 
(defined as persons aged ≥16 years) in the United States for 
1994–2013. This report is a part of the Summary of Notifiable 
Noninfectious Conditions and Disease Outbreaks — United States, 
which encompasses various surveillance years but is being 
published in 2016 (1). The Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks appears in the same volume of 
the Morbidity Mortality Weekly Report (MMWR) as the annual 
Summary of Notifiable Infectious Diseases (2).
Background
Since 1987, NIOSH and state health departments have 
maintained the Adult Blood Lead Epidemiology and 
Surveillance (ABLES) Program, a state-based surveillance 
program of laboratory-reported adult BLLs (3). The BLL 
is an often-used estimate of recent external exposure to lead 
(4,5). This report summarizes data on elevated BLLs among 
employed adults during January 1, 1994–December 31, 2013.
Information is provided by geographic division and 
reporting state, for “all cases” reported by a state (these include 
cases among adult residents in the reporting state plus cases 
identified by the reporting state but occurring among persons 
who reside in another state) and “state-residents” only, by 
exposure source, for BLLs ≥10 µg/dL (definition of elevated 
BLL from 2009 until 2014) (3,6–8), and for BLLs ≥25 µg/dL 
(previous definition of elevated BLL) (9). The current case 
definition (BLL ≥5 µg/dL) was adopted in 2015 and became 
effective in 2016, on the basis of mounting evidence for adverse 
health outcomes among adults with BLLs between 5 µg/dL 
and 25 µg/dL (4,5). State prevalence rates of elevated BLLs 
(≥10 µg/dL) for 2013 are categorized into two groups (above 
or below the national prevalence rate) (Figure 1). Trends 
of national prevalence rates of BLLs ≥10 µg/dL and BLLs 
≥25 µg/dL from 1994 to 2013 are provided (Figure 2).
ABLES is the only program conducting nationwide adult 
lead exposure surveillance. It has provided the occupational 
safety and health community with essential information for 
setting research and intervention priorities. ABLES’ impact is 
achieved through its longstanding strategic partnerships with 
state ABLES programs, federal agencies, and worker-affiliated 
organizations. For example, in 2008, the Occupational Safety 
and Health Administration (OSHA) updated its National Lead 
Emphasis Program to reduce occupational lead exposure by 
targeting unsafe conditions and high-hazard industries (10). To 
accomplish this objective, OSHA used national ABLES data to 
identify industries whose employees exhibit high BLLs. OSHA 
has agreements with state ABLES programs to use their lead 
exposure data to target workplace inspections.
Although federal funding for state ABLES programs was 
discontinued in September 2013, a total of 30 states continue 
to collaborate with NIOSH (down from a peak of 41 states) to 
provide data. In August 2015, funding to support adult BLL 
surveillance was resumed at a reduced level. To sustain lead 
exposure surveillance and prevention activities, state ABLES 
programs share resources with two other CDC programs: 
the Childhood Lead Poisoning Prevention Program and 
the Environmental Public Health Tracking Program. Since 
September 2013, NIOSH has continued to provide technical 
assistance to states with adult blood lead surveillance programs 
and maintains the ABLES website for reporting ABLES findings.
The BLL is a direct index of a worker’s exposure to lead 
as well as an indication of the potential for adverse effects 
from that exposure (4,5). The half-life of lead in blood is 
approximately 40 days in males (11), so the BLL is an estimate 
primarily of recent exposure to lead. Because lead accumulates 
in bone and BLL is in equilibrium with bone lead, the BLL 
might be elevated in some persons who have not had recent 
exposure to lead. Because this equilibrium can lead to persistent 
BLL elevations, the public health burden of elevated BLLs in 
adults is measured as prevalence. In contrast, the public health 
burden of elevated BLLs in children aged <3 years is measured 
as incidence because these young children have little lead 
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storage in their bones at birth and thus their early childhood 
blood lead tests reflect recent exposures.
Over the past several decades in the United States, a marked 
reduction has occurred in environmental sources of lead, and 
protection from occupational lead exposure has improved. As 
a result, there is an overall decreasing trend in the mean BLL 
and in the prevalence of elevated BLLs among adults. During 
2011–2012, the mean BLL in adults in the United States was 
1.09 µg/dL (12). Nonetheless, lead exposures among adults 
continue to occur at unacceptable levels (3).
Data Sources
The ABLES program is a state-based surveillance system 
of adult BLLs. The number of cases (numerator) is currently 
provided by ABLES programs in 30 states (29 states provided 
data on BLLs ≥10 µg/dL). The number of employed adults 
(denominator) is obtained from the Local Area Unemployment 
Statistics (LAUS), Bureau of Labor Statistics, in the U.S. 
Department of Labor (http://www.bls.gov/data). A direct link 
to annual averages of states’ employment status of the civilian 
noninstitutionalized population is available (http://www.bls.
gov/lau/staadata.txt). NIOSH consolidates data from reporting 
state ABLES programs, conducts data quality control, analyzes 
the data, and disseminates the findings among stakeholders. 
State ABLES programs 1) collect data on adult BLLs from 
laboratories and physicians through mandatory reporting; 
2) assign unique identifiers to each adult to account for 
multiple BLL records per person, protect individual privacy, 
and permit longitudinal analyses; 3) follow-up on adults with 
BLLs ≥10 or ≥25 µg/dL with laboratories, health care providers, 
employers, or workers to ensure completeness of information 
(e.g., the industry in which the adult is employed and whether 
the exposure source is occupational, nonoccupational, or both); 
4) provide guidance and information to workers and employers 
to prevent lead exposures; and 5) submit data annually to 
NIOSH. Most ABLES states submit data on all BLLs (both 
occupational and nonoccupational) to NIOSH, including 
records from adults whose BLLs fall below the state mandatory 
reporting requirement.
Interpreting Data
The primary measure of adult lead exposure in the United 
States is the national prevalence rate of elevated BLLs among 
employed adults. This measure is provided by the ABLES 
program and can be used to estimate the magnitude and 
monitor trends of lead exposures and to target areas requiring 
further investigation or interventions.
Efforts to reduce lead exposures have resulted in considerable 
progress in reducing the prevalence of elevated BLLs. However, 
many adults in the United States continue to have BLLs 
known to be associated with acute and chronic adverse effects 
in multiple organ systems ranging from subclinical changes 
in function to symptomatic intoxication. These include 
neurologic, cardiovascular, reproductive, hematologic, and 
kidney adverse effects. The risks for adverse chronic health 
effects are even higher if the exposure is maintained for 
many years (4,5). Current research has found decreased renal 
function associated with BLLs at ≤5 µg/dL and increased risk 
of hypertension and essential tremor at BLLs <10 µg/dL (13).
Prevalence rates of adults with BLLs ≥25 µg/dL are available 
since 1994. Beginning in 2002, state ABLES programs reported 
individual BLL laboratory test results and state of residence. 
Formerly, state resident and nonresident data could not be 
separated. When an adult has multiple blood lead tests in a 
given year, only the highest BLL for that adult in that year is 
counted. Prevalence rates of BLLs ≥10 µg/dL are available for 
FIGURE 1. Prevalence rate* of adults with blood lead levels (BLLs) 
≥10 µg/dL, by state — State Adult Blood Lead Epidemiology and 
Surveillance (ABLES) programs, United States, 2013†
≥20.4 adults per 100,000 employed
<20.4 adults per 100,000 employed
Not an ABLES state or did not submit BLLs ≥10 µg/dL data
* Rate per 100,000 employed adults aged ≥16 years. State-resident prevalence 
rate might be lower for some states. Data from the Adult Blood Epidemiology 
and Surveillance (ABLES) Program, National Institute for Occupational Safety 
and Health (NIOSH/CDC). Denominators for 2013 extracted from 2015 U.S. 
Department of Labor, Bureau of Labor Statistics, Local Area Unemployment 
Statistics program (http://www.bls.gov/lau/staadata.txt).
† The national rate in 2013 was 20.4 cases per 100,000 employed adults aged 
≥16 years. A total of 30 states submitted data in 2013: Alabama, Alaska, Arizona, 
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, 
Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, 
Nebraska, New Jersey, New Mexico, New York, North Carolina, Oklahoma, 
Oregon, Pennsylvania, Vermont, Washington, Wisconsin, and Wyoming. 
Massachusetts provided data for BLLs ≥25 µg/dL. In 2013, Missouri (111.8) and 
Iowa (53.7) reported the highest prevalence rates of elevated blood lead levels.
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2010 forward. Prevalence rates of BLLs ≥25 µg/dL are a subset 
of prevalence rates of BLLs ≥10 µg/dL. In the United States, 
most lead exposures among adults are occupational (9). A total 
of 29 states submitted work-relatedness information in 2013. 
Prevalence rate differences across states could reflect improved 
compliance with required OSHA monitoring in some states.
These counts and rates of elevated BLLs must be considered 
minimum estimates of the actual magnitude of the problem of 
lead exposures in the United States. This is for multiple reasons:
• not all states participate in the ABLES program;
• not all employers provide BLL testing to lead-exposed 
workers as required by OSHA regulations;
• not all nonoccupationally exposed adults are tested; and
• some laboratories might not report all tests as required by 
state laws or regulations.
For specific explanations, interpretation, and possible 
updates on data for any individual state, the state ABLES 
program investigator should be contacted directly. Contact 
information is available at http://www.cdc.gov/niosh/topics/
ABLES/state.html.
Methods for Identifying Elevated 
BLLs Among Employed Adults
Beginning in 2016, a nationally reportable case of an 
employed adult with an elevated BLL is defined as a case in an 
employed person aged ≥16 years at the time of blood collection 
with a venous blood lead level ≥5 µg/dL of whole blood. The 
standardized diagnostic test is the BLL test using a venous 
blood sample. All participating state health departments have 
a requirement for laboratories and/or health care providers 
FIGURE 2. National prevalence rate* of reported cases of elevated blood lead levels,† by year — State Adult Blood Epidemiology and 



















































(No. of reporting states) 
Prevalence rates BLLs ≥25 µg/dL 
Prevalence rates BLLs ≥10 µg/dL 
Abbreviation: BLL = blood lead level.
* Per 100,000 employed adults aged ≥16 years. Denominator data extracted from 2015 U.S. Department of Labor, Bureau of labor Statistics Local Area Unemployment 
Statistics (LAUS) program (http://www.bls.gov/lau/staadata.txt).
† Since 2009, the case definition for an elevated blood lead level is a BLL ≥10 µg/dL. For historical comparisons, prevalence rates at the previous case definition 
(BLL ≥25 µg/dL) are provided.
§ A total of 30 states submitted data in 2013 (down from 41 states in 2012): Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, 
Indiana, Iowa, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, New York, North Carolina, Oklahoma, 
Oregon, Pennsylvania, Vermont, Washington, Wisconsin, Wyoming. Massachusetts provided data for BLLs ≥25 µg/dL. For 2013, the first number is the number of 
states reporting BLLs ≥25 µg/dL (i.e., 30 states in 2013), and the second number is the number of states reporting BLLs ≥10 µg/dL (i.e., 29 states in 2013).
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to report laboratory blood lead results to the state health 
department. However, this requirement varies among ABLES 
states, ranging from the reporting of all BLLs to reporting only 
BLLs ≥40 µg/dL (3). The ABLES program ultimately aims to 
establish a national database for all BLL tests among adults 
and encourages all states to share information with NIOSH.
Publication Criteria
Cases meet the publication criteria if the employed adult 
(aged ≥ 16 years) had a venous BLL ≥25 µg/dL during 1994–
2013 or a venous BLL ≥10 µg/dL during 2010–2013. When 
an adult had multiple blood lead tests in a given year, only the 
highest BLL for that adult in that year was counted. Prevalence 
rates of BLLs ≥25 µg/dL are a subset of prevalence rates of 
BLLs ≥10 µg/dL and are included for historic comparison.
Highlights
In 2013, the prevalence rate of BLLs ≥10 µg/dL was 20.4 
adults per 100,000 employed population, calculated from 
29 reporting states. In 2013, a total of 30 states submitted data 
on 5,504 adults with BLLs ≥25 µg/dL, and 29 states submitted 
data on 20,880 adults with BLLs ≥10µg/dL (Table 1). A total 
of 23 states submitted individual level data, and seven states 
submitted count data only. Overall, the national prevalence 
rate of BLLs ≥10 µg/dL declined from 26.6 adults per 
100,000 employed in 2010 (among 37 states) to 20.4 in 2013 
(among 29 reporting states). In 2013, of the 29 reporting 
states, 12 had prevalence rates of BLLs ≥10µg/dL equal to or 
above the national prevalence rate (20.4/100,000) (Figure 1). 
The national prevalence rate of BLLs ≥25 µg/dL among state 
residents and nonresidents declined from 14.0 adults per 
100,000 employed in 1994 (among 17 states) to 5.2 in 2013 
(among 30 states).
Historically, in the United States, most lead exposures among 
adults have been occupational. In 2013, a total of 29 states 
submitted data on 5,491 adults with BLLs ≥25 µg/dL of 
which 944 (17.2%) had no known exposure history (Table 2). 
Among the 4,547 adults with known exposure, 93.7% had 
occupational exposure, ranging from 42.9% to 100% among 
reporting states. Individual level data on 2,313 occupational 
cases with BLLs ≥25 µg/dL were available from 22 states. The 
majority of these adults were employed in four main industry 
sectors: manufacturing (n = 1,227 [53.1%]), construction 
(n = 468 [20.2%]), services (n = 194 [8.4%]), and mining 
(n = 182 [7.9%]). Within manufacturing, the majority of cases 
(n = 878; 71.6%) were among workers employed in storage 
battery manufacturing (North American Industry Classification 
System [NAICS] 33591), alumina and aluminum production 
and processing (NAICS 33131), and nonferrous metal (except 
copper and aluminum) rolling, drawing, extruding, and 
alloying (NAICS 33149) industries. Within construction, 
the majority of cases (n = 329 [70.3%]) were among workers 
employed in painting and wall covering contractors (NAICS 
23832); highway, street, and bridge construction (NAICS 
23731); and residential building construction (NAICS 23611) 
industries. Within the services sector, the majority of cases 
(n = 128 [66%]) were among workers employed in remediation 
services (NAICS 56291); all other amusement and recreation 
industries (NAICS 71399); automotive, mechanical, and 
electrical repair and maintenance (NAICS 81111); and fitness 
and recreational sports centers (NAICS 71394). Copper, 
nickel, lead, and zinc mining (NAICS 21223) accounted for 
98.9% of the mining cases.
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TABLE 1. Reported numbers of cases and prevalence rates of adults* with blood lead levels ≥10 µg/dL and blood lead levels ≥25 µg/dL, by 
geographic division and area — state Adult Blood Lead Epidemiology and Surveillance programs, United States, 2013†
Division/State
No. of employed 
state-resident 
adults (in 1,000s)
Blood lead levels ≥10 µg/dL Blood lead levels ≥25 µg/dL§
All cases¶ State residents** All cases State residents
No. (Rate) No. (Rate) No. (Rate) No. (Rate)
Total 105,474 20,880 (20.4) 19,603 (19.2) 5,504 (5.2) 5,183 (4.9)
New England
Connecticut 1,724 331 (19.2) 313 (18.2) 62 (3.6) 61 (3.5)
Massachusetts 3,272 —†† (—) — (—) 126 (3.9) 105 (3.2)
Vermont 336 47 (14.0) 47 (14.0) 12 (3.6) 12 (3.6)
Mid Atlantic
New Jersey 4,164 832 (20.0) 832 (20.0) 158 (3.8) 158 (3.8)
New York 8,891 1,873 (21.1) 1,731 (19.5) 295 (3.3) 270 (3.0)
Pennsylvania 5,964 2,928 (49.1) 2,915 (48.9) 1,533 (25.7) 1,527 (25.6)
East North Central
Illinois 5,961 1,279 (21.5) 1,253 (21.0) 283 (4.7) 279 (4.7)
Indiana 2,947 596 (20.2) 596 (20.2) 113 (3.8) 113 (3.8)
Michigan 4,306 596 (13.8) 595 (13.8) 108 (2.5) 108 (2.5)
Wisconsin 2,877 687 (23.9) 686 (23.8) 105 (3.7) 105 (3.7)
West North Central
Iowa 1,594 856 (53.7) 856 (53.7) 202 (12.7) 202 (12.7)
Minnesota 2,819 598 (21.2) 598 (21.2) 107 (3.8) 107 (3.8)
Missouri 2,814 3,145 (111.8) 2,835 (100.8) 690 (24.5) 613 (21.8)
Nebraska 983 195 (19.8) 195 (19.8) 32 (3.3) 32 (3.3)
South Atlantic
Florida 8,783 888 (10.1) 863 (9.8) 270 (3.1) 266 (3.0)
Georgia 4,368 898 (20.6) 897 (20.5) 237 (5.4) 237 (5.4)
Maryland 2,917 275 (9.4) 234 (8.0) 75 (2.6) 62 (2.1)
North Carolina 4,310 219 (5.1) 218 (5.1) 99 (2.3) 99 (2.3)
East South Central
Alabama 2,012 928 (46.1) 548 (27.2) 433 (21.5) 299 (14.9)
Kentucky 1,892 478 (25.3) 468 (24.7) 94 (5.0) 92 (4.9)
West South Central
Louisiana 1,965 380 (19.3) 380 (19.3) 92 (4.7) 92 (4.7)
Oklahoma 1,707 144 (8.4) 121 (7.1) 29 (1.7) 27 (1.6)
Mountain
Arizona§§ 2,804 178 (6.3) 178 (6.3) 20 (0.7) 20 (0.7)
Colorado 2,591 103 (4.0) 41 (1.6) 29 (1.1) 15 (0.6)
New Mexico 859 48 (5.6) 48 (5.6) 13 (1.5) 13 (1.5)
Wyoming 292 66 (22.6) 66 (22.6) 12 (4.1) 12 (4.1)
Pacific
Alaska 340 123 (36.1) 62 (18.2) 8 (2.4) 6 (1.8)
California 17,003 1,825 (10.7) 1,790 (10.5) 192 (1.1) 191 (1.1)
Oregon 1,761 92 (5.2) 79 (4.5) 12 (0.7) 9 (0.5)
Washington 3,217 272 (8.5) 158 (4.9) 63 (2.0) 51 (1.6)
 * An employed person aged ≥16 years at the time of blood collection. When an adult had multiple blood lead tests in a given year, only the highest blood lead level 
for that adult in that year was counted. Rate per 100,000 employed adults. Data from the Adult Blood Epidemiology and Surveillance (ABLES) Program, National 
Institute for Occupational Safety and Health (NIOSH/CDC). Denominators extracted from 2015 U.S. Department of Labor, Bureau of Labor Statistics, Local Area 
Unemployment Statistics (LAUS) program (http://www.bls.gov/lau/staadata.txt).
 † A total of 30 states participated in the ABLES Program in 2013.
 § The numbers and rates of adults with BLLs ≥25 µg/dL are subsets of the numbers and rates of adults with BLLs ≥10 µg/dL.
 ¶ All cases reported by a state. These include cases among adult residents in the reporting state plus cases identified by the reporting state but who reside in another state.
 ** Adults residing in the reporting state.
 †† 10–15 µg/dL BLL data were not available.
 §§ Data from Arizona were available only for January to August 2013.
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TABLE 2. Reported numbers of adults* with blood lead levels ≥25 µg/dL, by exposure source and area — state Adult Blood Lead Epidemiology 
and Surveillance programs, United States, 2013†
Division/State
Occupational§ Nonoccupational Unknown Total
No. (%) No. (%) No. (%) No.
Total 4,262 (77.6) 285 (5.2) 944 (17.2) 5,491
New England
Connecticut 37 (59.7) 23 (37.1) 2 (3.2) 62
Massachusetts 71 (56.3) 24 (19.0) 31 (24.6) 126
Vermont 3 (25.0) 4 (33.3) 5 (41.7) 12
Mid Atlantic
New Jersey 105 (66.5) —¶ (—) 53 (33.5) 158
New York 191 (64.7) 78 (26.4) 26 (8.8) 295
Pennsylvania 1,449 (94.5) — (—) 84 (5.5) 1,533
East North Central
Illinois 177 (62.5) 14 (4.9) 92 (32.5) 283
Indiana 67 (59.3) — (—) 46 (40.7) 113
Michigan 70 (64.8) 28 (25.9) 10 (9.3) 108
Wisconsin 88 (83.8) 9 (8.6) 8 (7.6) 105
West North Central
Iowa 200 (99.0) 2 (1.0) — (—) 202
Minnesota 92 (86.0) 3 (2.8) 12 (11.2) 107
Missouri 682 (98.8) 8 (1.2) — (—) 690
Nebraska 25 (78.1) 2 (6.3) 5 (15.6) 32
South Atlantic
Florida 82 (30.4) 11 (4.1) 177 (65.6) 270
Georgia 100 (42.2) — (—) 137 (57.8) 237
Maryland 57 (76.0) 4 (5.3) 14 (18.7) 75
North Carolina 89 (89.9) 8 (8.1) 2 (2.0) 99
East South Central
Alabama 353 (81.5) — (—) 80 (18.5) 433
Kentucky — (—) — (—) 94 (100.0) 94
West South Central
Louisiana 78 (92.9) 5 (6.0) 1 (1.2) 84
Oklahoma 7 (24.1) 2 (6.9) 20 (69.0) 29
Mountain
Arizona 12 (80.0) 3 (20.0) – (—) 15
Colorado 4 (13.8) 3 (10.3) 22 (75.9) 29
New Mexico 4 (30.8) 3 (23.1) 6 (46.2) 13
Wyoming 12 (100.0) — (—) – (—) 12
Pacific
Alaska 5 (62.5) — (—) 3 (37.5) 8
California 146 (76.0) 45 (23.4) 1 (0.5) 192
Oregon 7 (58.3) 1 (8.3) 4 (33.3) 12
Washington 49 (77.8) 5 (7.9) 9 (14.3) 63
* An employed person aged ≥16 years at the time of blood collection. When an adult had multiple blood lead tests in a given year, only the highest blood lead level 
for that adult in that year was counted.
† Among the 30 reporting states, 29 states submitted data on exposure source in 2013. These data include adult residents in the state and residents of other states 
reported by the state ABLES programs.
§ Includes 23 cases coded with both occupational and nonoccupational exposure source.
¶ No cases were reported.
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Preface
This report provides data concerning childhood blood lead 
levels (BLLs) in the United States during 2007–2013. These 
data were collected and compiled from raw data extracts sent by 
state and local health departments to CDC’s Childhood Blood 
Lead Surveillance (CBLS) system. These raw data extracts 
have been de-identified and coded into a format specifically 
for childhood lead reporting. The numbers of children aged 
<5 years reported to CDC for 2013 with newly confirmed 
BLLs ≥10 µg/dL are provided in tabular form by month 
(Table 1) and geographic location (Table 2). The incidence 
of BLLs ≥10 µg/dL is reported by age group for 2007–2013 
(Table 3). The numbers of children aged <5 years with BLLs 
5–9 µg/dL for 2013 are reported (Table 4). For the period 
2007–2013, the numbers of children newly confirmed with 
BLLs ≥70 µg/dL are summarized (Figure 1) as well as the 
percentage of children with BLLs ≥5 µg/dL (Figure 2). This 
report is a part of the Summary of Notifiable Noninfectious 
Conditions and Disease Outbreaks — United States, which 
encompasses various surveillance years but is being published in 
2016 (1). The Summary of Notifiable Noninfectious Conditions 
and Disease Outbreaks appears in the same volume of MMWR 
as the annual Summary of Notifiable Infectious Diseases (2).
Background
Permanent neurologic damage and behavioral disorders have 
been found to be associated with lead exposure at blood levels 
at or below 5 µg/dL (3–6). No safe BLLs in children have been 
identified (7). Studies examining children with high BLLs 
(≥70 µg/dL) have shown severe neurologic problems, including 
seizures, comas, and death (8). Children aged <5 years are at 
increased risk because their bodies are growing rapidly and 
they tend to put their hands or other objects, which might be 
contaminated with lead dust, into their mouths. 
In 1991, CDC recommended that BLLs ≥10 µg/dL in 
children should prompt public health action by the state or 
local health departments with follow-up testing (9). In 1995, 
the Council of State and Territorial Epidemiologists (CSTE), in 
collaboration with CDC, designated elevated BLLs as the first 
noninfectious condition to be added to the list of conditions 
designated as reportable at the national level (10).
In May 2012, the Advisory Committee on Childhood 
Lead Poisoning Prevention* (ACCLPP) recommended 
the use of a reference range for blood lead (11). ACCLPP 
recommended that the upper value of the reference range be 
based on the 97.5th percentile of the National Health and 
Nutritional Examination Survey† (NHANES). A generated 
BLL distribution in children aged 1–5 years (currently 5 µg/dL) 
is used by clinical and public health care providers to identify 
children with elevated BLLs (11).
In 2012, a total of 29 states and New York City identified 
and reported approximately 138,000 children aged <6 years 
with BLLs ≥5 µg/dL (12). Federal funding for reporting BLLs 
ended in 2012, and several states lost their statewide lead 
programs. By 2013, the number of children reported to CDC 
with BLLs ≥5 µg/dL had decreased, as had the number of states 
reporting data to CDC (12). For this report, CDC examined 
reported BLLs of children aged <5 years in three categories: 
children with BLLs ≥10 µg/dL, children with new reports of 
BLLs ≥10 µg/dL, and children with BLLs 5–9µg/dL.)
Data Sources
Results of blood lead tests for children from state and local 
health departments were sent to CDC’s Healthy Homes and 
Lead Poisoning Prevention Program (HHLPPP). When federal 
funding was available, prior to 2013, states submitted data on 
a quarterly basis. After funding ended in 2012, a total of 27 
states, the District of Columbia, and New York City continued 
Corresponding author: Jaime Raymond, Division of Emergency and 
Environmental Health Services, National Center for Environmental 
Health, CDC. Telephone: 770-488-3627; E-mail: zvu0@cdc.gov.
* ACCLPP advised and guided the Secretary and Assistant Secretary of the U.S. 
Department of Health and Human Services and the Director of CDC regarding 
new scientific knowledge and technical developments and their practical 
implications for childhood lead poisoning prevention efforts (http://www.cdc.
gov/nceh/lead/acclpp/acclpp_main.htm).
† NHANES is a program of studies designed to assess the health and nutritional 
status of adults and children in the United States (http://www.cdc.gov/nchs/
nhanes.htm).
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to submit data to CDC in 2013 while 14 states that had lost 
funding for their childhood lead program could not provide 
data. Most of the states that continued to have childhood 
lead programs had sustainable funding through the state in 
which the health departments would verify the data collected 
for blood lead testing. The test results compiled and analyzed 
by state health departments and submitted to CDC comprise 
the CBLS database.
State and local childhood blood lead surveillance systems 
retain the results of blood lead tests of children reported to 
state health departments by private laboratories, as well as state 
and local government laboratories. The reporting criteria of 
BLLs from the laboratories to the state are set by each state 
and vary across jurisdictions. A set of core data variables have 
been established by CDC and participating states that should 
be collected for every child at the time of the blood lead 
test. These variables include identification and demographic 
information (e.g., date of birth, race, or ethnicity), laboratory 
information (e.g., venous or capillary blood test), date of blood 
lead test, address information such as city and zip code, and 
test result (13). Each child is assigned a unique identifier that 
corresponds to the de-identified and de-duplicated data sent 
to CDC. CDC checks each state-submitted record for correct 
formatting, coding and content. Records not meeting CDC 
TABLE 1. Number and percentage of reported new cases of blood lead levels ≥10 µg/dL among children aged <5 years, by month — Childhood 
























No. (%) Total No.
538 (6.5) 469 (5.7) 416 (5.1) 543 (6.6) 718 (8.7) 739 (9.0) 947 (11.5) 1,053 (12.8) 965 (11.7) 823 (10.0) 566 (6.0) 453 (5.5) 8,230
* A total of 29 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New Mexico, New York City, North Carolina, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Vermont, West Virginia, and Wisconsin).
TABLE 2. Reported number of newly identified cases of blood lead 
levels ≥10 µg/dL among children aged <5 years, by geographic region 














New York City 639
Pennsylvania 1,240
























TABLE 2. (Continued) Reported number of newly identified cases of 
blood lead levels ≥10 µg/dL among children aged <5 years, by 
geographic region and state —Childhood Blood Lead Surveillance 
System, United States, 2013
Region/State No.

























* No data were reported for 2013.
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criteria are summarized in file processing reports that are sent 
to states for correction. Certain errors, if not corrected, prevent 
the record from being entered in CDC’s CBLS database. For 
states with an error rate >10%, no data are loaded into CBLS, 
and the state must correct the problems before sending the 
records back to CDC.
Interpreting Data
In this report, state surveillance data are presented for 
children aged <5 years who were tested for lead at least once 
during 2007–2013 and whose tests were reported to CDC. 
Having a confirmed BLL ≥10 µg/dL is defined as having one 
venous blood lead test ≥10 µg/dL or two capillary blood lead 
tests ≥10 µg/dL drawn within 12 weeks of each other (14). 
Incidence data rates are presented by the date of the confirmed 
blood lead test. Date are reported by the jurisdiction of the 
child’s residence at the time of the confirmed blood lead test. 
State health departments check for duplicate laboratory reports 
for children and completeness of the laboratory report before 
sending the data to CDC. After data are sent, CDC also checks 
to ensure the completeness and accuracy of the data.
The data provided in this report are useful for analyzing 
childhood blood lead trends and determining relative 
morbidity numbers. However, reporting practices affect how 
these data are interpreted. Childhood blood lead reporting 
is likely incomplete, and completeness of the records might 
vary depending on state, laboratory, or BLL range (e.g., BLLs 
<10 µg/dL might not be required to be reported in some states). 
Independent of the actual incidence of disease, factors such as 
changes in the methods of surveillance or introduction of new 
diagnostic tests (e.g., use of a portable handheld analyzer) can 
cause changes in the reported blood lead levels.
In 2007, a total of 38 states, New York City, and the District 
of Columbia reported data to CDC. During 2007–2013, the 
number of states collecting and reporting childhood blood 
lead data to CDC fluctuated. Federal funding from CDC to 
state and local health departments ended in September 2012. 
For this reason, no states were required to report childhood 
blood lead data to CDC in 2013. Nevertheless, 29 jurisdictions 
(27 states, New York City, and the District of Columbia) did 
collect and report data to CDC. Although the varying number 
 TABLE 3. Reported number of new cases and incidence rate per 
100,000 children aged <5 years with blood lead levels ≥10 µg/dL, by 
age group — Childhood Blood Lead Surveillance System, United 
States, 2007–2013*
Year
<1 yr 1–4 yrs
No. Rate No. Rate
2007† 2,055 47.75 18,398 110.72
2008§ 1,852 43.00 15,251 90.41
2009¶ 1,608 38.69 13,432 78.76
2010** 1,412 34.05 11,647 68.05
2011†† 1,185 29.89 10,532 65.25
2012§§ 860 21.81 9,369 58.31
2013¶¶ 777 19.55 7,453 46.89
 * Denominators are calculated as estimates of all children living in the United 
States from U.S. Census data. 
 † A total of 40 jurisdictions reported data to CDC (Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New 
Hampshire, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, Washington, 
West Virginia, and Wisconsin).
 § A total of 38 jurisdictions reported data to CDC (Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Nevada, New Jersey, New Hampshire, New York, 
New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode 
Island, Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 ¶ A total of 38 jurisdictions reported data to CDC (Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Nevada, New Jersey, New Hampshire, New York, 
New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode 
Island, Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 ** A total of 37 jurisdictions reported data to CDC (Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Nevada, New Jersey, New Hampshire, New 
York, New York City, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, 
Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 †† A total of 36 jurisdictions reported data to CDC (Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New York, New 
York City, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, 
Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 §§ A total of 30 jurisdictions reported data to CDC (Alabama, Arizona, 
Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Missouri, New Jersey, New Hampshire, New York, New York City, 
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Vermont, West Virginia, 
and Wisconsin).
 ¶¶ A total of 29 jurisdictions reported data to CDC (Alabama, Arizona, 
Connecticut, District of Columbia, Georgia, Illinois, Indiana, Kentucky, 
Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, New Jersey, New Hampshire, New Mexico, New York City, North 
Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, 
Vermont, West Virginia, and Wisconsin).
TABLE 4. Number of children aged <5 years with blood lead levels 
5–9 µg/dL, by sample type and age — Childhood Blood Lead 
Surveillance System, United States, 2013*
Age at time of blood 
lead test (yrs) Capillary/Unknown (%) Venous (%)
<1 3,960 (61.2) 2,510 (38.8)
1 14,035 (56.4) 10,866 (43.6)
2 11,999(57.2) 8,967 (42.8)
3 6,728 (57.2) 5,028 (42.8)
4 5,609 (56.0) 4,408 (44.0)
Total 42,331 (57.1) 31,779 (42.9)
* A total of 29 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, 
District of Columbia, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New 
Hampshire, New Mexico, New York City, North Carolina, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Vermont, West Virginia, and Wisconsin).
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of states reporting data from year to year during 2007–2013 
limits the extent to which trends can be analyzed, the data 
nonetheless can indicate BLLs in children for a particular year.
Methods for Identifying 
Childhood Blood Lead
Elevated blood lead levels has been a 
notifiable condition since 1995 (9). CDC 
asks state health departments to report all 
blood lead test data for children to HHLPPP, 
regardless of the BLL. Each state has its own 
laws and regulations regarding blood lead test 
reporting to the state health department. Of 
the 35 programs funded in 2014 by CDC, 
33 required electronic reporting from the 
laboratory to the state health department.
Before ACCLPP’s mid-2012 recommendation 
to use the 97.5 percentile from NHANES, 
currently 5 µg/dL, the “level of concern” was 
10 µg/dL (10). For this report, elevated BLLs are 
defined as confirmed BLLs ≥10 µg/dL. Data on 
children with BLLs ≥5 µg/dL also are reported. 
Publication Criteria
Reports of children aged <5 years with BLLs 
5–9µg/dL and confirmed BLLs ≥10 µg/dL 
during 2007–2013.
Highlights
Lead exposure in children can cause 
permanent neurologic damage (3). Behavioral 
disorders are associated with lead exposure even 
at detectable blood levels at or below 5 µg/dL 
(3–6). The most common highly concentrated 
source of lead for children in the United States 
is lead paint. When paint containing lead 
deteriorates into flakes, chips, or fine dust, it 
is easily inhaled or ingested by small children.
In 2011, the last full calendar year of federal 
funding from CDC, 34 states,§ District of 
Columbia, and New York City submitted 
BLL data to CDC; however, by 2013, only 
FIGURE 1. Number of children aged <5 years with newly confirmed blood lead levels 














* For 2007, a total of 40 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, 
Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New 
Jersey, New Hampshire, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2008, a total of 39 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, 
Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Jersey, 
New Hampshire, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, 
Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2009, a total of 39 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, 
Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, 
New Hampshire, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, 
Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2010, a total of 37 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, 
Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, 
New Hampshire, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, 
Rhode Island, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2011, a total of 36 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, 
Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New 
Hampshire, New York, New York City, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, 
Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 For 2012, a total of 30 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, District of 
Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, 
Michigan, Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New York, New York City, 
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Vermont, West Virginia, and Wisconsin).
 For 2013, a total of 29 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, District of 
Columbia, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New Mexico, New York City, North 
Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Vermont, West Virginia, 
and Wisconsin).
§ States and jurisdictions reporting data included Alabama, Arizona, California, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, New Hampshire, New Jersey, New York, New 
York City, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, 
Vermont, Virginia, Washington, West Virginia, and Wisconsin.
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27 states,¶ District of Columbia, and New York City submitted 
data (a 21% reduction in contributors). Although the decline 
in the number of health departments submitting data to CDC 
makes it difficult to assess trends over time, it is still possible to 
evaluate new cases in children with confirmed BLLs ≥10 µg/dL 
and cases in children with BLL 5–9 µg/dL from the states that 
continue to submit data to CDC.
In 2013, during the warmest weather months (July–
September), 2,965 new cases were identified, more than in 
any other consecutive 3-month period (Table 1). In warm 
weather, windows that possibly are painted with lead-based 
paint are opened and closed, creating lead dust in the air and 
on the ground. Repainting and renovation activities also are 
more common in warm-weather months. Increased presence 
and activity of children in and around the home might lead to 
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* For 2007, a total of 40 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New Hampshire, 
New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2008, a total of 39 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Jersey, New Hampshire, New York, 
New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2009, a total of 39 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, New Hampshire, New York, 
New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2010, a total of 37 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, New Hampshire, New York, 
New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Vermont, Virginia, West Virginia, and Wisconsin).
 For 2011, a total of 36 jurisdictions reported data to CDC (Alabama, Arizona, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New York, New York 
City, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin).
 For 2012, a total of 30 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, 
Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New York, New York City, Ohio, Oklahoma, 
Oregon, Pennsylvania, Rhode Island, Vermont, West Virginia, and Wisconsin).
 For 2013, a total of 29 jurisdictions reported data to CDC (Alabama, Arizona, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New Hampshire, New Mexico, New York City, North Carolina, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Vermont, West Virginia, and Wisconsin).
¶ States and jurisdictions reporting data included Alabama, Arizona, District of 
Columbia, Georgia, Illinois, Indiana, Kentucky, Maryland, Massachusetts, 
Minnesota, Mississippi, Missouri, New Hampshire, New Jersey, New York City, 
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Vermont, West Virginia, 
and Wisconsin.
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children having more contact with contaminated dust, surfaces, 
and soil (15). This contact can lead to higher BLLs in the late 
summer and early fall.
The East North Central region reported the greatest number 
of new cases in 2013, with 2,997 children aged <5 years with 
confirmed BLLs ≥10 µg/dL reported to CDC, followed by the 
Mid-Atlantic region with 2,472 children (Table 2). These two 
regions (comprising eight state and local health departments 
that reported data) accounted for 67% of the new cases 
in the United States and almost 47% of the children aged 
<5 years tested and reported to CDC for 2013. The other 
seven geographic areas (comprising 21 state and local health 
departments that reported data to CDC for 2013) accounted 
for the remaining 33% of new cases and for 53% of the children 
aged <5 years tested and reported to CDC for 2013.
The number of new cases, defined as cases in children aged 
<5 years with a first-ever confirmed BLL ≥10 µg/dL, that were 
reported to CDC continued to decrease during 2007–2013 
(Table 3). Although not all jurisdictions reported data to 
CDC, the denominator is the entire child population aged 
<1 year and aged 1–4 years from the U.S. Census across all 
years. Children aged 1–4 years continue to have a higher rate 
of confirmed BLLs ≥10 µg/dL than other children across all 
years, possibly because of increased hand-to-mouth activity 
and mobility for older children.
The numbers of newly confirmed children with BLLs 
≥70 µg/dL during 2007–2013 are presented in graphic form 
(Figure 1). Changes in the number of jurisdictions reporting 
data to CDC over these 7 years make it difficult to discern any 
trend or clear pattern. One Healthy People 2010 environmental 
health objective is eliminating BLLs ≥10 µg/dL (16). These 
children have BLLs at least seven times above the Healthy 
People 2010 goal.
Prevalence data indicate that 74,110 children aged <5 years 
had a BLL 5–9µg/dL in 2013 (Table 4). Although a single 
capillary test is not a confirmatory test, in 2013, of the 
approximately 74,000 children aged <5 years who were tested 
and who were reported to CDC as having BLLs 5–9µg/dL, 
31,779 ( 43%) had a confirmed 5–9 µg/dL by venous sample 
type. The mid-2012 change in the reference value and the 
loss of federal funding to state and local health departments 
from CDC made it difficult for most states to extend follow 
up testing for capillary tests 5–9µg/dL. Although venous 
blood lead samples have been the gold standard, one study 
has shown that capillary blood draws are suitable alternatives 
to venous blood draws when screening children aged <6 years 
to determine lead exposure and provide reasonable estimates 
at the population level (17).
During 2007–2013, a majority of the children aged <5 years 
with BLLs ≥5 µg/dL had BLLs 5–9 µg/dL (Figure 2). The 
percentage of children with confirmed BLLs ≥10 µg/dL 
increased from 7.5% to 13.3% during the same period. CDC, 
along with state and local health departments, continue efforts 
to reduce BLLs ≥5 µg/dL and confirmed BLLs ≥10 µg/dL 
through screening and primary prevention (18).
Effective surveillance requires state and local health 
departments to track a substantial number of children and 
their blood lead test results over time. More detailed annual 
summaries describing the number of children tested for lead 
by state, county, and BLL are published periodically by CDC. 
A summary of childhood lead exposure in 2014, the most 
recent year for which data are available, is provided at http://
www.cdc.gov/nceh/lead.
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Preface
CDC’s National Institute for Occupational Safety and Health 
(NIOSH), state health departments, and other state entities 
maintain a state-based surveillance program of confirmed 
silicosis cases. Data on confirmed cases are collected and 
compiled by state entities and submitted to CDC. This report 
summarizes information for cases of silicosis that were reported 
to CDC for 2003–2011 by Michigan and New Jersey, the only 
states that continue to provide data voluntarily to NIOSH. 
The data for this report were final as of January 8, 2015. Data 
are presented in tabular form on the number and distribution 
of cases of silicosis by year (Table 1), duration of employment 
in occupations with potential exposure to dust containing 
respirable crystalline silica (Table 2), industry (Table 3), and 
occupation (Table 4). The number of cases by year is presented 
graphically (Figure). This report is a part of the Summary of 
Notifiable Noninfectious Conditions and Disease Outbreaks — 
United States, which encompasses various surveillance years 
but is being published in 2016 (1). The Summary of Notifiable 
Noninfectious Conditions and Disease Outbreaks appears in the 
same volume of MMWR as the annual Summary of Notifiable 
Infectious Diseases (2).
Background
Silicosis, a form of pneumoconiosis, is a progressive 
occupational lung disease caused by the inhalation, deposition, 
and retention of respirable dust containing crystalline silica. 
There is no effective specific treatment, and patients with 
silicosis can be offered only supportive care. Silicosis is 
preventable by using nonsilica substitution materials, effective 
dust control measures, and personal protective equipment.* 
Occupational exposure to respirable dust containing 
crystalline silica occurs in mining, quarrying, sandblasting, 
rock drilling, construction, pottery making, stone masonry, 
and tunneling operations (3). The Occupational Safety and 
Health Administration (OSHA) estimates that >2 million 
workers are currently exposed† to respirable crystalline silica in 
industries where exposure might occur, including 1.85 million 
workers in the construction industry and 320,000 workers in 
general industry and maritime workplaces (4,5). Typically a 
disease of long latency, silicosis usually is diagnosed through 
a chest radiograph after ≥10 years of exposure to respirable 
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topics/silicacrystalline/control_measures_silica.html.
† National compliance standards for silica dust exposure (the Mine Safety and 
Health Administration [MSHA] and the Occupational Safety and Health 
Administration [OSHA]) use permissible exposure limits (PEL) based on the 
American Conference of Governmental Industrial Hygienists threshold limit 
value. These began to be applied in the early 1970s and included limits on 
exposure to silica through regulation of respirable mixed mine dust in 
underground coal mines using the MSHA’s formula: (10 mg/m3)/(% quartz), 
and direct limits on exposure to crystalline silica as respirable quartz using the 
formulas: (10 mg/m3)/(%quartz + 2) for metal/nonmetal mining and general 
industry or (250 million particles per cubic foot)/(%quartz + 5) for the 
construction industry (currently for the construction industry, sampling, 
analysis, and calculations are the same as general industry, except an additional 
calculation to convert to millions of particles per cubic foot is conducted to 
determine overexposure according to OSHA’s National Emphasis Program–
Crystalline Silica at https://www.osha.gov/pls/oshaweb/owadisp.show_
document?p_table=DIRECTIVES&p_id=3790). For more information, see 
Lowering Miners’ Exposure to Respirable Coal Mine Dust, Including 
Continuous Personal Dust Monitors; Final Rule, available at https://www.gpo.
gov/fdsys/pkg/FR-2014-05-01/pdf/2014-09084.pdf, Criteria for a 
Recommended Standard: Occupational Exposure to Respirable Coal Mine Dust 
at http://www.cdc.gov/niosh/docs/95-106/pdfs/95-106.pdf, Occupational 
Safety and Health Standards, Toxic and Hazardous Substances, 1910.1000, 
TABLE Z-3 Mineral Dusts at https://www.osha.gov/pls/oshaweb/owadisp.
show_document?p_table=STANDARDS&p_id=9994, Safety and Health 
Regulations for Construction, Occupational Health and Environmental 
Controls, 1926.55 App A, Gases, vapors, fumes, dusts, and mists at https://
w w w. o s h a . g o v / p l s / o s h a w e b / o w a d i s p . s h o w _ d o c u m e n t ? p _
table=STANDARDS&p_id=10629, and OSHA Frequently Asked Questions, 
Silica Advisor at https://www.osha.gov/dsg/etools/silica/faq/faq.html.
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TABLE 1. Number and percentage* of silicosis cases, by year — 
Michigan and New Jersey, 2003–2011
Year
Michigan New Jersey Total
No. (%) No. (%) No. (%)
2003 34 (16.8) 7 (7.8) 41 (14.0)
2004 28 (13.9) 16 (17.8) 44 (15.1)
2005 30 (14.9) 8 (8.9) 38 (13.0)
2006 19 (9.4) 10 (11.1) 29 (9.9)
2007 22 (10.9) 11 (12.2) 33 (11.3)
2008 23 (11.4) 16 (17.8) 39 (13.4)
2009 14 (6.9) 7 (7.8) 21 (7.2)
2010 21 (10.4) 8 (8.9) 29 (9.9)
2011 11 (5.4) 7 (7.8) 18 (6.2)
Total 202 (100.0) 90 100.0 292 (100.0)
Source: Sentinel surveillance data as of January 8, 2015.
* Percentages might not sum to 100% due to rounding.
TABLE 2. Number and percentage* of silicosis cases, by number of 
years of employment in jobs with potential exposure to silica — 
Michigan and New Jersey, 2003–2011
No. yrs. employment
Michigan New Jersey Total
No. (%) No. (%) No. (%)
<10 20 (9.9) 8 (8.9) 28 (9.6)
10–19 19 (9.4) 17 (18.9) 36 (12.3)
20–29 54 (26.7) 10 (11.1) 64 (21.9)
30–39 57 (28.2) 10 (11.1) 67 (22.9)
≥40 25 (12.4) 9 (10.0) 34 (11.6)
Unknown 27 (13.4) 36 (40.0) 63 (21.6)
Total 202 (100.0) 90 (100.0) 292 (100.0)
Source: Sentinel surveillance data as of January 8, 2015.
* Percentages might not sum to 100% due to rounding.
TABLE 3. Number and percentage* of silicosis cases, by primary industry — Michigan and New Jersey, 2003–2011
Industry (NAICS 2002)
Michigan New Jersey Total
No. (%) No. (%) No. (%)
Agriculture, forestry, fishing and hunting 1 (0.5) 1 (1.1) 2 (0.7)
Mining 17 (8.4) 12 (13.3) 29 (9.9)
Mining (except oil and gas) (212) 17 (8.4) 11 (12.2) 28 (9.6)
All other mining industries (213) —† (—) 1 (1.1) 1 (0.3)
Construction 34 (16.8) 23 (25.6) 57 (19.5)
Specialty trade contractors (238) 32 (15.8) 15 (16.7) 47 (16.1)
Heavy and civil engineering construction (237) 2 (1.0) 5 (5.6) 7 (2.4)
All other construction industries (236) — (—) 3 (3.3) 3 (1.0)
Manufacturing 139 (68.8) 45 (50.0) 184 (63.0)
Primary metal manufacturing (331) 106 (52.5) 3 (3.3) 109 (37.3)
Nonmetallic mineral product manufacturing (327) 10 (5.0) 28 (31.1) 38 (13.0)
Transportation equipment manufacturing (336) 13 (6.4) 2 (2.2) 15 (5.1)
Miscellaneous manufacturing (339) 4 (2.0) 3 (3.3) 7 (2.4)
Fabricated metal product manufacturing (332) 3 (1.5) 3 (3.3) 6 (2.1)
All other manufacturing industries (325, 333–335) 3 (1.5) 6 (6.7) 9 (3.1)
Wholesale trade 1 (0.5) — (—) 1 (0.3)
Retail trade 1 (0.5) — (—) 1 (0.3)
Transportation and warehousing 2 (1.0) 2 (2.2) 4 (1.4)
Professional, scientific, and technical services — (—) 1 (1.1) 1 (0.3)
Administrative and support and waste management and 
remediation services
— (—) 1 (1.1) 1 (0.3)
Health care and social assistance 1 (0.5) — (—) 1 (0.3)
Arts, entertainment, and recreation — (—) 1 (1.1) 1 (0.3)
Other services (except public administration) 4 (2.0) 3 (3.3) 7 (2.4)
Repair and maintenance (811) 4 (2.0) 3 (3.3) 7 (2.4)
Public administration (0.5) — (—) 1 (0.3)
Unclassified 1 (0.5) 1 (1.1) 2 (0.7)
Total 202 (100.0) 90 (100.0) 292 (100.0)
Abbreviation: NAICS = North American Industry Classification System.
Source: Sentinel surveillance data as of January 8, 2015.
* Percentages might not sum to 100% due to rounding.
† Indicates no cases reported.
crystalline silica dust. Nodular silicosis also can develop within 
5–10 years of exposure to higher concentrations of crystalline 
silica. A clinical continuum exists between the accelerated and 
the chronic forms of silicosis. Acute silicosis has a different 
pathophysiology than accelerated or chronic silicosis in that 
it might develop within weeks of initial exposure and is 
associated with exposures to extremely high concentrations† 
of crystalline silica. Respiratory impairment is severe, and the 
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disease is usually fatal within a year of diagnosis. In addition, 
occupational exposure to respirable crystalline silica puts 
workers at increased risk for other serious health conditions, 
including chronic obstructive lung disease, kidney and 
connective tissue disease, tuberculosis and other mycobacterial-
related diseases, and lung cancer (6). In 1997, the International 
Agency for Research on Cancer (IARC) classified crystalline 
silica as carcinogenic to humans (7), and this classification was 
reconfirmed in 2012 (8).
During 1999–2013, a total of 2,065 decedents (age-adjusted 
death rate: 0.57 per 1 million persons aged ≥15 years) had 
silicosis listed as the cause of death on the death certificate.§ 
The annual number of silicosis deaths declined from 185 in 
1999 to 111 in 2013 (9,10). Analysis of 1968–2005 data 
indicated that silicosis-attributable years of potential life lost 
before age 65 years decreased substantially during 1968–2005, 
but the decline slowed during the last 10 years of that period 
(11). However, the number of hospitalizations for which 
silicosis was listed as one of the discharge diagnoses did not 
decline during 1997–2011.¶ Cases of silicosis continue to occur 
despite the existence of legally enforceable exposure limits.† In 
2014, silicosis with progressive massive fibrosis was observed 
in a male aged 37 years who worked for an engineered stone 
countertop company as a polisher, laminator, and fabricator 
(12). Silicosis in any of its clinical forms is consistently 
TABLE 4. Number and percentage* of silicosis cases, by primary occupation — Michigan and New Jersey, 2003–2011
Occupation (COC 2000)
Michigan New Jersey Total
No. (%) No. (%) No. (%)
Management (022) —† (—) 1 (1.1) 1 (0.3)
Architecture and engineering (145, 150) 1 (0.5) 2 (2.2) 3 (1.0)
Healthcare practitioners and technical (313) 1 (0.5) — (—) 1 (0.3)
Protective service (374) 1 (0.5) — (—) 1 (0.3)
Building and grounds cleaning and maintenance 5 (2.5) 2 (2.2) 7 (2.4)
Janitors and building cleaners (422) 5 (2.5) 1 (1.1) 6 (2.1)
Grounds maintenance workers (425) — (—) 1 (1.1) 1 (0.3)
Office and administrative support (561, 562, 570) 3 1.5 — (—) 3 (1.0)
Farming, forestry, and fishing (605) — (—) 1 (1.1) 1 (0.3)
Construction and extraction 50 (24.8) 32 (35.6) 82 (28.1)
Construction laborers (626) 20 (9.9) 9 (10.0) 29 (9.9)
Brickmasons, blockmasons, and stonemasons (622) 11 (5.4) 2 (2.2) 13 (4.5)
Other extraction workers (694) 7 (3.5) 2 (2.2) 9 (3.1)
All other construction and extraction occupations (620–621, 623–625, 632, 
635–636, 642, 644, 652–653, 660, 673, 682–684)
12 (5.9) 19 (21.1) 31 (10.6)
Installation, repair, and maintenance (712, 715, 722, 733–735, 762) 7 (3.5) 8 (8.9) 15 (5.1)
Production 115 (56.9) 35 (38.9) 150 (51.4)
Production workers, all other (896) 39 (19.3) 2 (2.2) 41 (14.0)
Molders and molding machine setters, operators, and tenders, metal 
and plastic (810)
27 (13.4) 1 (1.1) 28 (9.6)
Grinding, polishing, and buffing machine tool setters, operators, and 
tenders, metal and plastic (800)
17 (8.4) 1 (1.1) 18 (6.2)
Metal furnace and kiln operators and tenders (804) 9 (4.5) — (—) 9 (3.1)
Crushing, grinding, polishing, mixing, and blending workers (865) 4 (2.0) 5 (5.6) 9 (3.1)
First—line supervisors/managers of production and operating workers (770) 6 (3.0) 1 (1.1) 7 (2.4)
Molders, shapers, and casters, except metal and plastic (892) — (—) 7 (7.8) 7 (2.4)
Inspectors, testers, sorters, samplers, and weighers (874) 3 (1.5) 3 (3.3) 6 (2.1)
Painting workers (881) 2 (1.0) 4 (4.4) 6 (2.1)
Miscellaneous assemblers and fabricators (775) — (—) 5 (5.6) 5 (1.7)
All other production occupations (801, 803, 813–814, 822, 831, 875–876) 8 (4.0) 6 (6.7) 14 (4.8)
Transportation and material moving (913, 920, 961–963) 4 (2.0) 8 (8.9) 12 (4.1)
Unclassifiable 15 (7.4) 1 (1.1) 16 (5.5)
Total 202 (100.0) 90 (100.0) 292 (100.0)
Abbreviation: COC = Census Occupation Code by the U.S. Census Bureau.
Source: Sentinel surveillance data as of January 8, 2015.
* Percentages might not sum to 100% due to rounding.
† Indicates no cases reported.
§ Source: CDC, National Center for Health Statistics, Multiple Cause-of-Death 
data files, 1999–2013 on CDC WONDER Online Database, released 2015, as 
compiled from data provided by the 57 vital statistics jurisdictions through the 
Vital Statistics Cooperative Program (http://wonder.cdc.gov/mcd-icd10.html).
¶ Source: Agency for Healthcare Research and Quality. HCUPnet, an on-line 
query system for National Statistics on All Stays (http://hcupnet.ahrq.gov).
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undercounted by the Survey of Occupational Injuries and 
Illnesses, an employer-based surveillance system maintained by 
the Bureau of Labor Statistics (13). An estimated 3,600–7,300 
new cases of silicosis might be occurring each year (13). In 
2008, the National Academy of Sciences recommended the 
continuation and expansion of surveillance efforts to prevent 
silicosis and other interstitial lung diseases (14).
Cases of silicosis are sentinel events that indicate the need 
for intervention (15). Silicosis was put under nationwide 
surveillance as part of the National Public Health Surveillance 
System in 1999** and became a nationally notifiable 
and standard condition in 2009.†† In 2010, the national 
surveillance case definition for silicosis was added to CDC’s 
National Notifiable Diseases Surveillance System (NNDSS).§§
Since 2005, NIOSH has supported efforts by states to 
conduct surveillance for silicosis under the State-Based 
Occupational Health and Safety Surveillance cooperative 
agreement. Between 1987 and 2005, different cooperative 
agreements were in place, including the Sentinel Event 
Notification system for Occupational Risks (SENSOR). In 
1987, some states initiated active silicosis surveillance under 
SENSOR and began providing data voluntarily to NIOSH 
(16,17). Since 1992, data summaries have been published in 
a series of reports.¶¶ The number of states*** that conduct 
silicosis surveillance varies by year based on funding support 
by NIOSH. Currently, Michigan and New Jersey are funded 
to continue to conduct sentinel case-based silicosis surveillance 
and interventions. These two states are the only states that 
continue to provide data voluntarily to NIOSH.
This report summarizes data for silicosis cases that met the 
surveillance case definition for a confirmed silicosis case for 
2003–2011 as reported by Michigan and New Jersey. Data 
from state programs are updated annually and are available 
through the CDC’s Work-Related Lung Disease Surveillance 
System (eWoRLD).†††
Data Sources
In 1987, some states initiated active silicosis surveillance 
under SENSOR and began providing data voluntarily to 
NIOSH (16,17). The number of states conducting silicosis 
surveillance varies by year.†† Two states, Michigan and New 
Jersey, continue to conduct sentinel case-based silicosis 
surveillance and interventions and provide data voluntarily 
to NIOSH.
Interpreting the Data
In this report, state surveillance data for confirmed silicosis 
cases are presented by the year of the reporting source, industry, 
occupation, and duration of employment in occupations 
with potential exposure to silica dust. The reporting source 
year is the year of a silicosis-related clinician report, hospital 
discharge, death, or year of a workers’ compensation claim. If 
a case is ascertained from multiple data sources over multiple 
years, the year reported is the first year the case is ascertained 
from any data source.
Reporting practices affect how the data should be interpreted. 
Silicosis is frequently not recognized or reported by clinicians. 
Although multiple data sources are used, case ascertainment 
likely is incomplete. The data provided in this report are based 
on data from two states and might not be generalizable.
Methods for Identifying Silicosis
State sentinel silicosis surveillance programs identify 
suspected cases of silicosis through health care provider reports, 
hospital discharge or outpatient data, state death certificate 
data, and Workers’ Compensation data. Other data sources 
include the identification by the index case of additional cases 
among co-workers at a work place, referrals from industrial 
hygienists conducting inspections at companies, employer 
screenings, and referrals from other state health departments.
In New Jersey, clinicians and hospitals are required to report 
cases of silicosis directly to the state health department. In 
Michigan, physicians, hospitals, clinics or employers are 
required to report cases of silicosis directly to the Michigan 
Department of Licensing and Regulatory Affairs or to the state’s 
bona fide agent, Michigan State University.
Cases are confirmed using the surveillance case definition, 
which requires a history of occupational exposure to airborne 
silica dust and either or both: 1) a chest radiograph (or other 
 ** Source: Council of State and Territorial Epidemiologists position statement 
ENV 4 (http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/1999-
ENV-4.pdf ).
 †† Source: Council of State and Territorial Epidemiologists position statement 
09-OH-01 (http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/09-
OH-01.pdf ).
 §§ Source: CDC. Silicosis 2010 case definition (https://wwwn.cdc.gov/nndss/
conditions/silicosis/case-definition/2010).
 ¶¶ Work-Related Lung Disease (WoRLD) Surveillance Reports are available at 
http://www.cdc.gov/niosh/topics/surveillance/ords/NationalStatistics.html. 
The most recent data are available at http://wwwn.cdc.gov/eworld.
 *** A list of states conducting silicosis surveillance is available in Table A-1 on 
page A-7 at http://www.cdc.gov/niosh/docs/2008-143/pdfs/2008-143.pdf.
 ††† State-based case data are available at http://wwwn.cdc.gov/eworld/Grouping/
Silicosis/94#State-based Case Data.
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radiographic image, such as computed tomography) showing 
abnormalities interpreted as consistent with silicosis; or 
2) lung histopathology consistent with silicosis.§§ Medical 
record review and follow-up interviews are conducted with 
the reported case or their surviving next-of-kin, using a 
standardized telephone-administered questionnaire.
Publication Criteria
De-identified confirmed cases of silicosis case data are 
reported voluntarily to NIOSH on an annual basis. All 
confirmed cases are published.
Highlights
Silicosis is a progressive and preventable occupational lung 
disease caused by the inhalation, deposition, and retention 
of respirable dust containing crystalline silica. As a sentinel 
event, a case of silicosis indicates a failure to prevent exposure 
to crystalline silica dust.
For the period 2003–2011, silicosis surveillance programs 
in Michigan and New Jersey identified and confirmed 292 
cases; 28 (9.6%) had <10 years of potential exposure to silica 
dust. The manufacturing, construction, and mining industries 
accounted for 92% (n = 270) of the cases, with the greatest 
number of cases (184 [63%]) associated with manufacturing.




















Source: Sentinel surveillance data as of January 8, 2015.
* N = 292 (Michigan: 202; New Jersey: 90).
Morbidity and Mortality Weekly Report
78 MMWR / October 14, 2016 / Vol. 63 / No. 55 US Department of Health and Human Services/Centers for Disease Control and Prevention
References
 1. CDC. Summary of notifiable noninfectious conditions and disease 
outbreaks—United States. MMWR Morb Mortal Wkly Rep 2014;63(55).
 2. CDC. Summary of notifiable infectious diseases and conditions—United 
States, 2014. MMWR Morb Mortal Wkly Rep 2014;63(54).
 3. Leung CC, Yu ITS, Chen W. Silicosis. Lancet 2012;379:2008–18. http://
dx.doi.org/10.1016/S0140-6736(12)60235-9
 4. Occupational Safety and Health Administration. OSHA Factsheet. 
OSHA’s Proposed Crystalline Silica Rule: construction. Washington, 
DC: US Department of Labor, Occupational Safety and Health 
Administration. https://www.osha.gov/silica/factsheets/OSHA_
FS-3681_Silica_Construction.v2.html
 5. Occupational Safety and Health Administration. OSHA Factsheet. 
OSHA’s Proposed Crystalline Silica Rule: general industry and maritime. 
Washington, DC: US Department of Labor, Occupational Safety and 
Health Administration. https://www.osha.gov/silica/factsheets/OSHA_
FS-3682_Silica_GIM.html
 6. CDC, National Institute for Occupational Safety and Health. Health 
effects of occupational exposure to respirable crystalline silica. Cincinnati, 
Ohio: US Department of Health and Human Services, CDC, National 
Institute for Occupational Safety and Health; 2002. DHHS (NIOSH) 
Pub No. 2002-129. http://www.cdc.gov/niosh/docs/2002-129/
pdfs/2002-129.pdf
 7. International Agency for Research on Cancer. IARC monographs on 
the evaluation of carcinogenic risks to humans. Vol. 68: silica, some 
silicates, coal dust and para-aramid fibrils. Lyon, France: International 
Agency for Research on Cancer, World Health Organization; 1997. 
http://monographs.iarc.fr/ENG/Monographs/vol68/index.php
 8. International Agency for Research on Cancer. IARC monographs on 
the evaluation of carcinogenic risks to humans. Vol. 100C: a review of 
human carcinogens: arsenic, metals, fibers, and dusts. Lyon, France: 
International Agency for Research on Cancer, World Health 
Organization; 2012. http://monographs.iarc.fr/ENG/Monographs/
vol100C/index.php
 9. Bang KM, Attfield MD, Wood JM, Syamlal G. National trends in 
silicosis mortality in the United States, 1981–2004. Am J Ind Med 
2008;51:633–9. http://dx.doi.org/10.1002/ajim.20607
 10. Bang KM, Mazurek JM, Wood JM, White GE, Hendricks SA, Weston 
A. Silicosis mortality trends and new exposures to respirable crystalline 
silica—United States, 2001–2010. MMWR Morb Mortal Wkly Rep 
2015;64:117–20.
 11. CDC. Silicosis-related years of potential life lost before age 65 years—
United States, 1968–2005. MMWR Morb Mortal Wkly Rep 
2008;57:771–5.
 12. Friedman GK, Harrison R, Bojes H, Worthington K, Filios M. Notes 
from the field: silicosis in a countertop fabricator—Texas, 2014. MMWR 
Morb Mortal Wkly Rep 2015;64:129–30.
 13. Rosenman KD, Reilly MJ, Henneberger PK. Estimating the total number 
of newly-recognized silicosis cases in the United States. Am J Ind Med 
2003;44:141–7. http://dx.doi.org/10.1002/ajim.10243
 14. National Research Council and Institute of Medicine. Respiratory 
Diseases Research at NIOSH. Committee to Review the NIOSH 
Respiratory Disease Research Program. Rpt. No. 4, Reviews of Research 
Programs of the National Institute for Occupational Safety and Health. 
Washington, DC: The National Academies Press; 2008. http://www.
nap.edu/catalog/12171
 15. Rutstein DD, Mullan RJ, Frazier TM, Halperin WE, Melius JM, Sestito 
JP. Sentinel Health Events (occupational): a basis for physician 
recognition and public health surveillance. Am J Public Health 
1983;73:1054–62. http://dx.doi.org/10.2105/AJPH.73.9.1054
 16. CDC. Silicosis surveillance—Michigan, New Jersey, Ohio, and 
Wisconsin, 1987–1990. MMWR Surveill Summ 1993;42(No. 
SS-5):23–8.
 17. Maxfield R, Alo C, Reilly MJ, et al. Surveillance for silicosis, 1993—
Illinois, Michigan, New Jersey, North Carolina, Ohio, Texas, and 
Wisconsin. MMWR Surveill Summ 1997;46(No. SS-1):13–28.
Morbidity and Mortality Weekly Report
MMWR / October 14, 2016 / Vol. 63 / No. 55 79US Department of Health and Human Services/Centers for Disease Control and Prevention
Preface
CDC collects data on foodborne and waterborne disease 
outbreaks reported by all U.S. states and territories through the 
Foodborne Disease Outbreak Surveillance System (FDOSS) 
(http://www.cdc.gov/foodsafety/fdoss/surveillance/index.
html) and the Waterborne Disease and Outbreak Surveillance 
System (WBDOSS) http://www.cdc.gov/healthywater/
surveillance), respectively. These two systems are the primary 
source of national data describing the number of reported 
outbreaks; outbreak-associated illnesses, hospitalizations, 
and deaths; etiologic agents; water source or implicated 
foods; settings of exposure; and other factors associated with 
recognized foodborne and waterborne disease outbreaks in 
the United States.
FDOSS and WBDOSS share an enhanced reporting 
platform, the National Outbreak Reporting System (NORS) 
(http://www.cdc.gov/nors). NORS also collects information 
on disease outbreaks with modes of transmission other than 
food and water, including person-to-person contact, animal 
contact, and environmental contamination.
This report summarizes data on foodborne disease outbreaks 
reported during 1973–2013 and waterborne disease outbreaks 
reported during 1971–2013; waterborne disease outbreak data 
for 2013 are preliminary. This report is a part of the Summary 
of Notifiable Noninfectious Conditions and Disease Outbreaks — 
United States, which encompasses various surveillance years 
but is being published in 2016 (1). The Summary of Notifiable 
Noninfectious Conditions and Disease Outbreaks appears in the 
same volume of MMWR as the annual Summary of Notifiable 
Infectious Diseases (2).
Background
Foodborne Disease Outbreak Surveillance
Foodborne diseases caused by known pathogens result in an 
estimated 9.4 million illnesses each year in the United States 
(3). Only a minority of foodborne illnesses, hospitalizations, 
and deaths occur as part of recognized outbreaks (4). However, 
information gathered from foodborne disease outbreak 
surveillance activities provide valuable insights into the agents 
that cause foodborne illness, types of implicated foods and 
ingredients, and settings in which transmission occurs.
Surveillance for foodborne disease outbreaks provides insight 
into the effectiveness of regulations and control measures, helps 
identify new and emerging pathogens, provides information 
regarding the food preparation and consumption settings in 
which outbreaks occur, informs prevention and control measures 
in the food industry by identifying points of contamination, and 
can be used to describe trends in outbreaks over time.
Foodborne disease outbreaks have been nationally notifiable 
since 2010; however, CDC has collected reports of foodborne 
disease outbreaks through FDOSS since 1973. Initially a 
paper-based system, FDOSS became web-based in 1998 and 
was transitioned to NORS in 2009.
Waterborne Disease Outbreak 
Surveillance
Despite advances in water management and sanitation, 
waterborne disease and outbreaks continue to occur in the 
United States. CDC collects data on waterborne disease 
outbreaks associated with drinking water, recreational water, 
and other water exposures through WBDOSS. Waterborne 
disease outbreaks have been nationally notifiable since 2010; 
however, reports of waterborne disease outbreaks have been 
collected by CDC since 1971. Initially utilizing a paper-
based reporting process, the system transitioned to web-based 
reporting with the launch of NORS in 2009.
Foodborne (1973–2013) and Waterborne (1971–2013) 
Disease Outbreaks — United States
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CDC uses waterborne disease outbreak surveillance data 
to identify the types of etiologic agents, settings, recreational 
water venues, and drinking water systems associated with 
waterborne disease outbreaks; inform regulations and public 
awareness activities to promote healthy swimming and safe 
drinking water; and establish public health priorities to improve 
prevention efforts, guidelines, and regulations at the local, state, 
territorial, and federal levels.
Data Sources
Foodborne Disease Outbreak Surveillance
State, local, and territorial health departments use a 
standard form (CDC form 52.13, http://www.cdc.gov/
nors/pdf/NORS_CDC_5213.pdf ) to report foodborne 
disease outbreaks to CDC. Data requested for each outbreak 
include reporting state; date of first illness onset; the number 
of illnesses, hospitalizations, and deaths; the etiology; the 
implicated food vehicle; the setting of food preparation and 
consumption; and contributing factors. Multistate outbreaks 
(i.e., those in which exposure to the implicated food occurred in 
more than one state) typically are reported to FDOSS by CDC.
Only reports meeting the definition of a foodborne disease 
outbreak, defined as the occurrence of two or more cases of a 
similar illness resulting from the ingestion of a common food, 
are included in this summary. Outbreaks occurring on cruise 
ships that have both U.S. and international ports and those in 
which the food was eaten outside the United States, even if the 
illness occurred in the United States, are not reported to FDOSS.
Laboratory and clinical guidelines for confirming an etiology 
are specific to each bacterial, chemical/toxin, parasitic, and viral 
agent (http://www.cdc.gov/foodsafety/outbreaks/investigating-
outbreaks/confirming_diagnosis.html). Suspected etiologies 
are those that do not meet the confirmation guidelines. The 
cause of the outbreak is categorized as “multiple etiologies” if 
more than one etiologic agent is reported.
Waterborne Disease Outbreak 
Surveillance
State, local, and territorial health departments use a standard 
form (CDC form 52.12, http://www.cdc.gov/nors/forms.html) 
to report waterborne disease outbreaks to CDC. Data requested 
for each outbreak include reporting state; date of first illness 
onset; the number of illnesses, hospitalizations, and deaths; 
the etiology; the type of water exposure (e.g., recreational); 
the implicated venue or system, the setting of exposure; water 
quality indicators; and contributing factors.
Only reports meeting the definition of a waterborne disease 
outbreak, which is the occurrence of two or more cases of a 
similar illness resulting from exposure to a common water 
source, are included in this summary. WBDOSS includes 
reports of all types of illness outbreaks associated with water; 
this includes both gastrointestinal illness outbreaks and 
respiratory illness outbreaks (e.g., outbreaks of legionellosis, 
which causes a respiratory illness). Outbreaks occurring on 
cruise ships and those in which the water exposure occurred 
outside the United States or its territories, even if the illness 
occurred in the United States, are not included in WBDOSS.
Interpreting Data
Reported outbreaks represent only a small fraction of all 
foodborne and waterborne illnesses that occur each year and 
the outbreak data reported here are subject to limitations. 
Outbreaks caused by certain pathogens or vehicles might be 
more likely to be recognized, investigated, or reported. Some 
illnesses reported as sporadic (i.e., not outbreak-associated) 
are likely not recognized as being part of a reported outbreak 
or might be part of an undetected outbreak. In addition, 
all outbreak-related illnesses might not be identified during 
an investigation, smaller outbreaks might not come to the 
attention of public health authorities, and some outbreaks 
might not be investigated or reported to CDC.
Reporting practices for foodborne and waterborne disease 
outbreaks vary among states and territories, which might have 
differing definitions or interpretations of which events are 
reportable and unique laws related to disease outbreak reporting. 
Thus, variations in reporting rates by state or territory might 
reflect variations in levels of effort and funding for foodborne 
and waterborne disease outbreak investigation, rather than true 
differences in outbreak incidence rates by state. NORS maintains 
a dynamic database; this report includes data available on May 1, 
2015, for foodborne disease outbreaks and May 4, 2015, for 
waterborne disease outbreaks; data published in this Summary 
might differ from those published earlier or later.
Methods for Identifying Foodborne 
and Waterborne Disease Outbreaks
CDC provides guidance for states and other jurisdictions 
for reporting foodborne and waterborne disease outbreaks 
(http://www.cdc.gov/nors/forms.html). As for all notifiable 
conditions, reporting to CDC is voluntary, and state and 
local laws, regulations, and practices vary. For example, CDC 
advises states to report outbreaks having cases occurring 
in the same household; however, state, local, or territorial 
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jurisdictions might determine that these outbreaks do not 
require investigation or might deem them nonreportable at 
the state or territorial level.
Publication Criteria
Foodborne disease outbreaks are defined as two or more 
cases of a similar illness resulting from ingestion of a common 
food. Waterborne disease outbreaks are defined as two or more 
cases of a similar illness linked epidemiologically by time and 
location to exposure to water or water-associated chemicals 
volatized into the air.
Highlights
Foodborne Disease Outbreaks
During 1973–2013, CDC received reports of 30,251 
foodborne disease outbreaks with 742,945 outbreak-associated 
illnesses from the 50 states, Puerto Rico, the District of Columbia, 
and freely associated states/territories. An average of 738 (range: 
298–1,404) outbreaks were reported each year (Figure 1). The 
average annual number of foodborne disease outbreaks reported 
to CDC increased in 1998 in comparison to previous years, 
coinciding with the transition to an electronic reporting system, 
and decreased in 2009 in comparison to 1998–2008 coinciding 
with the transition to reporting through NORS. In 2013, a total 
of 792 single-state exposure outbreaks were reported with 11,786 
illnesses by 47 states and Puerto Rico (Table) (Figure 2); an 
additional 26 multistate outbreaks (i.e., exposure to the implicated 
food occurred in more than one state) with 1,530 associated 
illnesses also were reported. CDC periodically publishes more 
detailed annual summaries describing the implicated foods, 
etiologic agents, settings, and points of contamination associated 
with foodborne disease outbreaks (http://www.cdc.gov/foodsafety/
fdoss/data/annual-summaries/index.html).
Waterborne Disease Outbreaks
During 1971–2013, CDC received reports of 1,957 
waterborne disease outbreaks with 642,782 outbreak-associated 
illnesses from 50 states and six freely associated states/territories. 
An average of 46 waterborne outbreaks was reported each year 
(Figure 1). In 2013, a total of 55 outbreaks causing at least 
2,824 illnesses occurred in 21 states. No multistate outbreaks 
were reported; waterborne disease outbreak data for 2013 are 
preliminary (Table) (Figure 3). CDC periodically publishes 
more detailed summaries of waterborne disease outbreaks 
associated with recreational water and of waterborne disease 
outbreaks associated with drinking water (http://www.cdc.gov/
healthywater/surveillance/surveillance-reports.html).



















Transition to electronic reporting system
* Waterborne disease outbreak data for 2013 are preliminary. CDC partners with state agencies and the Environmental Protection Agency to review, summarize, and 
publish waterborne disease outbreak data separately from this report. CDC also reviews, summarizes, and publishes foodborne disease outbreak data separately 
from this report.
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TABLE. Number of reported foodborne and waterborne disease outbreaks and outbreak-associated illnesses, by geographical division and 
area — United States, 2013*
Area
Foodborne Waterborne All
Outbreaks Illnesses Outbreaks Illnesses Outbreaks Illnesses
United States 818 13,316 55 2,824 873 16,140
New England 44 788 1 140 45 928
Connecticut 13 248 —† — 13 248
Maine§ — — — — — —
Massachusetts 14 366 — — 14 366
New Hampshire 4 70 — — 4 70
Rhode Island 10 68 1 140 11 208
Vermont 3 36 — — 3 36
Mid-Atlantic 86 1,054 3 23 89 1,077
New Jersey 10 72 — — 10 72
New York 51 561 — — 51 561
Pennsylvania 25 421 3 23 28 444
Eastern North Central 158 2,165 17 2,139 175 4,304
Illinois 39 714 5 1,445 44 2,159
Indiana 6 46 2 23 8 69
Michigan 27 350 1 597 28 947
Ohio 65 723 9 74 74 797
Wisconsin 21 332 — — 21 332
Western North Central 79 1,403 10 64 89 1,467
Iowa 8 98 3 23 11 121
Kansas 14 356 — — 14 356
Minnesota 35 604 7 41 42 645
Missouri 8 90 — — 8 90
Nebraska 6 104 — — 6 104
North Dakota 7 94 — — 7 94
South Dakota 1 57 — — 1 57
FIGURE 2. Rate* of reported foodborne disease outbreaks and 
number† of outbreaks, by state — Foodborne Disease Outbreak 


















































* Incidence of outbreaks per 1 million population based on the 2012 U.S census 
estimates. Cutpoints for outbreak rate categories determined by using quartiles.
† N = 818 (includes 26 multistate outbreaks assigned as an outbreak to each 
state involved).
No reports 0.04–0.2 0.30–0.480.21–0.26 0.78–2





















FIGURE 3. Rate* of reported waterborne disease outbreaks and 
number† of outbreaks, by state — Waterborne Disease and Outbreak 
Surveillance System, United States, 2013
* Incidence of outbreaks per 1 million population based on the 2012 U.S census 
estimates. Cutpoints for outbreak rate categories determined by using quartiles.
† N = 55 (data are preliminary).
See table footnotes on page 83.
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TABLE. (Continued) Number of reported foodborne and waterborne disease outbreaks and outbreak-associated illnesses, by geographical 
division and area — United States, 2013*
Area
Foodborne Waterborne All
Outbreaks Illnesses Outbreaks Illnesses Outbreaks Illnesses
South Atlantic 120 1,622 12 88 132 1,710
Delaware§ — — — — — —
District of Columbia§ — — — — — —
Florida 36 323 4 25 40 348
Georgia 27 396 2 10 29 406
Maryland 23 228 1 14 24 242
North Carolina 10 239 — — 10 239
South Carolina 11 182 1 5 12 187
Virginia 13 254 4 34 17 288
West Virginia§ — — — — — —
Eastern South Central 30 433 4 64 34 497
Alabama 3 124 1 19 4 143
Kentucky 2 20 — — 2 20
Mississippi 1 3 — — 1 3
Tennessee 24 286 3 45 27 331
Western South Central 35 765 4 164 39 929
Arkansas 7 65 — — 7 65
Louisiana 7 90 2 144 9 234
Oklahoma 5 238 1 17 6 255
Texas 16 372 1 3 17 375
Mountain 67 1,427 3 23 70 1,450
Arizona 18 438 — — 18 438
Colorado 27 297 1 3 28 300
Idaho 4 19 — — 4 19
Montana 5 62 2 20 7 82
Nevada 2 430 — — 2 430
New Mexico 7 122 — — 7 122
Utah 3 31 — — 3 31
Wyoming 1 28 — — 1 28
Pacific 155 1,970 1 119 156 2,089
Alaska 10 66 — — 10 66
California 81 1,069 — — 81 1,069
Hawaii 8 192 — — 8 192
Oregon 28 368 1 119 29 487
Washington 28 333 — — 28 333
Territories 18 159 — — 18 159
Puerto Rico 18 159 — — 18 159
Multistate 26 1,530 — — 26 1,530
* Waterborne disease outbreak data for 2013 are preliminary. CDC partners with state and territorial agencies and the Environmental Protection Agency to review, 
summarize, and publish waterborne disease outbreak data separately from this report. CDC reviews, summarizes, and publishes foodborne disease outbreak data 
separately from this report.
† No data were reported for 2013.
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